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Abstract 
 
Molecular imaging is a non-invasive way to diagnose disease. Molecular imaging 
probes consist of a targeting entity that has a high affinity for a biological target 
and a signaling source for external detection. Multimodality imaging combines the 
advantages of different imaging modalities, at the same time eliminating their 
shortcomings, thereby providing more accurate results. This thesis focuses on 
the development of novel dual PET/fluorescence imaging agents based on 
peptides as targeting entities. 
Porphyrins are suitable for multimodality imaging applications due to their innate 
characteristics such as an ability to fluoresce and to coordinate metals. A gallium-
protoporphyrin IX(PPIX)-ghrelin based analogue was designed as a potential 
dual PET/fluorescence imaging probe for detection of growth hormone 
secretagogue receptor 1a (GHS-R1a) and it was found that fluorescence was not 
quenched upon coordination to Ga. The PPIX-ghrelin analogue was also 
successfully radiolabeled with 68Ga. The specific uptake of this analogue by the 
receptor target, GHS-R1a, was demonstrated through confocal fluorescence 
microscopy using OVCAR-8 cells transfected with GHS-R1a. Thus, these dual 
modality probes can aid in bridging the gap and extend research from in vitro 
fluorescence imaging to in vivo PET imaging.  69/71Ga-hematoporphyrin-bombesin 
analogues were synthesized as potential PET/fluorescence imaging probes for 
the gastrin releasing peptide receptor (GRP-R), but the reaction yields were low 
and all the components of the hematoporphyrin-bombesin mixture could not be 
coordinated with gallium and this mixture of coordinated and the uncoordinated 
analogues could not be analyzed by optical methods. Nonetheless, the ability of 
hematoporphyrin to act as a chelator for Ga and to couple to peptides was 
demonstrated.  
BODIPY dyes are widely used for fluorescence imaging but suffer from 
drawbacks such as complicated synthesis and small Stokes shifts. However, 
 
 
ii 
 
novel BF2-formazanate dyes have favourable properties such as convenient 
synthesis and optical properties that can be tuned by modifying the structure. 
BF2-formazanate- peptide based analogues were developed as fluorescence 
imaging agents for GHS-R1a and GRP-R. Use of a modified ghrelin sequence 
led to an improvement in the IC50 value. Specific uptake of the probes could be 
visualized through fluorescence microscopy.  
Keywords  
Optical imaging, positron emission tomography, protoporphyrin, 
hematoporphyrin, GHS-R1a, GRP-R, BF2-formazanate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Co-Authorship Statement 
 
Project conceptualization was provided by Dr. Leonard Luyt. 
Chapter 2 is a manuscript in preparation. The peptides were synthesized, 
purified, characterized, and radiolabeled by Neha Sharma. Optical analysis was 
carried out by Neha Sharma using the instruments in Dr. Robert Hudson’s lab. 
The in vitro competitive binding assays were performed by Dr. Jinqiang Hou. The 
OVCAR-8 cells and the OVCAR-8 cells transfected with GHS-R1a were cultured 
by Dr. Trevor Shephard and Tyler Lalonde. The confocal microscope imaging 
was performed by Neha Sharma. 
The peptides in chapter 3 were synthesized, purified, and characterized by Neha 
Sharma. Optical analysis was carried out by Neha Sharma. 68Ga labeling was 
carried out by Neha Sharma. 
Chapter 4 is a manuscript in preparation. This is a project in collaboration with the 
lab of Dr. Joe Gilroy. Compounds 4.1, 4.2, 4.15 were obtained from Dr. Joe 
Gilroy’s lab. All the peptides were synthesized, purified and characterized by 
Neha Sharma. Click reactions were performed by Neha Sharma with the help of 
Dr. Stephanie Barbon using the instruments in Dr. Joe Gilroy’s lab. The optical 
analysis was carried out by Neha Sharma using instruments in Dr. Joe Gilroy’s 
lab. The in vitro competitive binding assays were carried out by Dr. Jinqiang Hou 
and Emily Murrell. Fluorine-18 radiolabeling was performed by Neha Sharma. 
Fluorine-18 was donated by Dr. Michael Kovacs at the Nordal Cyclotron and PET 
Radiochemistry Facility in St. Josephs Hospital in London, Ontario. OVCAR-8 
cells and OVCAR-8 cells transfected with GHS-R1a were cultured by Tyler 
Lalonde and PC-3 cells were cultured by William Turnbull. Confocal fluorescence 
microscopy was performed by Neha Sharma. 
 
 
 
 
iv 
 
Acknowledgements 
 
First, I would like to extend my gratitude towards Dr. Luyt for giving me the 
opportunity to pursue my research interest in molecular imaging and for trusting 
me with all the projects I worked on. I also thank him for motivating me whenever 
I felt discouraged due to unsatisfactory results. And for providing me with the 
opportunity to present my work at international conferences. 
I would like to thank all past and present Luyt lab members for all their help. I 
thank them for never letting me miss my family and always making me feel like 
home. All of you have made my journey through graduate school a lot of fun. I 
thank Lihai Yu for helping me with radiochemistry, JQ Hou and Emily Murrell for 
running binding assays, Dr. Trevor Shephard, Tyler Lalonde and William Turnbull 
for all the help with cell culture. I would also like to thank Dr. Stephanie Barbon 
from Dr. Gilroy’s lab for all her help. 
I also thank my family for all their support without which I would have never been 
able to follow my goal of doing PhD in Canada. Thanks for believing in me and 
always being proud of me. 
And, finally my husband Arun for being my support in my difficult times, for 
always encouraging me to get through challenging situations, for always being 
patient with me and for listening to my complaints. I could not have made it so far 
without him.  
 
 
 
 
 
 
v 
 
Table of Contents 
 
Abstract…………………………………………………………..………………..i  
Co-Authorship Statement……………………………………..…………….… iii 
Acknowledgements…………………………………………..……..….….……iv 
Table of Contents……………………………………………..…………………v 
List of Tables……………………………………………….........…………..… xi 
List of Figures…………………………………………...………………...……xiii 
List of schemes…………………………………………….............…..……..xvii 
List of abbreviations……………………………………………...…………..xviii 
Chapter 1….……………………………………………………………….......…1 
       1 Introduction………………………………………………..………………1 
1.1 Molecular Imaging………………………………………………1 
1.2 Imaging Modalities…………………………………………..….2 
1.3 Imaging Probes……………………………………...……….…5 
1.4 PET Imaging…………………………………………………….7 
      1.4.1 Radioisotopes for PET…………………………………..9 
               1.4.1.1 Fluorine-18………………………………….…...9 
                           1.4.1.1.1 Methods for 18F labeling……….......10 
               1.4.1.2 Gallium-68…………………………….…..…....15 
1.5 Optical Imaging………………………………………...….…..17 
      1.5.1 Fluorescence Imaging………………………...............18 
 
 
vi 
 
1.6 Multimodality Imaging…………….…………………………..20 
1.7 Targeted Imaging Probes Based on peptide……...…….…24 
1.8 Growth Hormone Sectretagogue Receptor and Ghrelin.....25 
1.9 Click Chemistry………………………………………………..28 
1.10 Porphyrins………………………………….………....……...30 
1.11 Summary………………...……...........................................34 
1.12 References……………………………………………..…….34 
 
Chapter 2…………………………………………………….….................…..43 
2 The Development of a Ga-Ghrelin-Protoporphyrin IX Analogue for Imaging                                   
of GHSR-1a Receptor………………….………………...……………..……..43 
                  2.1 Introduction………………….……………………...…...……43 
                  2.2 Result and Discussion…………….……………...………….48 
                         2.2.1 Synthesis of PPIX-ghrelin(1-8) Analogue…………..49 
                         2.2.2 69/71Ga Coordination……………………………….....54 
                         2.2.3 Optical Analysis………………………...........……….55 
                         2.2.4 In vitro Fluorescence Imaging of 69/71Ga-PPIX-ghrelin 
                                  (1-8)...…………………………………….……......…..57 
                         2.2.5 Optimization of 68Ga Labeling of Ghrelin(1-8)- 
                                  PPIX……………………………………………......…..60 
                         2.2.6 Competitive Binding Assays IC50 for ghrelin(1-8)- 
                                  PPIX…………………………………………......……..64 
                   2.3 Conclusions…………………….………………......………..66 
 
 
vii 
 
                   2.4 Experimental…………………….....………………......……66 
                   2.5 Acknowledgements…………..………. ………………....…74      
                   2.6 References…………………………….……………….........74 
         
Chapter 3…………………………………………….………......……………..78 
3 The Development of Ga-peptide-Hematoporphyrin Derivatives As 
   Imaging Agents………………………………………...……………............78  
                 3.1 Introduction……………………..………………...…............78 
        3.2 Results and Discussion………….………………...………..83 
 3.2.1 69/71Ga Coordination of Hematoporphyrin…...……...85 
                        3.2.2 Optical Analysis………………………………………..88 
 3.2.3 Synthesis of HP-AEEA-[β-Ala11, Phe13, Nle14]-   
          bombesin(7-14) analogues…………......…………....89        
       3.2.4 69/71Ga Coordination of HP-AEEA- 
                [β-Ala11, Phe13, Nle14]-bombesin (7-14)  
                Analogues………………………………......………….92 
       3.2.5 68Ga Labeling of Hematoporphyrin…………………..95 
  3.3 Conclusions………………………….……...………...……..97 
                   3.4 Experimental………………………………...............………99 
                   3.5 Acknowledgements……………………...............………..104 
                   3.6 References………………………….…………..................104 
 
Chapter 4………………………………………………………………………109 
 
 
viii 
 
4 The Development of Ghrelin-Formazanate Boron Difluoride Dyes as 
Imaging Agents……………………………………...…...………………......109  
                   4.1 Introduction……………………………….…………………109 
                   4.2 Result and Discussion………………………….………….113 
       4.2.1 Study of Fluorescence Properties of FMZ Dyes 
                Using Fibroblast Cells……………………………...113  
       4.2.2 Trials for 18F/19F Isotope Exchange Reaction……115 
                          4.2.3 Synthesis of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)- 
                                   FMZ Alkyne Analogue by Click Chemistry……….123 
                           4.2.4 Optical Analysis of [Dpr3,Tyr8,(Lys(N3))9]ghrelin 
                                    (1-9)-FMZ Alkyne Analogue………………………127 
                          4.2.5 In Vitro Fluorescence Imaging Using OVCAR-8 
                                   Cells Transfected With GHS-R1a……………..….128 
                                    
                          4.2.6 Competitive Binding Assay……………….………..131 
 4.2.7 Attempted Synthesis of Ghrelin (1-19)-FMZ 
          Analogue 4.11 by Click Chemistry……………..…132                   
 
                        4.2.8 Synthesis of [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ    
                                 Methoxy Analogue by Click Chemistry…………...134 
                          4.2.9 Optical Analysis……………………………….…….136 
                          4.2.10 In Vitro Fluorescence Imaging Using OVCAR-8 
                                     Cells Transfected with GHS-R1a…………..……137 
 
 
ix 
 
 
                          4.2.11 Competitive Binding Assay…………….…………140 
                          4.2.12 Alternate Route for Synthesis of Imaging 
                                     Probe…………………………………………….….141 
                          4.2.13 Stability Analysis of BF2-formazanate Dyes……146 
                          4.2.14 Synthesis of [D-Phe6, β-Ala11, Phe13, Nle14]  
                                     bombesin 6-14-(PEG)7-FMZ Analogue 4.23…...150   
 
                          4.2.15 Optical Analysis……………………………………151 
                          4.2.16 In Vitro Fluorescence Imaging Using PC-3 
                                     Cells………………………………………………...153 
                          4.2.17 Competitive Binding Assay……………………….155 
                 4.3 Conclusions……………………………………….......……..156 
                 4.4 Experimental…………………………………………………157 
                 4.5 Acknowledgements………………………………………….167 
                 4.6 References…………………………………………………...167 
 
Chapter 5………………………………………………………………………172 
5 Conclusions…………………………………………………………………172 
                 5.1 Concluding Remarks……………………………………..…172 
                 5.2 References…………………………………………………...178 
6 Appendix…………………………………………………………………….180 
                 6.1 Chapter 2 UPLC Traces…………………………………….180 
 
 
x 
 
                 6.2 Chapter 2 ESI+ Mass Spectrums…………………………..182 
                 6.3 Chapter 2 IC50 Curves………………………………………184 
                 6.4 Chapter 3 UPLC Traces…………………………………….185 
                 6.5 Chapter 4 UPLC Traces…………………………………….187 
                 6.6 Chapter 4 ESI+ Mass Spectrums…………………………..191 
                 6.7 Chapter 4 IC50 Curves……………………………………....195  
                 6.8 Permission for Figures………………………………………197  
Curriculum Vitae………………………………………………………………212       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
List of Tables 
 
Table 1.1 Comparison between different imaging modalities…………...….5 
Table 1.2 Radionuclides commonly used in PET, their half life and method                    
of production……………………….…...…………………………..……….…...9 
Table 1.3 Reported modified ghrelin analogues and their IC50 values...…27  
Table 2.1 Photophysical data for PPIX and PPIX analogues.............…....56 
Table 2.2 Different conditions for optimization of conditions for                       
radiolabeling with 68Ga…………………………..……………............……...63 
Table 3.1 Calculated m/z and observed m/z for 69/71Ga-hematoporphyrin               
species 3.1, 3.2, 3.3 and 3.4…………………..……………………..……….87 
Table 3.2 Photophysical data for HP and 69/71Ga-HP analogues…………88 
Table 4.1. Different conditions for optimization of 18F/19F exchange                      
reaction of 4.2………………………...………………………………….….  117 
Table 4.2 Conditions for 18F/19F exchange reaction of 4.2 using 0.1 M                       
SnCl4 solution and 125 µL TBAB……………………...…………….….…..118 
Table 4.3 Conditions for 18F/19F exchange reaction of 4.2 using 0.1 M                       
SnCl4 solution and 80 µL TBAB………………………………….......……..119 
Table 4.4 Conditions for 18F/19F exchange reaction of 4.2 using 0.25 M                     
SnCl4 solution and 125 µL TBAB…………………………………………...120 
Table 4.5 Conditions for 18F/19F exchange reaction of 4.2 using 0.25 M                     
SnCl4 solution and 125 µL TBAB and microwave at 400C…………….…121 
Table 4.6 Conditions for 18F/19F exchange reaction of 4.2 using 1 M SnCl4                 
solution and 125 µL TBAB………………………………………………..…122 
Table 4.7 Different conditions for optimization of click reaction of 4.2 with                
compound 4.6 using CuSO4……………………………..…………….........124 
 
 
xii 
 
Table 4.8 Different conditions for optimization of click reaction of 4.2 with                
compound 4.6……………………………………………..…………….….…125 
Table 4.9 Photophysical data for FMZ alkyne 4.2 and          
[Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne analogue 4.7…...………..127 
Table 4.10 Photophysical data for FMZ alkyne 4.15 and     
[Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ methoxy analogue 4.16 .…..…..136 
Table 4.11 Photophysical data for FMZ alkyne 4.15 and                                                 
[D-Phe6, β-Ala11, Phe13, Nle14] bombesin 6-14-(PEG)7-FMZ analogue                         
4.23 ………………………………………………………………..…………..152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
List of Figures 
Figure 1.1 General design of the imaging probe………………………..…...6 
Figure 1.2 Pictorial representation of an annihilation event…………..…….8 
Figure 1.3 Schematic for the direct labeling approach for 18F labeling…..13 
Figure 1.4 Schematic for the prosthetic group approach for 18F labeling..14 
Figure 1.5 Bifunctional chelators commonly used for 68Ga coordination...16 
Figure 1.6 Simplified depiction of Jablonski diagram………………………18 
Figure 1.7 Fluorescence images using traditional fluorophore, NIR-I and                   
NIR-II fluorophores. .…………………….....................................................20 
Figure 1.8 Structure of natural ghrelin (1-28)………………………………..26 
Figure 1.9 Depiction of Cu(I)-catalyzed azide-alkyne click reaction……...28 
Figure 1.10 Depiction of Strain promoted azide-alkyne cycloaddition                     
reaction using cyclooctyne…………………………………………..………..30  
Figure 1.11 Structure of porphine…………………………………………….31 
Figure 1.12 Structure of porphyrin related compounds…………..………..32 
Figure 1.13 Representative (a) absorption spectrum (showing Soret and                        
Q bands) and (b) emission spectrum for free base porphyrin…………….33              
Figure 2.1 Structure of proposed imaging probe…………………………...49 
Figure 2.2 Absorption and emission spectra for 2.8 and 2.9……………...57 
Figure 2.3 Confocal fluorescence micrographs of OVCAR-8 cells 
stained with 2.9 ……………………………………………………………......59 
Figure 2.4 UV trace for standard compound 2.9 (blue), Radio                       
chromatogram for compound 2.10 (red)………..…………………….……..64 
 
 
xiv 
 
Figure 2.5 Half-maximal inhibitory concentration curve of a) compound 2.9                   
and b) compound 2.8 against [125I]-human ghrelin in HEK 293/GHS-R1a          
cells………………………………………………………………………….…..65 
Figure 3.1 Structures of various porphyrin species comprising hematoporphyrin 
mixture…………………………………………………………………….…….84 
Figure 3.2 Structures of the 69/71Ga coordinated hematoporphyrin……… 86  
Figure 3.3 HPLC chromatogram for 69/71Ga coordinated hematoporphyrin 
species………………………………………………………………….……….87 
Figure 3.4 Absorption and emission spectra for HP and 69/71Ga-HP….….89 
Figure 3.5 General design of the imaging probe……………………...........90 
Figure 3.6 HPLC trace for crude mixture of products obtained by coupling                     
[β-Ala11, Phe13, Nle14]-bombesin (7-14)-AEEA with HP……….…….……..92 
Figure 3.7 HPLC trace for crude mixture of products obtained by coordinating        
69/71Ga to [β-Ala11, Phe13, Nle14]-bombesin (7-14)-AEEA-HP………….….95 
Figure 3.8 UV trace for standard compound i.e. mixture of 3.1 and      
radiochromatogram for 68Ga labeling………………………………………..97 
Figure 4.1 Depiction of closed, open, and linear forms of formazans…..111 
Figure 4.2 Confocal fluorescence micrographs of mouse fibroblast cells                 
stained with BF2 formazanate complex 4.1 and DAPI.………………......114 
Figure 4.3 General structure of the targeted imaging probe…………….115 
Figure 4.4 Chromatograms for 18F/19F exchange reaction of 4.2 using                           
0.1 M SnCl4 and 125 µL TBAB……………………………………….…..…118 
Figure 4.5 Chromatograms for 18F/19F exchange reaction of 4.2 using                          
0.1 M SnCl4 and 80 µL TBAB…………....................................................119 
Figure 4.6 Chromatograms for 18F/19F exchange reaction of 4.2 using                         
0.25 M SnCl4 and 125 µL TBAB……………………………….…….……..120 
 
 
xv 
 
Figure 4.7 Chromatograms for 18F/19F exchange reaction of 4.2 using                          
0.25 M SnCl4 and 125 µL TBAB and microwaving at 400 C.………….....121 
Figure 4.8 Chromatograms for 18F/19F exchange reaction of 4.2 using                             
1 M SnCl4 and 125 µL TBAB.………………………………………….…….122 
Figure 4.9 Absorption (blue), emission (red) for A: FMZ dye 4.2 and B: 
[Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne analogue 4.7 ……………128 
Figure 4.10 Confocal fluorescence micrographs of OVCAR-8 cells  
stained with 4.7 (in red) and DAPI (in blue)………………………………..130 
Figure 4.11 Half-maximal inhibitory concentration curve of 
[Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne analogue 4.7 against                            
[125I]-human ghrelin in HEK 293/GHS-R1a cells……………………..……132 
Figure 4.12 Absorption (blue), emission (red) for A: FMZ dye 4.15 and B: 
[Dpr3,Thr8,(Lys(N3))9]ghrelin (1-9)-FMZ methoxy analogue 4.16  ………137 
Figure 4.13 Confocal fluorescence micrographs of OVCAR-8 cells stained 
with 4.16……………………………………………………………………….139                                                                                                                                                                                
Figure 4.14 Half-maximal inhibitory concentration curve of                                           
ghrelin(1-9)-FMZ analogue 4.16 against [125I]-human ghrelin in                                          
HEK 293/GHS-R1a cells……………………………………………………..141 
Figure 4.15 HPLC chromatograms for click reaction between FMZ                            
alkyne 4.2 and lysine azide. …………………….…………………………..144 
Figure 4.16 Structure of compounds synthesized during click reaction                  
between FMZ alkyne 4.2 and lysine azide………………………..……….145 
Figure 4.17 Structure of Formazanate methoxy dye 4.15……................146 
Figure 4.18 HPLC chromatogram for stability analysis of FMZ methoxy                   
alkyne dye 4.15 in TFA…………………………………………...………… 147 
Figure 4.19 HPLC chromatograms for stability analysis of FMZ dye 4.15. 
………………………………………………………………………………….148 
 
 
xvi 
 
Figure 4.20 HPLC chromatograms for stability analysis of FMZ dye 4.15                           
in Phenylsilane and Tetrakis triphenylphosphine Pd(0)…………………..149 
Figure 4.21 Absorption (blue), emission (red) for A: FMZ dye 4.15 and                          
B: [D-Phe6, β-Ala11, Phe13, Nle14] bombesin 6-14-(PEG)7-FMZ analogue 
4.23…………………………………………………………………….……….153 
Figure 4.22 Confocal fluorescence micrographs of PC-3 cells stained  
with 4.23 (in red) and DAPI (in blue)………………………………………..154 
Figure 4.23 Half-maximal inhibitory concentration curve of                             
bombesin(7-14)-FMZ analogue 4.23 against [125I]-bombesin in PC3 
cells…………………………………………………………………………….155 
Figure 5.1 Structures of parent BF2-formazanate dyes 4.2 and 4.15......176 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvii 
 
List of Schemes 
 
Scheme 2.1 Route for synthesis of 2.1 by coupling PPIX to 2,2’-
(ethylenedioxy)bis(ethylamine)……………………………………………….50 
Scheme 2.2 Route for coupling of PPIX to 2,2' -(ethylenedioxy)bis(ethylamine)              
in solution…………………………………………………………………….….51 
Scheme 2.3 Route for synthesis of PPIX-linker-ghrelin analogue 2.8……53 
Scheme 2.4 Route for coordination to 69/71Ga………………………………55 
Scheme 2.5 Route for radiolabeling with 68Ga……………………………...62 
Scheme 3.1 Route for synthesis of imaging probe comprising                           
hematoporphyrin species coupled to bombesin analogue ………..….......91 
Scheme 3.2 Route for 69/71Ga coordination……………………….…………94 
Scheme 3.3 Synthetic route for radiolabeling of HP with Ga-68………….96 
Scheme 4.1. Route for synthesis of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ              
alkyne analogue 4.7………………………………………………...………..126 
Scheme 4.2 Route for attempted synthesis of ghrelin(1-19)-FMZ alkyne             
analogue 4.11……………………………………………….…………..……133 
Scheme 4.3. Route for synthesis of [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ          
analogue 4.16……………………………………………………….………...135 
Scheme 4.4. Proposed alternate route for synthesis of ghrelin(1-19)-FMZ              
alkyne analogue 4.20……………………………………………………......142 
Scheme 4.5. Route for synthesis of [D-Phe6, β-Ala11, Phe13, Nle14] bombesin(6-
14)-(PEG)7-FMZ analogue 4.23………………………………….………….151 
 
 
 
xviii 
 
                                List of Abbreviations 
 
Ac2O : acetic anhydride 
ACN : acetonitrile 
AcOH : acetic acid 
ADIBO : azadibenzocyclooctyne  
ADIBOT : azadibenzocyclooctatriazoles 
AEEA : aminoethanolethylamine 
Alloc : allyloxycarbonyl 
aq : aqueous 
BFC : bifunctional chelating agents 
BN : bombesin 
BN-LP : bombesin like peptides 
BODIPY : 4,4’-difluoro-4-bora-3a,4a-diaza-s-indacene  
BPDS : Bathophenanthroline disulphonate 
BRS-3 : bombesin receptor subtype 3 
BRS-4 : bombesin receptor subtype 4 
BSA : bovine serum albumin 
CT : computed tomography  
DAPI : 4’,6-diamino-2-phenylindole 
DBU : 1,8-diazabiclclo[5.4.0]undec-7-ene 
DCM : dichloromethane 
 
 
xix 
 
DIPEA : N,N-diisopropylethylamine 
DMF : N,N-dimethylformamide 
DMSO : dimethylsulfoxide 
DOTA : 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
Dpr : diaminopropanoic acid 
DTPA : diethylene triamine pentaacetic acid 
EDC : N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
EDTA : ethylenediaminetetraacetic acid 
equiv : equivalents 
ESI : electrospray ionization 
EtOH : ethanol 
FBAM :  fluorobenzaldehyde-O-[6-(2,5-dioxo-pyrrol-1-yl)-hexyl]oxime  
FBS : fetal bovine serum 
FDG : 2-deoxy-2’-fuoro-deoxy-glucose 
Fmoc : fluorenylmethyloxycarbonyl 
FMZ : formazanate 
FV : fluoview 
GHS-R1a : growth hormone secretagogue receptor 1a 
GHS-R1b : growth hormone secretagogue receptor 1b 
GRP : gastrin releasing peptide 
GRP-R : gastrin releasing peptide receptor 
HATU : (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazole[4,5-b]pyridinium 3-
oxid Hexafluorophosphate 
 
 
xx 
 
HBED : N,N’-Bis(2-hydroxybenzyl)ethylenediamine-N,N’-diacetic acid 
HCTU : O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium  
HEPES : (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid          
HOBt : hydroxybenzotrizole 
HPLC : high performance liquid chromatography 
HRMS : high resolution mass spectrometry 
IC50 : half maximal inhibitory concentration 
ICG : indocyanine green 
keV : kilo electron volt 
m/z : mass by charge ratio 
MBq : megabecquerel 
MeOH : methanol 
MRI : magnetic resonance imaging 
MW : microwave 
NIR : near infrared region 
NLS : nuclear localization sequences 
NMB : neuromedin-B 
NODAGA : 1,4,7-triazacyclononane, 1-glutaric acid-4,7-acetic acid 
NOTA : 1,4,7-Triazacyclononane-N,N’,N’’-triacetic acid 
OI : optical imaging 
PBS : phosphate buffer saline 
PC : prostate cancer 
PDT : photodynamic therapy 
 
 
xxi 
 
PEG : polyethylene glycol 
PET : positron emission tomography 
Pip : piperidine 
PMDETA : Pentamethyldiethylenetriamine 
PPIX : protoporphyrin IX 
PyBrOP : bromotripyrrolidinophosphonium hexafluorphosphate 
r.t. : room temperature 
RP : reverse phase 
rpm : revolutions per minute 
RPMI : Rosewell Park Memorial Institute medium 
Ser : serine 
SN : substitution nucleophilic 
SPAAC : strain promoted azide alkyne cycloaddition  
SPECT : single photon emission computed tomography 
SST : somatostatin receptor 
TBAB : tetrabutylammonium bicarbonate 
TBME : tert-butylmethyl ether 
TBTA : Tris(benzyltrizolylmethyl)amine 
tBuOH : tertiary butanol 
Tf2O : triflic anhydride 
TFA : trifluoroacetic acid 
TfOH : trifluoromethanesulfonic acid 
THF : tetrahydrofuran 
 
 
xxii 
 
TIPS: triisopropylsilane 
TMSOTf : trimethylsilyl triflate 
Tren : Tris(2-aminoethyl)amine 
UHPLC : ultra high performance liquid chromatography 
uPAR : urokinase-type plasminogen activator receptor 
 
 
1 
 
 
                                      Chapter 1 
 
1 Introduction 
 
1.1 Molecular Imaging 
There has been a tremendous growth in the field of medical imaging over the 
past few decades. The main goal of medical imaging is the construction of a 
visual account of the body’s interior for clinical evaluation. Structural or 
conventional imaging involves the detection of anatomical abnormalities, while on 
the other hand, functional imaging reveals the physiological activities within a 
tissue. 
Molecular imaging, which is defined as the visualization, characterization and 
quantification of biological processes at cellular and subcellular levels1, unveils 
the clinical biology of the disease process and plays a significant role in the early 
assessment and analysis of the disease.2 Molecular imaging also helps in 
diagnosing, staging, evaluating therapeutic targets, providing personalized 
patient care and monitoring therapy. Molecular imaging can be used for patient 
stratification into those with the probability to respond and others who will not 
respond to therapy. These kind of personalized treatment plans will not only lead 
to improved patient outcome but will also result in the judicious use of the 
resources, hence the cost of health care can be controlled.3 Perhaps the most 
impressive feature of molecular imaging is that it is non-invasive and does not 
involve the use of more invasive procedures such as surgery or biopsy. 
Moreover, the biological processes can be examined with good temporal and 
spatial resolution.4 The role of molecular imaging has become more significant 
since the development of imaging instrumentation that is capable of higher 
resolution.  
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In particular, molecular imaging has become a vital component of cancer care 
since it leads to the early detection and determination of the precise location of a 
tumour before the appearance of the symptoms and before the other diagnostic 
methods can detect abnormalities.4 The extent to which the disease has spread 
to other organs of the body can also be determined. The most effective therapy 
can be determined depending upon the molecular characteristics of the tumour 
and the individual traits of the patient. Molecular imaging can help in monitoring 
the progression of the disease as well as diagnosing the recurrence of cancer.5  
 
1.2 Imaging Modalities 
The choice of the imaging modality is governed by the kind of application that is 
desired and the nature of the imaging probe that is available. For example, 
certain imaging modalities such as magnetic resonance imaging (MRI) and 
computed tomography (CT) provide anatomical information but do not provide 
functional information. Due to the small size of the early lymph nodes, they may 
not be characterized by CT.  Nuclear imaging modalities can provide information 
related to the functional or metabolic activity of the tissues leading to the early 
detection of the disease. Nuclear medicine imaging employs a tiny quantity of 
radioactive substance, which is administered to the subject. Special cameras are 
utilized to detect the gamma radiation that is emitted by the radioisotope and 
computer created images provide accurate illustration of the region being 
scanned.6  
The two most widely used nuclear medicine imaging modalities are positron 
emission tomography (PET) and Single photon emission tomography (SPECT). 
PET is a technique in which the detector identifies pairs of gamma rays that are 
emitted indirectly from a positron emitting radioisotope.7 Receptor targeted PET 
imaging is directed towards imaging the molecular markers that are 
overexpressed in various types of cancers and therefore is a useful way for 
imaging cancer. PET imaging is discussed in detail in section 1.4. Another related 
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imaging modality is SPECT. Here, a gamma emitting radionuclide is introduced 
into the body and the SPECT scanner detects the gamma ray emission. The 
detector rotates and collects multiple two-dimensional images at several angles 
around the patient.7 This way three dimensional images of the accumulation of 
the radiotracer are obtained. PET involves the detection of pairs of oppositely 
emitted photons in coincidence whereas in SPECT, the emitted photons are 
unidirectional, causing the determination of the exact region of emission of the 
gamma rays to be a more difficult task and therefore, leading to lower resolution 
and decreased sensitivity.7 The most commonly used radionuclide for SPECT is 
99mTc, which is a generator produced radioisotope with a half life of 6 hours, 
which is optimal duration allowing for radiosynthesis and acquisition of images. 
Other radioisotopes used for SPECT imaging are 111In8 and 67Ga.9 
Another widely used imaging modality is MRI and is based on nuclear magnetic 
resonance. The hydrogen atoms from the water present in the body, when 
exposed to the external magnetic field, become aligned. The scanner produces 
radiofrequency pulses, creating a variable magnetic field. The absorption of 
energy by the protons flips their spin. On removing the variable magnetic field, 
the protons return to their normal spins through relaxation.10 This produces a 
radio signal which can be detected and an image can be created. The rate at 
which the protons return to the normal state varies for the different tissues in the 
body. Therefore, contrast can be generated among the different tissues 
depending on the relaxation characteristics of the protons in that tissue.  MRI aids 
in visualization of the anatomical and functional aspects of the cancer tissues 
with high resolution. The contrast agents typically utilized for MRI can either 
produce negative image contrast or positive image contrast. Gadolinium (Gd) 
based contrast agents produce T1- weighted tumour images. On the other hand 
superparamagnetic nanoparticles provide T2- weighted contrast images.11 
Recently the application of MRI for the detection of breast cancer micro 
metastases was demonstrated using a peptide-Gd-DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) based contrast agent.12 
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The field of X-ray CT (computed tomography) came into being with the arrival of 
digital computers that could reconstruct objects from projections. Since then, it 
has come a long way owing to the use of numerous parallel detectors that aid in 
three-dimensional scanning of large regions in shortened time durations.13 
Tomographic images of certain areas of the scanned object are created by 
obtaining X-ray images from various angles. A computer processed combination 
of these X-ray images produces a CT scan.13  Recently the use of CT in the field 
of nuclear medicine imaging has increased as it is being used in combination with 
PET or SPECT. In fact, there are quite a few similarities between the concepts, 
such as image reconstruction from projections, that form the basis of both CT and 
PET or SPECT. 
Optical imaging is yet another commonly used imaging modality. It makes use of 
light to derive the information regarding the cellular and molecular processes in 
the living system. Fluorescence imaging employs certain fluorophores which 
upon being excited by the light sources e.g. lasers, fluoresce to release light of 
higher wavelength. A wide variety of fluorophores such as quantum dots14 and 
dyes like cyanine15, fluorescein16, IR-78017 and have been analysed for 
applications in optical imaging with promising results.  
The different imaging modalities have their own strengths and weaknesses. 
Some modalities such as MRI provide more anatomical information than other 
modalities. Some imaging modalities have a high sensitivity and low resolution 
e.g. PET and some modalities such as MRI on the other hand have low 
sensitivity but higher resolution.18 Therefore, combining two or more modalities 
through multimodality imaging can provide more accurate results. Multimodality 
imaging is discussed in detail later in this chapter. Table 1.1 provides a 
comparison between the various imaging modalities. 
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Imaging Modality Sensitivity Resolution 
Nuclear (PET) 10-15M 1-2 mm 
MRI 10-9M-10-6M 25-100 µm 
CT 10-6M 50-200 µm 
Optical (in vitro) 10-12M Sub-µm  
 
Table 1.1 Comparison between different imaging modalities.18 
 
 
1.3 Imaging Probes 
The characteristics of an imaging probe greatly influence the outcome of the 
imaging analysis. The imaging probe is an agent that aids in visualizing, 
characterizing, and quantifying the biological processes taking place within a 
living system.19 The imaging probe may be injected into the blood stream, 
inhaled, or swallowed by the patient followed by an external detection which can 
help in the diagnosis of the disease, monitoring the progression of the disease as 
well as following the response to therapy. An imaging probe that is not specific 
and selective for the biological target is not very effective as it will also be taken 
up by other tissues and hence there will be a poor contrast between the diseased 
and the healthy tissue, invalidating the results obtained from the imaging study.  
Therefore, an optimal imaging probe should have high affinity and high specificity 
for the biological target, as well as have good in vivo stability, an optimal rate of 
clearance from the body and possess minimal potential toxicity.20 A targeted 
imaging probe is composed of a signaling source, a targeting entity and often but 
not always, a linker joining the signaling source and the targeting entity. The 
signaling source is responsible for the generation of the signal for imaging. The 
characteristics of the ‘label’ decide the applicability of the imaging probe for the 
imaging modality e.g. fluorescent molecules are required as a ‘label’ for optical 
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imaging, positron emitting radioisotopes for PET, gamma emitting radioisotope 
for SPECT and magnetic molecules are desired as ‘labels’ for application in 
MRI.19 The targeting entity, as the name suggests is accountable for binding to 
the biological target. The biological target could be a receptor that is 
overexpressed in some type of cancer. The targeting entity can be a small 
molecule, peptide, protein, or an antibody. The linker not only connects the 
signaling source and the targeting entity but also helps in improving the 
pharmacokinetics of the imaging probe depending on the hydrophilic or 
hydrophobic characteristics of the linker. The linker may also help to increase the 
distance between the targeting entity and the signaling source such that the 
presence of the signaling source does not affect the affinity of the targeting entity 
for the biological target. The linker can be comprised of a polyethylene glycol 
chain or poly amino acids, as examples. The main criteria to be considered while 
choosing a linker are the length of the linker, the presence of any charges, the 
hydrophilicity and the flexibility associated with the linker.19 
 
 
 
Figure 1.1 General design of the imaging probe. 
 
 
Before advancing with the development of the imaging probe, it is essential to 
recognize a relevant target related to the biological process under investigation.20  
The identification of suitable targets has become more straightforward owing to 
7 
 
 
the increasing availability of a variety of biological data mining tools. Moreover, 
the location and the distribution of the biological target can also be analyzed. 
Despite all the recent developments in the field of molecular imaging, there 
remain many aspects related to the imaging probe development that require 
improvement. It is sometimes seen that the imaging probe shows good binding 
for the receptor in vitro but the results from in vivo analysis are not very 
promising. One of the main hurdles is the arduous process of developing an ideal 
imaging probe with excellent affinity for the biological target and having the least 
possible non-specific uptake.21 All this has led to a constant need for the 
development of novel biomarkers appropriate for cancer imaging as well as for 
the advancement of chemistry and biology techniques for the design of imaging 
probes with improved pharmacokinetics.5 The development of more advanced 
instruments will also help in contributing towards improved spatial and temporal 
resolution.  
The two imaging modalities that form the basis of this thesis are PET and optical 
imaging and are discussed in detail below. 
 
1.4 PET Imaging                                                                                                                                            
PET is a non-invasive technique that facilitates the evaluation of the functional 
and metabolic processes in tissues, typically much before the structural or 
anatomical changes can be detected. Initially PET was used only for research but 
gradually it made its way into clinics and hospitals notably in the field of oncology 
for diagnosis, cancer staging, and monitoring response to treatment.22  
PET requires the use of a positron emitting radioisotope that decays by emitting a 
positron, which is the antimatter of an electron and has the same mass as an 
electron but possesses a positive charge. After emission, the positron travels 
through the surrounding tissue until it collides with a nearby electron. This 
distance that the positron travels is known as the positron range.7 The positron 
range travelled depends on the energy of the emitted positron and is unique for 
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every radioisotope. The greater the positron energy, the longer the distance 
travelled before annihilation with the electron, causing a larger loss in spatial 
resolution.23 The annihilation process generates two 511 keV gamma rays 
approximately 1800 from each other. The simultaneous detection of these pairs of 
gamma rays by an array of surrounding detectors aids in determining the location 
of the annihilation.7 Figure 1.2 depicts a pictorial representation of the annihilation 
process. Despite the fact that it is hard to determine the precise location of 
annihilation, acquiring multiple coincidence events along all the lines affords 
sufficient information to reconstruct various events which have been recorded 
into an image and hence giving adequate information about the spatial 
distribution of radioactivity.23    
 
 
Figure 1.2 Pictorial representation of an annihilation event. Positron upon 
annihilation with electron, emits two gamma rays at 1800.  The array of 
surrounding detectors detects the pairs of gamma rays. 
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1.4.1 Radioisotopes for PET 
1.4.1.1 Fluorine-18 
There are several positron emitting radioisotopes e.g. carbon-11, nitrogen-13, 
fluorine-18, copper-64, gallium-68 and iodine-124 etc. that have been utilized to 
label diagnostically relevant compounds. Table 1.2 depicts some of the 
commonly used PET radionuclides. 
 
 
 
Radionuclide Half life Method of production 
F-18 109.7 minutes Cyclotron 18O(p,n)18F 
Ga-68 68 minutes 68Ge/68Ga generator 
Cu-64 12.7 hours Cyclotron 64Ni(p,n)64Cu 
C-11 20.4 minutes Cyclotron 14N(p,ɑ)11C 
Y-86 14.7 minutes Cyclotron 86Sr(p,n)86Y 
Zr-89 3.27 days Cyclotron 89Y(p,n)89Zr 
 
Table 1.2 Radionuclides commonly used in PET, their half life and method of 
production.23,24 
 
Among all the radioisotopes employed for PET, 18F is most commonly used, 
essentially due to the role of 2-deoxy-2’-fluoro-D-glucose (18F-FDG) as a 
successful commercial radiopharmaceutical for cancer imaging. There is an 
increased uptake of FDG by the tumour due to the increased metabolism of 
glucose by tumour cells.23 Although it has been approved by the FDA and is 
considered the gold standard in PET imaging, 18F-FDG also has uptake in 
regions of high natural glucose metabolism such as the kidneys and the brain. 
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This has led to the need for the development of novel targeted PET radiotracers 
that will have high specificity for the biological target and will not be taken up by 
the healthy tissue. 18F possesses some of the most appropriate physical 
properties for applications as a PET radionuclide. It has high positron decay ratio 
(97%), low positron energy, half-life of 110 minutes that provides sufficient time 
for more complicated radiosynthesis, lengthy in vivo evaluation and easy 
transportation to clinical centers that do not have radiochemistry facilities.25 18F is 
synthesized in a cyclotron where oxygen-18 enriched water is used as a target. 
The hydride ions produced in the ion chamber are passed through an electron 
stripper and form protons, which are then bombarded onto the target to convert 
18O to 18F.26 
 
In spite of being a strong nucleophile, fluoride ion undergoes hydrogen bond 
formation with the surrounding water and the nucleophilicity is hampered. The 
nucleophilicity can be improved by employing a phase transfer catalyst such as 
Kryptofix222 or tetrabutylammonium bicarbonate.26     
The tremendous increase in the demand of 18F based PET imaging probes 
emphasizes the necessity of straightforward and effective 18F labeling 
procedures.   
  
1.4.1.1.1 Methods for 18F Labeling 
Nucleophilic Substitution  
The positron emitter 18F has been introduced into many molecules through 
nucleophilic substitution reactions. To carry out aliphatic nucleophilic fluorination, 
the leaving group in the precursor undergoes SN2 substitution with 18F-fluoride. 
The selection of an appropriate leaving group is important for the success of such 
reactions. The commonly employed leaving groups are tosylate,27 sulfonate28, 
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triflate29 and mesylate.30 Nucleophilic aliphatic fluorination reactions usually result 
in decent radiochemical yields, require mild reaction conditions such as moderate 
reaction temperature and shorter reaction duration. A variety of PET 
radiopharmaceuticals used in clinics including 18F-FDG, 18F-choline31 are 
synthesized using this methodology.  
The presence of an electron withdrawing group, such as NO2 or CN positioned 
ortho or para relative to the leaving group, activates the phenyl ring and makes it 
able to undergo aromatic nucleophilic substitution reactions with F-.26 Usually 
these reactions require heating at higher temperatures which limits their 
application in the case of more sensitive molecules such as peptides and 
proteins. The frequently employed leaving groups for such type of reactions are 
nitro32 and trimethyl-ammonium.33 Several 18F PET radiotracers have been 
reported to be synthesized using this methodology, e.g. 18F-fluorodopamine34 and 
18F-altanserin35.  
Isotope exchange reactions involving the exchange of 18F with 19F, can also be 
carried out using nucleophilic substitution reactions.36,37 However, it is difficult to 
separate 18F labeled compound from the 19F precursor, therefore isotope 
exchange reactions typically result in low specific activity (activity per quantity of 
molecule).  
Boron can also act as a fluoride binding site for labeling of biomolecules. This 
approach involves the reaction of aryl boronic ester with nucleophilic 18F and 
potassium hydrogen fluoride (KHF2) resulting in the formation of [18F]-
organotrifluoroborates.25 This approach involves just a single radiochemistry step 
and the step involving the azeotropic drying of 18F-fluoride can be eliminated 
since this reaction is carried out under partial aqueous conditions. Using this 
strategy, a biotinylated 18F-aminophenyltrifluoroborate was synthesized.38 Aryl 
hydroxyl or alkoxy silanes react with 18F-fluoride leading to the formation of 
triorganofluorosilane.   
Nucleophilic substitution reactions are used for most of the reported 18F labeling 
procedures.    
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Electrophilic Fluorination 
For the generation of the electrophilic 18F-F2, the addition of 19F-F2 is required to 
extract 18F-F2 from the target.39 This leads to a lower specific activity and 
decreases the yield of production from the cyclotron.26  High yield of production 
from the cyclotron and high specific activity are critical factors for PET imaging. 
Therefore, most methods of 18F labeling in nuclear medicine focus on the use of 
18F-fluoride using nucleophilic substitution reactions. Several improved 
methodologies have been utilized to achieve a higher specific activity using 
electrophilic fluorination and there are many reports depicting synthesis of 
compounds through electrophilic radiofluorination.40,41 Recently, 18F-labeled 
derivatives of resazurin were synthesized as potential PET imaging probes using 
this methodology.42    
 
Direct Labeling of Biomolecules 
In the direct labeling method, the molecule is reacted directly with 18F-fluoride 
(Figure 1.3). The molecule may be altered previously in order to be made suitable 
for the radiolabeling procedure.43 There are a few reports of introduction of 18F 
directly to peptides. One of the drawbacks of this technique is that it is quite 
challenging to label directly without effecting the functional groups on the side 
chains of the peptides. Direct 18F labeling of monomeric and dimeric cyclic RGD 
peptides modified with 4-NO2-3-CF3 arenes was reported, demonstrating one 
step radiofluorination of a peptide with good yield, and high specific activity.44 The 
labeled peptides were evaluated in vitro and in vivo for specific binding to 
integrins. One step 18F fluorination was also achieved for a bombesin peptide 
modified with tetramethylammonium leaving group under mild radiolabeling 
conditions.45 In another report Al18F was coordinated to a chelator 1,4,7-
triazacyclononane-1,4,7-trisacetic acid (NOTA), bound to a bombesin peptide in a 
one pot synthesis.46 
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Figure 1.3 Schematic for the direct labeling approach for 18F labeling. 
 
Indirect Labeling of Biomolecules  
The indirect labeling method is often referred to as the prosthetic group approach 
for radiofluorination (Figure 1.4). A prosthetic group is a small molecule that can 
be radiolabeled with ease and is subsequently attached to the more sensitive 
biomolecule (such as a targeting peptide) using mild reaction conditions. The 
synthetic methodologies that are commonly used to conjugate the prosthetic 
group to the peptide include acylation, alkylation or amidation reactions.43 
Synthesis of 18F-labeled prosthetic group is usually carried out in 2-3 steps, 
followed by the purification steps. To obtain a high radiochemical yield, the focus 
should be on using synthetic steps that are less time consuming and high 
yielding.43 The selection of an appropriate prosthetic group is essential for the 
development of 18F labeled biomolecules. Several prosthetic groups have been 
established using nucleophilic approaches. The development of 3-18F-
fluoropropanesulfonyl chloride as prosthetic group for radiofluorination of amines 
has been reported.47 Recently, novel thiol reactive, fluorobenzaldehyde-O-[6-(2,5-
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dioxo-pyrrol-1-yl)-hexyl]oxime (FBAM) prosthetic group was developed for 
conjugation to small peptides and other biomolecules.48  
 
 
Figure 1.4 Schematic for the prosthetic group approach for 18F labeling. 
 
Bioorthogonal Approach / Click Chemistry  
Bioorthogonal reactions refer to the chemical reactions that can occur inside the 
living systems without interacting with the biological system.43 These reactions 
are very selective and can be performed in biological media. Therefore, several 
bioorthogonal reaction approaches have been utilized to introduce 18F into 
biomolecules. One such approach makes use of azide-alkyne click chemistry. 
The orthogonal nature of these reactions prevents the need for protecting the 
other functional groups. This strategy involves the development of 18F-labeled 
small molecules having azide or alkyne functional groups and clicking them onto 
peptides or other biomolecules containing the analogous reactive component.43 
Several examples utilizing this approach are seen in the literature e.g. 18F-fluoro-
N-methyl-N-propargyl benzene sulphonamide was developed as a novel click 
chemistry building block for labeling of peptides, protein and oligonucleotides.49 
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More recently, the scientific community has become more interested in the 
development of approaches that do not involve the use of toxic copper in 
biological systems. This has led to the rise in the application of strain promoted 
azide alkyne cycloaddition reactions (SPAAC). The bent geometry of triple bond 
of the eight-membered ring in cyclooctyne, causes the activation barrier to 
decrease resulting in fast reaction rates.50 SPAAC reactions have been utilized to 
convert azide acceptors such as azadibenzocyclooctyne (ADIBO) into 
azadibenzocyclooctatriazoles (ADIBOT). Recently, RGD-PEG-ADIBOT-18F 
analogues were synthesized and high tumour uptake was demonstrated in 
U87MG tumour bearing mice.51 This methodology holds potential for 18F labeling 
of biomolecules for clinical applications. 
 
1.4.1.2 Gallium-68       
Another commonly used radioisotope for PET imaging is 68Ga. It is a generator 
eluted radioisotope with a half-life of 68 minutes. It decays into the stable 68Zn 
through 89% positron emission.52 The parent isotope 68Ge has a half-life of 271 
days, permitting the use of a 68Ge/68Ga generator for up to one year. This 
eliminated the requirement of having a cyclotron on site for isotope production, 
making 68Ga a convenient and economical PET isotope. 68Ge/68Ga generators 
employ an inorganic matrix such as TiO2 or SnO2 to immobilize 68Ge, which 
decays into 68Ga (+3) and is eluted with a mobile phase such as dilute HCl.53 The 
energy associated with the positron emitted from 68Ga is more than that from 18F, 
which can result in a lower resolution.  
Over the last few years, several bifunctional chelating agents (BFC) have been 
developed to coordinate radiometals such as 68Ga. Chelating agents contain 
atoms such as N, O, S that can form bonds with metal ions by donating lone pair 
of electrons. Bifunctional chelators can coordinate to the radiometal, at the same 
time possess functional groups that are suitable for the attachment of a 
biomolecule e.g. peptide. Several factors affect the stability of the metal-chelator 
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complex such as size of the cavity of the chelator and the ionic radius of the 
radiometal, number of donor atoms provided by the chelator, the coordination 
geometry preference of the radiometal.54 Figure 1.5 depicts some of the 
bifunctional chelators commonly used for 68Ga coordination. Target specific 68Ga 
PET agents are developed using this bifunctional chelating approach.52 A 
bifunctional chelator on one end is attached to a targeting entity that has a high 
affinity for the receptor leading to the accumulation in the target tissue. And on 
the other end, it forms a complex with the radiometal, leading to stabilization of 
the radiometal in vivo.    
 
 
 
Figure 1.5 Chelators commonly used for 68Ga coordination.                                                                        
A lot of attention has been given to the development of 68Ga based 
radiopharmaceuticals targeting the somatostatin receptor. Lately, peptide 
conjugates based on 68Ga-DOTA-TOC((D)-Phe1-Thy3-octreotide),55 68Ga-DOTA-
NOC(Nal3-octreotide),56 68Ga-DOTA-TATE(Tyr3-octreotide)57 have shown 
potential as efficient PET imaging agents for this receptor target. More recently, 
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68Ga-NOTA-bombesin was evaluated for PET imaging of prostate cancer.58 68Ga-
DOTA-trastuzumab has also been evaluated as a PET imaging agent for 
targeting the human epidermal growth factor.59   68Ga is easily available through 
68Ge/68Ga generators, therefore is a highly desired PET isotope. But there is a 
need of developing novel chelators that will permit the use of a variety of 
biomolecules and receptor analogues.    
 
1.5 Optical Imaging 
Optical imaging is an economical, sensitive, fast, and proficient technique for the 
non-invasive detection of cancer. It makes use of light to investigate the cellular 
and molecular changes associated with the tumour. The lower limits of detection 
for optical imaging probes are expected to extend to picomolar or femtomolar 
concentrations in the near future.60 For in vivo optical imaging, when the 
excitation light penetrates the tissue, it undergoes scattering. The degree of 
scattering for biological tissues varies inversely with the wavelength such that the 
degree of scattering is greater when the excitation light is in the UV and visible 
range. Furthermore, the absorption of light by biological molecules such as 
hemoglobin, melanins and flavins is also greater in the visible region.61 These 
biological molecules dissipate the excitation photons as heat and reduce the 
emission signal intensity of a fluorophore significantly.62  Tissue autofluorescence 
is another limiting factor, with several biological tissues such as NADH 
(nicotineamide adenine dinucleotide) and flavins causing background tissue 
autofluorescence.61 
To overcome these challenges and to be able to image at greater depths, light in 
the first near infrared region window (NIR-I) with emission ranging between 650-
900 nm is being employed. At these wavelengths, the absorption by hemoglobin, 
lipids and water is very low.63 Tissue scattering and autofluorescence are also 
reduced. A targeted optical imaging agent consists of a targeting entity and an 
optically active probe.64 The targeting entity plays a crucial role in determining the 
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specificity and selectivity of the optical imaging agent. While designing the optical 
probe, stability, contrast and toxicity are some of the important criteria to be 
considered.  
 
1.5.1 Fluorescence Imaging 
Fluorescence imaging involves the application of external light of suitable 
wavelength to excite a fluorescent molecule. After absorbing light, the fluorophore 
is excited to a higher energy level. The excited molecule relaxes by emitting light 
of lower energy and longer wavelength, which is recorded by the detector. The 
excited fluorophore may also undergo intersystem crossing to triplet state and 
relax through phosphorescence. Figure 1.6 shows a simplified depiction of the 
fluorescence process. 
 
 
 
Figure 1.6 Simplified depiction of the Jablonski diagram 
A number of organic fluorescent dyes such as cyanine,15 porphyrin,65 
phthalocyanine,66 and BODIPY67 have been used as fluorophores for 
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fluorescence imaging. The choice of the dye as the fluorophore is guided by its 
optical properties such as absorption/emission wavelengths, extinction 
coefficient, fluorescence quantum yield and Stokes shift.68 Additionally, the ease 
of synthesis, stability, resistance to photobleaching and solubility are also 
important factors to be considered. 
Recently, the focus has shifted to the development of NIR dyes with tumour 
targeting properties.69 NIR dyes that have been approved by the FDA are 
indocyanine green (ICG) and methylene blue.  Their emission range lies in the 
first NIR window (NIR-I). There are various examples of the application of ICG for 
fluorescence imaging of cancer.69 Analysis of ICG for detecting sentinel lymph 
node in breast cancer patients was reported by Chi and coworkers.70  Despite the 
fact that the imaging results using NIR-I imaging probes are superior to those 
obtained from traditional fluorophores, there is a better improvement in the image 
quality obtained from fluorophores emitting in the second NIR window (NIR-II) 
(1000-1700nm). More recently, the synthesis and evaluation of NIR-II small 
molecule (CH1055) for in vivo imaging and image guided surgery was described 
by Antaris and coworkers.71 Other fluorescent probes based on quantum dots14 
and nanoparticles72 have also been reported.   
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Figure 1.7 a) Fluorescence image using traditional fluorophore © Wiley, b) 
Fluorescence image using NIR-I fluorophore © American Association for Cancer 
Research, c) and d) comparison between images obtained using NIR-I and NIR-II 
fluorophores respectively © Nature Publishing Group. Adapted with permission 
from a) ref 73 (Wiley) , b) ref 74 (American Association for Cancer Research), c) 
and d) ref 75 (Nature Publishing Group). 
 
1.6 Multimodality Imaging 
Cancer is a complicated phenomenon; therefore, a single imaging modality might 
not be adequate to comprehend the many processes associated with cancer. The 
advantages of various imaging modalities can be combined to achieve a more 
exhaustive analysis of physiological and structural events occurring in the tumour 
tissue.76 Of all the imaging modalities that are currently available, each has its 
own strengths and shortcomings. Researchers always encounter issues such as 
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high cost, low resolution, poor sensitivity, and exposure to ionizing radiations, 
which need to be mitigated in order to enhance the efficacy of the imaging 
technique.25 Multimodality imaging aims at combining two or more imaging 
techniques, thereby bringing together their advantages, and at the same time 
eliminating the weaknesses associated with each imaging modality 
independently. Consequently, more useful data can be acquired than can be 
obtained using a single modality. 
The preliminary attempts towards achieving multimodality imaging were made by 
combining the functional and anatomical data obtained from fusing nuclear 
techniques such as PET and SPECT with X-ray CT.77 Since then a lot of 
progress has been made in this field. More recently, focus has shifted towards 
combining PET and MRI, due to the development of fused PET/MRI scanners.78  
Owing to a better soft tissue contrast, multidimensional functional, structural and 
morphological information, this is considered superior to PET/CT. PET/MRI 
affords exceptional structural, functional and metabolic information that aids in 
understanding the pathophysiological processes associated with cancer.79 Some 
challenges can emerge while combining PET or SPECT with MRI due to mutual 
interference between the two systems e.g. PET and SPECT might interfere with 
the magnetic field and the radiofrequency from the MRI system.80 Several 
methodologies have been developed to overcome these challenges such as use 
of optic fibers,81 APD based detectors82 etc. Dual PET/MRI nanoparticle 89Zr-
ferumoxytol was used for the non-invasive mapping of the lymph nodes by 
Thorek and coworkers.83 In another recent study, 67Ga or 64Cu labelled 
superparamagnetic iron oxide nanoparticles were analyzed as PET/SPECT-MRI 
single probe imaging agents.84 
Dual MRI/optical imaging combines the advantages of optical imaging such as 
high sensitivity, operational simplicity with high spatial resolution and high soft 
tissue contrast from MRI.77 Further both the techniques do not employ harmful 
ionizing radiations as is the case with PET and SPECT. Anatomical and 
physiological information from deep lying tissues can be obtained using MRI/NIR 
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optical imaging probes. The use of nanoprobes for dual modality MRI/optical 
imaging is widely known. The first example of application of paramagnetic 
quantum dots coupled to RGD peptide targeted to human endothelial cells in vitro 
was shown by Mulder and coworkers.85  In another example Mn3[Co(CN)6]2 
nanocubes were developed as contrast agents for MRI and two photon 
fluorescence imaging.86 More recently, Qiao and coworkers demonstrated the 
application of Fe2O3 nanoparticles based osteopontin targeted MRI/optical probe 
for imaging of atherosclerotic plaque.87  
Development of combined nuclear/optical methods for imaging cancer has 
gained a lot of interest lately. Nuclear methods such as PET and SPECT have 
high sensitivity and are valuable tools for whole body imaging.88 Due to low 
spatial resolution, PET/SPECT may not be able to analyze the heterogeneity of 
the tissues at cellular levels. On the other hand, optical imaging is characterized 
by high spatial resolution, but can be disadvantageous owing to the low 
penetration depths. Therefore, integrating the two modalities will aid in imaging 
from the whole body down to cellular level and successive surgical intervention.88 
Although not usually preferred, but the use of a separate biomarker for PET and 
optical imaging respectively is feasible. The drawback of this strategy is that the 
bio distribution and pharmacokinetics of the two biomarkers will be different and 
the results from the two techniques will not be compatible.89 For instance, if a 
targeting peptide is conjugated to a fluorophore for application in fluorescence 
imaging in one case. But for application in PET imaging the same targeting 
peptide is radiolabeled with 18F through a prosthetic group, then the two imaging 
probes might have different in vivo pharmacokinetics owing to the different 
lipophilicity of the fluorophore and the 18F prosthetic group. In one literature report 
the in vivo pharmacokinetics of imaging probes comprised of the same targeting 
peptide, but with different radioisotopes (64Cu-DOTA-RGD, 18F-FB-RGD and 125I-
RGD), were compared.90 The 125I compound demonstrated higher tumour uptake 
as compared to the 18F and 64Cu imaging probes. 18F-FB-RGD showed rapid 
tumour clearance and higher retention in gall bladder and intestines. 64Cu-DOTA-
23 
 
 
RGD on the other hand, showed prolonged tumour retention and higher liver 
uptake. This demonstrates that the structural differences in the imaging entity can 
lead to different behaviour in vivo even though it uses the same targeting entity. 
Therefore, in order to have more accurate results, a hybrid marker with minimal 
structural modifications is needed. 
Fluorescent proteins e.g. green fluorescent protein or red fluorescent protein, 
fluorescent small molecule dyes, quantum dots are some of the reporter probes 
that can be used in a combined PET/optical imaging agent.64 These types of dual 
modality PET/optical imaging probes will aid in narrowing the gap between in 
vitro optical imaging and in vivo PET imaging as the results obtained from in vitro 
optical imaging can be carried forward to the next level i.e. in vivo PET imaging. 
The combined findings from both the modalities will provide more useful results.  
A recent example of the application of photo click chemistry for the synthesis of 
dual PET/optical imaging probe targeted for urokinase-type plasminogen 
activator receptor (uPAR) was demonstrated by Sun and coworkers.91 In this 
study, targeting peptide AE105 functionalized with alkene was photo clicked with 
68Ga-NOTA attached tetrazole. The diazole photo-click linker between the 
targeting peptide and PET chelator NOTA acted as the fluorescent entity for 
optical imaging. The results from fluorescent imaging depicted the specificity of 
this imaging probe for uPAR receptors on U87MG cells. This probe was used for 
fluorescence imaging of U87MG cells. Further this dual modality probe was also 
investigated in vivo PET imaging done using mice bearing U87MG xenografts. 
PET imaging results were consistent with the optical imaging results and 
confirmed the in vivo specificity of the probe for the receptor.  
Another 124I labeled pyropheophorbide derivative was synthesized and the 
specificity for benzodiazepine receptor (PBR) was demonstrated through in vitro 
optical imaging using RIF cells. Further a high tumour uptake was also 
demonstrated through in vivo PET imaging in mice injected with the RIF tumour.92  
The development of multimodal instrumentation has aided in the application of 
different modalities in conjunction, providing a better understanding of the 
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disease. Several multimodal imaging probes have been developed so far. But the 
field of multimodality imaging is still progressing rapidly necessitating the 
development of novel multimodality imaging probes with superior properties such 
as ease of synthesis, elimination of structural modifications and improved 
pharmacokinetic properties etc.     
 
1.7 Targeted Imaging Probes Based on Peptides 
The targeted imaging probes have the potential to show improved signal due to 
increased target uptake as compared to the traditional non-targeted imaging 
probes. Therefore, there is a need for designing targeted imaging probes that 
have high affinity, specificity for the target, high accumulation in the target tissue 
and fast clearance from the non-target tissues, high stability in vivo and are safe 
to use.93 Due to their advantages over small molecules and antibodies, peptides 
are considered ideal candidates for targeted imaging. Peptide based probes can 
contain up to 50 amino acids. Peptides possess favourable pharmacokinetics, 
such as fast clearance from blood and non-target tissues. They have good target 
tissue uptake, and low cellular toxicity.94 Moreover, the solid phase peptide 
synthesis approach allows easy, convenient, and reproducible synthesis of 
peptides. 
Recent development in the field of molecular biology has introduced several 
disease targets including peptide receptors e.g. somatostatin (SST), integrin, 
gastrin releasing peptide receptor (GRP-R), growth hormone secretagogue 
receptor (GHS-R), that are overexpressed in various carcinomas.95,96,97,98 Peptide 
based probes are constructed based on naturally occurring peptides. The 
peptides in their natural forms are prone to degradation due to peptidases and 
proteases found in vivo.99 In order to improve the in vivo stability, the peptide 
sequence that is essential for binding to the target is determined and the peptide 
is modified to increase the biological half-life. The peptides can be modified by 
introducing unnatural amino acids and D-amino acids which will not be easily 
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recognized by the enzymes in vivo.99 Furthermore, acetylation of the N-terminus 
or amidation of the C-terminus can also be carried out to prevent degradation by 
exopeptidases. Cyclization of the peptide can restrain the 3-D conformation and 
can also enhance the stability of the peptide. Much care should be taken while 
modifying the peptide sequence so as not to hamper its binding affinity for the 
target.100  For example, cyclic somatostatin peptides required extensive  structure 
activity analysis prior to determining a sequence that was effective for in vivo 
application.101 A stable cyclic somatostatin derivative was designed by the 
introduction of disulfide bridge between Cys3 and Cys14 residues.102 Another 
research group developed improved somatostatin analogue by the replacement 
of phenylalanine with unnatural amino acids such as difluorophenylalanine.103 
Several peptides have been labeled with appropriate imaging tags leading to the 
development of novel targeted imaging probes. Recently, a short peptide 
sequence CAQK that selectively binds to injured brain in mouse and humans was 
identified by in vivo phage display. CAQK coated nanoparticles containing 
silencing oligonucleotides helped in delivery of siRNA to injured brain tissue. This 
example demonstrated a useful methodology for the delivery of therapeutics to 
regions of acute brain injury.104  
 
1.8 Growth Hormone Secretagogue Receptor and Ghrelin 
Growth hormone secretagogue receptor (GHS-R) has been found to be highly 
expressed in variety of cancer types such as prostate cancer, breast cancer and 
ovarian cancer.98,105,106 Therefore, GHS-R1a has the potential to act as a 
promising target for cancer imaging. GHS-R1a is a G-protein coupled receptor 
comprising of 366 amino acids and has seven transmembrane domains. GHS-
R1a is present in the hypothalamus and pituitary of various mammalian 
species.107 The receptor is responsible for various physiological functions such as 
release of growth hormone, regulation of appetite and food intake, modulation of 
gastrointestinal motility and secretion, managing cell proliferation and survival, 
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regulation of pancreatic secretion and energy homeostasis.107 Two isoforms, 
GHS-R1a and GHS-R1b, have been discovered. GHS-R1a is considered to be 
the active form and has been the center of interest for researchers. 
Peptide ghrelin was discovered as the endogenous ligand for the receptor.108 
Ghrelin is a 28 amino acid peptide that was originally purified from the rat 
stomach.109 Figure 1.8 depicts the structure of ghrelin. It has a N-octanoyl 
modification at the third serine residue which is catalyzed by ghrelin O-acyl 
transferase. It is mainly produced in the stomach, but is also found in other 
tissues such as duodenum, lung, heart, pancreas, pituitary and hypothalamus. 
 
Figure 1.8 Structure of natural ghrelin (1-28). 
 
The structural activity relationship of ghrelin peptides has been a subject of 
research for many groups. The octanoyl modification at the Ser-3 position is 
necessary for the biological activities of ghrelin. The desoctanoyl version of the 
peptide has been found to be less potent than the original peptide.108  The 
replacement of Ser-3 with aromatic amino acid such as tryptophan did not affect 
the activity but the replacement with aliphatic amino acids hindered the activity 
drastically.110 
In another study Ser-3 was replaced by diaminopropionic acid (Dpr) and then 
coupled to octanoic acid, thereby substituting the ester linkage with amide 
linkage. The presence of this amide bond enhanced the potency of the peptide 
fragment.111 The ester linkage in the parent peptide is prone to enzymatic 
degradation by esterases and proteases therefore, the amide linkage plays a key 
role in the in vivo stability. The presence of a positive charge at the N-terminus is 
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essential for identification by GHS-R1a. Table 1.3 summarizes some of the 
modified ghrelin analogues and their literature IC50 values. The N-terminal 
pentapeptide was found to be the minimal sequence essential for activity.111 
 
Ghrelin analogue Residue 3 Reported IC50 
(nM) 
Ghrelin (1-28) Ser(CO(CH2)6CH3) 0.25 
Ghrelin (1-28) Ser(-) >10000 
Ghrelin (1-28) Ser(CO-CH3) >2000 
Ghrelin (1-28) Dpr(CO(CH2)6CH3) 0.42 
Ghrelin (1-18) Ser(CO(CH2)6CH3) 0.77 
Ghrelin (1-14) Ser(CO(CH2)6CH3) 7.1 
Ghrelin (1-5) Ser(CO(CH2)6CH3) 55 
Ghrelin (1-4) Ser(CO(CH2)6CH3) 889 
 
Table 1.3 Reported modified ghrelin analogues and their IC50 values.98  
 
Previously, in order to develop potential imaging probes for GHS-R1a, fluorine 
and rhenium containing ghrelin (1-5) and ghrelin (1-14) analogues were 
synthesized by modifying the octanoyl group at the Ser-3 position. The most 
promising of these analogues had IC50 values as low as 28.0 nM.112 Fluorescein-
ghrelin (1-18) analogue was synthesized by coupling the fluorescent dye 
fluorescein to C-terminus of ghrelin through a lysine residue that was added to 
the C-terminus.113 This demonstrated the possibility of modifying ghrelin (through 
lysine) at the C-terminus for conjugating it to a number of useful molecules. 
Recently, ghrelin agonists and antagonists were attached to bifunctional chelator 
1,4,7-triazacyclononane, 1-glutaric acid-4,7-acetic acid (NODAGA) which was 
radiolabeled with 68Ga and evaluated in vitro and the bio distribution was 
analyzed in rodents.114 These compounds demonstrated the ability to act as 
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potential PET imaging agents. Since ghrelin is a relatively new ligand for 
targeting GHS-R1a, a lot of research is still being conducted to develop ghrelin 
based imaging probes with increasing binding affinity for the receptor.  
 
 
1.9   Click Chemistry 
 
Figure1.9 Depiction of Cu(I)-catalyzed azide-alkyne click reaction. 
 
Click chemistry is one of the most common approach that is employed for 
attaching the imaging tag to the targeting entity e.g. for coupling a fluorophore to 
a targeting peptide. Owing to the orthogonal nature of these reactions the need 
for protecting the other functional groups can be eliminated. Click chemistry is 
defined as a reaction that involves coupling of molecular fragments in an 
effective, chemoselective, high yielding manner with little or no byproducts.115 
The most commonly studied among these types of reactions is the azide-alkyne 
[3+2] cycloaddition reaction often referred to as ‘click reaction’ (Figure 1.9). Other 
kinds of click reactions include thio-ene click reaction, Diels-Alder, and Michael 
addition reaction.116 The uncatalyzed azide-alkyne cycloaddition, also known as 
Huisgen reaction, requires high temperature and produces a mixture of 1,4 and 
1,5-disubstitution products.117 The Cu(I) catalyzed azide-alkyne cycloaddition was 
first described by Meldal118 and Sharpless119 independently. This reaction 
converts azides and terminal alkynes exclusively into 1,4-disubstituted 1,2,3-
triazoles. The synthesis of 1,5-disubstituted triazole starting from azide and 
terminal alkyne using ruthenium cyclopentadienyl complexes has also been 
described in literature.120  
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Several experimental conditions have been utilized for copper catalyzed azide-
alkyne cycloaddition reactions (CuAAC). Different copper catalysts that act as a 
source of Cu(I) species have been used. Cu(II) salt such as CuSO4 can be used 
as a pre-catalyst in the presence of reducing agent such as sodium ascorbate. 
Cu(I) compounds such as CuI or CuBr can also be used but the reaction has to 
be performed under anaerobic conditions so as to eliminate the chances of 
oxidation of Cu(I) to Cu(II).117  
While the use of ligands is not necessary for the click reaction to proceed, the 
presence of the ligand can certainly improve the rate of reaction as well as 
protect the Cu(I) species from oxidation.116 Polydentate N-donors and amines are 
the commonly employed accelerating ligands. Examples of some of the ligands 
used for CuAAC are tris(2-aminoethyl)amine (Tren),121 
tris(benzyltrizolylmethyl)amine (TBTA),122 bathophenanthroline disulphonate 
(BPDS),123 and pentamethyldiethylenetriamine (PMDETA).124  
The stability of natural peptides is an issue that could restrict their application as 
drug candidates and imaging agents. When an unnatural component is 
introduced in the peptide to enhance the stability, the resulting structure needs to 
still maintain the biological activity of the natural peptide. The structural studies of 
the amide bond and the triazole have shown similarities in terms of the size and 
the dipole moment and the replacement of amide by triazole does not disrupt the 
helical structure of the peptide.125 Therefore, triazole is considered as an isostere 
of the amide bond and can act as potential surrogate for the modification of the 
peptide. Bock and coworkers modified a naturally occurring tyrosinase inhibitor 
cyclo-[Pro-Val-Pro-Tyr] with triazole moiety which was shown to maintain the 
enzyme inhibitory acivity.126 Daumar and coworkers employed CuAAC reaction to 
attach a 18F prosthetic group to pHLIP peptide.127  
The use of CuAAC reactions can be ideal for several applications but can be 
problematic specifically for the applications involving biological systems as Cu(I) 
can be cytotoxic.128,129,130,131 Therefore, a lot of interest has been generated 
towards the development of copper free versions of azide-alkyne cycloaddition 
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reactions.50 Strain-promoted azide-alkyne cycloaddition reaction (SPAAC), is a 
copper free variant of the traditional CuAAC reaction.  
 
 
 
Figure 1.10 Depiction of strain promoted azide-alkyne cycloaddition reaction 
using cyclooctyne. 
 
The release of ring strain in a cycloalkyne, usually cyclooctyne, lowers the energy 
of activation for the cycloaddition step, increasing the efficacy of the reaction and 
eliminating the need of the Cu(I) catalyst. Subramanian and coworkers 
synthesized a novel EpCAM aptamer-fluorescent conjugate for imaging prostate 
cancer.132 Recently, 18F-labeled RGD analogues synthesized using SPAAC were 
evaluated as PET imaging probes.51 
 
1.10 Porphyrins 
Porphyrins are heterocyclic macromolecules composed of four pyrrole rings 
interconnected by methine bridges at the alpha C atoms.133 (Figure 1.11) This 
ring system possesses aromatic characteristics.  
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Figure 1.11 Structure of porphine. 
There are a variety of porphyrin and related compounds that are necessary for 
the proper functioning of biological processes that sustain life. For instance, 
porphyrin heme forms the fundamental part of hemoglobin that is responsible for 
oxygen transport. While porphyrin is a vital bio molecule, so is its metabolism.  
Failure in the metabolism of porphyrin can cause diseases such as porphyrias.134 
Other porphyrin related molecules are also found in the nature. These types of 
molecules are biologically very important. For example, chlorin systems such as 
chlorophyll are important for photosynthesis in plants. Bacteriochlorins such as 
bacteriochlorophylls are photosynthetic pigments found in certain bacteria. 
Chlorins and bacteriochlorins can be obtained by reduction of one or two double 
bonds respectively. Other porphyrin related compounds are phthalocyanines and 
naphthalocyanines which have one or two more benzo rings connected to pyrrole 
subunits respectively.  Structure of porphyrin and related compounds are shown 
in Figure 1.12.  
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Figure 1.12 Structure of porphyrin related compounds.   
                 
The central cavity of the porphyrin ring is suitable for chelating to a metal ion. A 
large number of examples can be seen in the literature where a vast range of 
metal ions can be chelated into the central cavity of the macrocycle (e.g. Mn, Cu, 
Zn, Pd, Pt, Fe, Ni, Co).135–140  
The electronic absorption spectrum of a typical free base porphyrin contains one 
intense Soret or B band around 400 nm and multiple weak Q bands between 
450-700 nm.133 The Soret band arises due to the transition from the ground 
singlet state to the second excited singlet state (S0           S2) and the Q-bands arise 
due to transition from the ground singlet state to the first excited singlet state    
(S0          S1).141 The number of Q-bands in the absorption spectra of free base 
porphyrins is reduced from four to two upon metalation. Another important 
characteristic of porphyrins is the tendency to exhibit fluorescence. In the case of 
certain metalloporphyrins that are coordinated to paramagnetic metal ions such 
as Cu(II) the fluorescence has been found to be quenched due to intersystem 
crossing to triplet state and non-radiative processes. Certain other 
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metalloporphyrins such as Pt(II)-porphyrins and porphyrins with heavy atoms 
such as halogens exhibit phosphorescence due to heavy atom effect that 
promotes intersystem crossing to triplet state.142 
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Figure 1.13    Representative (a) absorption spectrum (showing Soret and Q 
bands) and (b) emission spectrum for free base porphyrin (Protoporphyrin IX) 
(λex=405 nm). (UV absorption and emission spectrum were acquired in DMSO 
using Varian Carry 300 Bio UV-Vis spectrophotometer and Photon Technology 
International QM-4 SE spectrometer respectively). 
 
One of the features seen among porphyrins is pi-pi stacking between 2 or more 
units, which is a non-covalent attractive interaction between aromatic rings. 
These interactions between porphyrins result in aggregation in solution143 and will 
tend to lower their solubility. Aggregation can be followed and monitored by the 
changes in spectral properties. In general, aggregation leads to broadening and a 
blue shift of the Soret band.141  
The two important properties of porphyrins i.e. the ability to coordinate to metal 
ions and the tendency to exhibit fluorescence will be explored in this thesis for 
developing the porphyrins into PET/fluorescence imaging probes. 
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1.11 Summary 
This thesis focuses on the development of peptide based dual modality imaging 
probes as potential candidates for PET/fluorescence imaging. 
Chapters 2 and 3 focus on the application of porphyrins in the development of 
such probes. In chapter 2 the synthesis, in vitro fluorescence imaging and 68Ga 
labeling of PPIX-ghrelin based probe targeted for GHS-R1a is described. Here, 
PPIX was attached to the peptide ghrelin through a linker and then coordinated to 
Ga3+. Chapter 3 describes the design and attempted synthesis of an 
hematoporphyrin-bombesin based probe targeted for the GRP-R. The ability of 
hematoporphyrin to act as a chelator for gallium was demonstrated and 
hematoporphyrin was also radiolabeled with 68Ga.  
BF2-formazanates are new class of compounds that have interesting properties 
such as ease of synthesis, high molar extinction coefficient, good quantum yields, 
large Stokes shift and emission and absorption spectra that can be tuned based 
on structural modifications. Chapter 4 discusses the application of azide-alkyne 
click chemistry catalyzed by Cu(I) for the synthesis of fluorescent imaging probes 
based on BF2-formazanate-peptide conjugates. The uptake of these probes by 
the receptor targets GHS-R1a and GRP-R, is also shown through fluorescence 
microscopy.  
Chapter 5 presents the conclusions drawn from all the chapters and discusses 
the future directions of these research projects.   
 
1.12 References 
(1)  Pysz, M.; Gambhir, S. S.; Willmann, J. Clin Radiol. 2010, 65 (7), 500–516. 
(2)  Eckelman, W.; Glickson, J.; Levin, C.; Mathis, C.; Shulkin, B.; Sinusas, A.; 
Stabin, M.; Thakur, M.; Tsui, B.; Heertum, R. Van. J. Nucl. Med. 2007, 48 
(6), 19–21. 
(3)  More, L.; Peterson, T. E.; Manning, H. C. J. Nucl. Med. Technol. 2009, 37, 
35 
 
 
151–162. 
(4)  Willmann, J. K.; Bruggen, N. Van; Dinkelborg, L. M. Nat. Rev. Drug Discov. 
2008, 7, 591–607. 
(5)  Weissleder, R. Science  2006, 312, 1168–1172. 
(6)  Qin, Z.; Qin, Z. Mater. Technol. 2016, 7857, 1–6. 
(7)  Livieratos, L. In Radionuclide and Hybrid Bone Imaging; 2012; pp 345–359. 
(8)  Misri, R.; Saatchi, K.; Ng, S. S. W.; Kumar, U.; Häfeli, U. O. Nucl. Med. 
Biol. 2011, 38 (6), 885–896. 
(9)  Fuji, H.; Kosuda, S.; Suzuki, K.; Yorino, H.; Akita, S.; Negishi, H.; 
Nakamura, O.; Shitara, N.; Kubo, A. Ann. Nucl. Med. 1996, 10, 391–394. 
(10)  Grover, V. P. B.; Tognarelli, J. M.; Crossey, M. M. E.; Cox, I. J.; Taylor-
Robinson, S. D.; Mcphail, M. J. W. J. Clin. Exp. Hepatol. 2015, 5 (3), 246–
255. 
(11)  Blasiak, B.; Veggel, F. C. J. M.; Tomanek, B. J Nanomater. 2013, 2013. 
(12)  Zhou, Z.; Qutaish, M.; Han, Z.; Schur, R. M.; Liu, Y.; Wilson, D. L.; Lu, Z. 
Nat. Commun. 2015, 6, 1–11. 
(13)  Goldman, L. W. J. Nucl. Med. Technol. 2009, 35, 115–129. 
(14)  Zhu, Y.; Hong, H.; Xu, Z.; Li, Z.; Cai, W. Curr. Mol. Med. 2014, 13 (10), 
1549–1567. 
(15)  Yang, X.; Shi, C.; Tong, R.; Qian, W.; Zhau, H. E.; Wang, R.; Zhu, G.; 
Cheng, J.; Yang, V. W.; Cheng, T.; Henary, M.; Strekowski, L.; Chung, L. 
W. K. Clin. Cancer Res. 2010, 16, 2833–2844. 
(16)  Robertson, T. A.; Bunel, F.; Roberts, M. S. Cells 2013, 2, 591–606. 
(17)  Yi, X.; Yan, F.; Qin, W.; Wu, G.; Yang, X.; Shao, C.; Chung, L.; Yuan, J. 
Med. Sci. Monit. 2015, 21, 511–517. 
(18)  Cheon, J.; Lee, J. H. Acc. Chem. Res. 2008, 41 (12), 1630–1640. 
(19)  Chen, K.; Chen, X. Curr. Top. Med. Chem. 2013, 10 (12), 1227–1236. 
(20)  Agdeppa, E. D.; Spilker, M. E. AAPS J. 2009, 11 (2), 286–299. 
(21)  Manning, C.; Lander, A.; McKinley, E.; Mutic, N. J. J. Nucl. Med. 2008, 49, 
1401–1405. 
(22)  Zhu, A.; Lee, D.; Shim, H. Semin. Oncol. 2012, 38 (1), 55–69. 
(23)  Ametamey, S. M.; Honer, M.; Schubiger, P. A. Chem. Rev. 2008, 108, 
1501–1516. 
(24)  Nedrow, J. R.; Anderson, C. J. In Encyclopedia of Inorganic and 
36 
 
 
Bioinorganic Chemistry; 2016; pp 1–11. 
(25)  Smith, G. E.; Sladen, H. L.; Biagini, S. C. G.; Blower, P. J. Dalt. Trans. 
2011, 40 (23), 6196–6205. 
(26)  Tredwell, M.; Gouverneur, V. Angew. Chemie-Int. Ed. 2012, 51 (46), 
11426–11437. 
(27)  Wieringen, J. V.; Shalgunov, V.; Janssen, H. M.; Fransen, P. M.; Janssen, 
A. G. M.; Michel, M. C.; Booij, J.; Elsinga, P. H. J. Med. Chem. 2014, 57, 
391–410. 
(28)  Lu, S.; Lepore, S. D.; Li, S. Y.; Mondal, D.; Cohn, P. C.; Bhunia, A. K.; Pike, 
V. W. J. Org. Chem. 2010, 74 (15), 5290–5296. 
(29)  Jalilian, A. R.; Afarideh, H., Najafi, R. J. Pharm. Sci. 2000, 3 (1), 1–7. 
(30)  Wook, D.; Seong, Y.; Yoon, D. Nuc. Med. Biol. 2003, 30, 345–350. 
(31)  Rodnick, M. E.; Brooks, A. F.; Hockley, B. G.; Henderson, B. D.; Scott, P. J. 
Appl. Radiat. Isot. 2013, 78, 26–32. 
(32)  Jacobson, O.; Zhu, L.; Ma, Y.; Weiss, I. D.; Sun, X.; Niu, G.; Dale, O.; 
Chen, X. Bioconjugate Chem. 2012, 22 (3), 422–428. 
(33)  Khan, N. H.; Lee, B. C.; Lee, S. J. Label Comp. Radiopharm. 2002, 45, 
1045–1053. 
(34)  Chen, C. C.; Whatley, M.; Ling, A.; Adams, K. T.; Pacak, K.; Ph, D.; Sc, D. 
Clin. Endocrinol. 2010, 71 (1), 11–17. 
(35)  Plenevaux, A.; Hermanne, J. P. J. Cereb. Blood Flow Metab. 1995, 15, 
787–797. 
(36)  Liu, Z.; Radtke, M. A.; Wong, M. Q.; Lin, K.; Yapp, D. T.; Perrin, D. M. 
Bioconjugate Chem. 2014, 25, 1951–1962. 
(37)  Liu, S.; Lin, T. P.; Li, D.; Leamer, L.; Shan, H.; Li, Z.; Gabbaï, F. P.; Conti, 
P. S. Theranostics 2013, 3 (3), 181–189. 
(38)  Ting, R.; Adam, M. J.; Ruth, T. J.; Perrin, D. M. J. Am. Chem. Soc. 2005, 
127 (38), 13094–13095. 
(39)  Coenen, H. H. In PET Chemistry; 2007; pp 15–50. 
(40)  Speranza, M.; Shiue, C.; Wolf, A.; Wilbur, D.; Angelini, G. J. Fluor. Chem. 
1985, 30, 97–101. 
(41)  Stephenson, N. A.; Holland, J. P.; Kassenbrock, A.; Yokell, D. L.; Livni, E.; 
Liang, S. H.; Vasdev, N. J. Nucl. Med. 2015, 56, 489–492. 
(42)  Kachur, A. V.; Arroyo, A. D.; Popov, A. V; Saylor, S. J.; Delikatny, J. J. 
Fluor. Chem. 2015, 178, 136–141. 
(43)  Jacobson, O.; Kiesewetter, D. O.; Chen, X. Bioconjugate Chem. 2015, 26, 
37 
 
 
1–18. 
(44)  Jacobson, O.; Zhu, L.; Ma, Y.; Weiss, I. D.; Sun, X.; Niu, G.; Kiesewetter, 
D. O.; Chen, X. Bioconjugate Chem. 2011, 422–428. 
(45)  Becaud, J.; Mu, L.; Schubiger, P. A.; Ametamey, S. M.; Graham, K.; 
Stellfeld, T.; Lehmann, L.; Borkowski, S.; Berndorff, D.; Dinkelborg, L.; 
Srinivasan, A. Bioconjugate Chem. 2009, 20, 2254–2261. 
(46)  Mcbride, W. J.; Sharkey, R. M.; Karacay, H.; Souza, C. A. D.; Rossi, E. A.; 
Laverman, P.; Chang, C.; Boerman, O. C.; Goldenberg, D. M. J. Nucl. Med. 
2009, 50, 991–999. 
(47)  Löser, R.; Fischer, S.; Hiller, A.; Köckerling, M.; Funke, U.; Maisonial, A.; 
Brust, P.; Steinbach, J. Beilstein J. Org. Chem. 2013, 9, 1002–1011. 
(48)  Moore, T. M.; Akula, M. R.; Kabalka, G. W. Nat. Sci. 2016, 8, 1–7. 
(49)  Ramenda, T.; Steinbach, J.; Wuest, F. Amino Acids 2013, 44, 1167–1180. 
(50)  Jewett, J.; Bertozzi, C. Chem. Soc. Rev 2008, 23 (1), 1–7. 
(51)  Kim, H. L.; Sachin, K.; Jeong, H. J.; Choi, W.; Lee, H. S.; Kim, D. W. ACS 
Med. Chem. Lett. 2015, 6, 402–407. 
(52)  Banerjee, S.; Pomper, M. Appl. Radiat. Isot. 2013, 0, 2–13. 
(53)  Velikyan, I. Molecules 2015, 20 (7), 12913–12943. 
(54)  Brechbiel, M. W. J. Nucl. Med. Imaging 2009, 52 (2), 166–173. 
(55)  Hofmann, M.; Maecke, H.; Börner, A. R.; Weckesser, E.; Schöffski, P.; Oei, 
M. L.; Schumacher, J. Eur. J. Nucl. Med. 2001, 28 (12), 1751–1757. 
(56)  Wild, D.; Schmitt, J. S.; Ginj, M.; Mäcke, H. R.; Bernard, B. F.; Krenning, E.; 
Jong, M. De. E. J. Nucl. Med. Mol. Imaging 2003, 30 (10), 1338–1347. 
(57)  Hofman, M. S.; Hicks, R. J. Radiographics 1983, 111 (1), 500–516. 
(58)  Richter, S.; Wuest, M.; Bergman, C. N.; Krieger, S.; Rogers, B. E.; Wuest, 
F. Mol. Pharm. 2016, 13, 1347–1357. 
(59)  Beylergil, V.; Morris, P. G.; Smith-jones, P. M.; Modi, S.; Solit, D.; Hudis, C. 
A.; Lu, Y.; Donoghue, J. O.; Lyashchenko, S. K.; Carrasquillo, J. A.; 
Larson, S. M.; Akhurst, T. J. Nucl. Med. Commun. 2013, 34, 1157–1165. 
(60)  Luker, G. D.; Luker, K. E. J. Nucl. Med. 2008, 49, 1–4. 
(61)  Hong, G.; Antaris, A. L.; Dai, H. Nat. Biomed. Eng. 2017, 1–22. 
(62)  Jacques, S. L. Phys. Med. Biol. 2013, 58, 37–61. 
(63)  Weissleder, R.; Ntziachristos, V. Nat. Med. 2003, 9 (1), 123–128. 
(64)  Hellebust, A. Nanomedicine 2012, 7, 429–445. 
38 
 
 
(65)  Sujatha, V.; Sridhar, B.; Krishnamurthy, S.; Kumar, K. S. V.; Kumar, K. S.; 
Gautam, P. I. J. Anal. Chem. 2010, 2010, 3–6. 
(66)  Lobo, A. C. S.; Silva, A. D.; Tome, V. A.; Pinto, S. M. A.; Silva, E. F. F. J. 
Med. Chem. 2016, 59, 4688–4696. 
(67)  Hapuarachchige, S.; Montano, G.; Ramesh, C.; Rodriguez, D.; Henson, L. 
H.; Williams, C. C.; Kadavakkollu, S.; Johnson, D. L.; Shuster, C. B.; 
Arterburn, J. B. J. Am. Chem. Soc. 2011, 133 (17), 6780–6790. 
(68)  Luo, S.; Zhang, E.; Su, Y.; Cheng, T.; Shi, C. Biomaterials 2011, 32 (29), 
7127–7138. 
(69)  Holt, D.; Okusanya, O.; Judy, R.; Venegas, O.; Jiang, J.; Dejesus, E.; 
Eruslanov, E.; Quatromoni, J.; Bhojnagarwala, P.; Deshpande, C.; Albelda, 
S.; Nie, S.; Singhal, S. PLoS One 2014, 9 (7). 
(70)  Chi, C.; Ye, J.; Ding, H.; He, D.; Huang, W.; Zhang, G.; Tian, J. PLoS One 
2013, 8 (12), 24–28. 
(71)  Antaris, A. L.; Chen, H.; Cheng, K.; Sun, Y.; Hong, G.; Qu, C.; Diao, S.; 
Deng, Z.; Hu, X.; Zhang, B.; Zhang, X.; Yaghi, O. K.; Alamparambil, Z. R.; 
Hong, X.; Cheng, Z.; Dai, H. Nat. Mater. 2016, 15, 235–243. 
(72)  Qian, C.; Zhu, S.; Feng, P.; Chen, Y.; Yu, J.; Tang, X.; Liu, Y.; Shen, Q. 
ACS Appl. Mater. Interfaces 2015, 7, 4–12. 
(73)  Berg, K.; Selbo, P.; Weyergang, A.; Dietze, L.; Prasmickaite, L.; Bonsted, 
A.; Engesaeter, B.; Angell-Petersen, E.; Warloe, T.; Frandsen, N.; Hogset, 
A. J. Microsc. 2005, 218, 133–147. 
(74)  Rosenthal, E. L.; Warram, J. M.; Boer, E. De; Chung, T. K.; Korb, M. L.; 
Brandwein-gensler, M.; Strong, T. V; Schmalbach, C. E.; Morlandt, A. B.; 
Agarwal, G. Clin. Cancer Res. 2016, 21 (16), 3658–3666. 
(75)  Hong, G.; Lee, J. C.; Robinson, J. T.; Raaz, U.; Xie, L.; Huang, N. F.; 
Cooke, J. P. Nat. Med. 2012, 18 (12), 1841–1846. 
(76)  Louie, A. Chem. Rev. 2010, 110 (5), 3146–3195. 
(77)  Kang, P.; Liao, M.; Wester, M. R.; Leeder, J. S.; Pearce, R. E. Semin. Nucl. 
Med. 2010, 36 (3), 490–499. 
(78)  Scanner, W. P. E. T.; Delso, G.; Fu, S.; Ladebeck, R.; Ganter, C.; Nekolla, 
S. G.; Schwaiger, M.; Ziegler, S. I. J. Nucl. Med. 2011, 52 (12), 1914–1923. 
(79)  Martí-Bonmatí, L.; Sopena, R.; Bartumeus, P.; Sopena, P. Contrast Media 
Mol. Imaging 2010, 5 (4), 180–189. 
(80)  Vandenberghe, S.; Marsden, P. Phys. Med. Biol. 2015, 115, 115–154. 
(81)  Yamamoto, S.; Watabe, H.; Kanai, Y.; Watabe, T.; Aoki, M.; Sugiyama, E.; 
Kato, K.; Hatazawa, J.; Introduction, I. Med. Phys. 2012, 39 (11), 6660–
39 
 
 
6671. 
(82)  Pichler, B. J.; Judenhofer, M. S.; Catana, C.; Walton, J. H.; Kneilling, M.; 
Nutt, R. E.; Siegel, S. B.; Claussen, C. D.; Cherry, S. R. J. Nucl. Med. 
2006, 47, 639–648. 
(83)  Thorek, D. L. J.; Ulmert, D.; Diop, N. M.; Lupu, M. E.; Doran, M. G.; Huang, 
R.; Abou, D. S.; Larson, S. M.; Grimm, J. Nat. Commun. 2014, 5, 3097. 
(84)  Greguric, I.; Kim, B. J.; Pellegrini, P. A.; Bickley, S. A.; Tanudji, M. R.; 
Jones, S. K.; Hawkett, B. S.; Pham, B. T. T. I. J. Nano. Med. 2017, 12, 
899–909. 
(85)  Mulder, W. J. M.; Koole, R.; Brandwijk, R. J.; Storm, G.; Chin, P. T. K.; 
Strijkers, G. J. Nano. Letts. 2006, 6, 1–6. 
(86)  Huang, Y.; Hu, L.; Zhang, T.; Zhong, H.; Zhou, J.; Liu, Z.; Wang, H. Sci. 
Rep. 2013, 3, 1–7. 
(87)  Qiao, H.; Wang, Y.; Zhang, R.; Gao, Q.; Liang, X. Biomaterials 2017, 112, 
336–345. 
(88)  Nahrendorf, M.; Keliher, E.; Marinelli, B.; Waterman, P.; Feruglio, P. F.; 
Fexon, L.; Pivovarov, M.; Swirski, F. K.; Pittet, M. J.; Vinegoni, C.; 
Weissleder, R. PNAS 2010, 107, 7910–7915. 
(89)  Seibold, U.; Wängler, B.; Schirrmacher, R.; Wängler, C. BioMed Res. Int. 
2014, 2014, 1–13. 
(90)  Chen, X.; Park, R.; Tohme, M.; Shahinian, A. H.; Bading, J. R.; Conti, P. S. 
Bioconjugate Chem. 2004, 15, 41–49. 
(91)  Sun, L.; Ding, J.; Xing, W.; Gai, Y.; Sheng, J.; Zeng, D. Bioconjugate 
Chem. 2016, 27, 1200–1204. 
(92)  Pandey, S. K.; Gryshuk, A. L.; Sajjad, M.; Zheng, X.; Chen, Y.; Abouzeid, 
M. M.; Morgan, J.; Charamisinau, I.; Nabi, H. A.; Oseroff, A.; Pandey, R. K. 
J. Med. Chem. 2005, 48 (20), 6286–6295. 
(93)  Lee, S.; Xie, J.; Chen, X. Biochem. 2011, 49 (7), 1364–1376. 
(94)  Chen, K.; Conti, P. S. Adv. Drug Deliv. Rev. 2010, 62 (11), 1005–1022. 
(95)  Wängberg, B.; Nllsson, O.; Johanson, V.; Kölby, L.; Forssell-Aronsson, E.; 
Andersson, P.; Fjälling, M.; Tisell, L. E.; Ahlman, H. Oncologist 1997, 2 (1), 
50–58. 
(96)  Desgrosellier, J. S.; Cheresh, D. A. Nat. Rev. Cancer 2010, 10 (12), 890–
890. 
(97)  Sun, B.; Halmos, G.; Schally, A. V; Wang, X.; Martinez, M. Prostate 2000, 
303, 295–303. 
(98)  Yeh, A. H.; Jeffery, P. L.; Duncan, R. P.; Herington, A. C.; Chopin, L. K. 
40 
 
 
Clin. Cancer Res. 2005, 11 (23), 8295–8303. 
(99)  Charron, C. L.; Hickey, J. L.; Nsiama, T. K.; Cruickshank, D. R.; Turnbull, 
W. L.; Luyt, L. G. Nat. Prod. Rep. 2016, 33 (6), 761–800. 
(100)  Charlton, C. L. The Design and Synthesis of Ghrelin Analogues as Non‐
Invasive GHS‐R1a Imaging Probes, 2016. 
(101)  Herder, W.; Lely, A.; Lamberts, S. Postgr. Med. J 1996, 408, 403–408. 
(102)  Tornesello, A. L.; Buonaguro, L.; Tornesello, M.; Buonaguro, F. Molecules 
2017, 22, 1–21. 
(103)  Martín-gago, P.; Rol, Á.; Todorovski, T.; Aragón, E.; Martin-malpartid, P. 
Sci. Rep. 2016, 6, 1–9. 
(104)  Mann, A. P.; Scodeller, P.; Hussain, S.; Joo, J.; Kwon, E.; Braun, G. B.; 
She, Z.; Kotamraju, V. R.; Ranscht, B.; Krajewski, S. Nat. Commun. 2016, 
7, 1–11. 
(105)  Jeffery, P. L.; Murray, R. E.; Yeh, A. H.; McNamara, J. F.; Duncan, R. P.; 
Francis, G. D.; Herington, A. C.; Chopin, L. K. Endocr. Relat. Cancer 2005, 
12 (4), 839–850. 
(106)  Gaytan, F.; Morales, C.; Barreiro, M. L.; Jeffery, P.; Chopin, L. K.; 
Herington, A. C.; Casanueva, F. F.; Aguilar, E.; Dieguez, C.; Tena-
Sempere, M. J. Clin. Endocrinol. Metab. 2005, 90 (3), 1798–1804. 
(107)  Yin, Y.; Li, Y.; Zhang, W. Int. J. Mol. Sci. 2014, 15 (3), 4837–4855. 
(108)  Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K. 
Nature 1999, 402 (6762), 656–660. 
(109)  Kojima, M.; Kangawa, K. Horm. Res. 2001, 56, 93–97. 
(110)  Delporte, C. Scientifica 2013, 2013, 1–13. 
(111)  Bednarek, M. A.; Feighner, S. D.; Pong, S.; Mckee, K. K.; Hreniuk, D. L.; 
Silva, M. V; Warren, V. A.; Howard, A. D.; Ploeg, L. H. Y. Van Der; Heck, J. 
V. J. Med. Chem. 2000, 43, 4370–4376. 
(112)  Rosita, D.; Dewit, M. A.; Luyt, L. G. J. Med. Chem.  2009, 52, 2196–2203. 
(113)  Mcgirr, R.; Mcfarland, M. S.; Mctavish, J.; Luyt, L. G.; Dhanvantari, S. 
Regul. Pept. 2011, 172 (1–3), 69–76. 
(114)  Chollet, C.; Bergmann, R.; Pietzsch, J.; Beck-sickinger, A. G. Bioconjugate 
Chem. 2012, 23, 771–784. 
(115)  Verma, S. Int. J. Drug Dev. Res. 2015, 7 (4), 18–26. 
(116)  Liang, L.; Astruc, D. Coord. Chem. Rev. 2011, 255, 2933–2945. 
(117)  Finn, P. M. G.; Fokin, V.; Hein, J. E.; Fokin, V. V. Chem. Soc. Rev. 2010, 
39 (4), 1302–1315. 
41 
 
 
(118)  Tornoe, C. W.; Christensen, C.; Meldal, M. J. Org. Chem. 2002, 67 (I), 
3057–3064. 
(119)  Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. 
Chem. Int. Ed. 2002, 41 (14), 2596–2599. 
(120)  Zhang, L.; Chen, X.; Xue, P.; Sun, H. H. Y.; Williams, I. D.; Sharpless, K. 
B.; Fokin, V. V.; Jia, G. J. Am. Chem. Soc. 2005, 127, 15998–15999. 
(121)  Candelon, N.; Laste, D.; Diallo, A. K.; Aranzaes, J. R.; Astruc, D.; Vincent, 
J. Chem. Commun. 2008, 1, 741–743. 
(122)  Movahedi, A.; Moth-poulsen, K.; Eklöf, J.; Nydén, M.; Kann, N. React. 
Funct. Polym. 2014, 82, 1–8. 
(123)  Gill, H. S.; Marik, J. Nat. Protoc. 2011, 6 (11), 1718–1725. 
(124)  Croutxé-barghorn, C. Polym. Chem. 2016, 7 (48), 7383–7390. 
(125)  Horne, W.; Yadav, M.; Stout, C.; Ghadiri, M. J. Am. Chem. Soc. 2007, 126 
(47), 15366–15367. 
(126)  Bock, V. D.; Speijer, D.; Maarseveen, J. H. Van. Org. Biomol. Chem. 2007, 
5, 971–975. 
(127)  Daumar, P.; Wanger-Baumann, C. A.; Pillarsetty, N.; Fabrizio, L.; Carlin, S.; 
Andreev, O.; Reshetnyak, Y.; Lewis, J. S. Bioconjugate Chem. 2013, 23 
(8), 1557–1566. 
(128)  Jewett, J. C.; Sletten, E. M.; Bertozzi, C. R. J. Am. Chem. Soc. 132, 2010, 
3688–3690. 
(129)  Wolbers, F.; Braak, P.; Gac, S. Le; Luttge, R.; Andersson, H.; Vermes, I.; 
Berg, A. Van Den. Electrophoresis 27, 2006, 5073–5080. 
(130)  Tchounwou, P. B.; Newsome, C.; Williams, J.; Glass, K. Met. Ions Biol. 
Med. 2011, 10, 285–290. 
(131)  Gaetke, L. M.; Kuang, C. Toxicology 2003, 189, 147–163. 
(132)  Subramanian, N.; Sreemanthula, J. B.; Balaji, B.; Kanwar, J. R.; Biswas, J.; 
Krishnakumar, S. Chem. Commun. 2014, 50 (80), 11810–11813. 
(133)  Huang, H.; Song, W.; Rieffel, J.; Lovell, J. F. Front. Phys. 2015, 3 (23), 1–
15. 
(134)  Dailey, H. A.; Meissner, P. N. Cold Spring Harb. Perspect. Med. 2013, 3 
(4), 1–18. 
(135)  Cheng, W.; Haedicke, I. E.; Nofiele, J.; Martinez, F.; Beera, K.; Scholl, T. J.; 
Cheng, H. L. M.; Zhang, X. A. J. Med. Chem. 2014, 57 (2), 516–520. 
(136)  Mammana, A.; Asakawa, T.; Bitsch-Jensen, K.; Wolfe, A.; Chaturantabut, 
S.; Otani, Y.; Li, X.; Li, Z.; Nakanishi, K.; Balaz, M.; Ellestad, G. A.; Berova, 
42 
 
 
N. Bioorganic Med. Chem. 2008, 16 (13), 6544–6551. 
(137)  Borisov, S. M.; Zenkl, G.; Klimant, I. ACS Appl. Mater. Interfaces 2010, 2 
(2), 366–374. 
(138)  Sun, Z. C.; She, Y. Bin; Zhou, Y.; Song, X. F.; Li, K. Molecules 2011, 16 
(4), 2960–2970. 
(139)  Sharma, R. K.; Ahuja, G.; Sidhwani, I. T. Green Chem. Lett. Rev. 2009, 2 
(2), 101–105. 
(140)  Kumar, A.; Maji, S.; Dubey, P.; Abhilash, G. J.; Pandey, S.; Sarkar, S. 
Tetrahedron Lett. 2007, 48 (41), 7287–7290. 
(141)  Giovannetti, R. In Macro To Nano Spectroscopy; 2012; pp 87–109. 
(142)  Gouterman, M.; Gamal, K. J. Mol. Spectrosc. 1974, 100, 88–100. 
(143)  Hunter, C. A.; Sanders, J. K. M. J. Am. Chem. Soc. 1990, 112 (14), 5525–
5534. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                         
 
43 
 
 
                                        Chapter 2 
 
2 The Development of a Ga-Ghrelin-Protoporphyrin IX 
Analogue for Imaging of GHSR-1a Receptor 
 
2.1 Introduction 
Imaging technologies have experienced a tremendous growth in clinical 
applications over the last few years. A number of imaging technologies are 
complementary and their advantages can be coupled together to afford a better 
depiction of tumours and their environment.1 The application of a single unique 
probe for multimodality imaging is not mandatory for all purposes, but it certainly 
has benefits. A single probe will demonstrate the same pharmacokinetics and 
colocalization of signal for the individual imaging modalities.2 This becomes more 
evident in clinical diagnostics, where the modalities with high sensitivity typically 
have low resolution, such as PET and the modalities possessing high resolution 
have low sensitivity such as MRI. Therefore, bringing together PET and MRI can 
lead to a more accurate diagnosis. 
The first stage of multimodal imaging was the development of software tools for 
image co-registration, the second stage is the continuing development of 
multimodality instrumentation.  The final stage is the development of appropriate 
multimodality imaging agents.3  A variety of biomolecules provide suitable ground 
for the construction of imaging agents that can afford contrast for multiple 
imaging modalities. For instance, the use of a fluorescent multimodality agent for 
imaging in vitro, followed by the utilization of the same agent to conduct 
PET/SPECT/MRI in larger animals or patients.4 
Since the introduction of this concept, research has shown a significant 
advancement in the design of multimodal agents which includes the development 
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of novel chelators, superior fluorophores and more in vivo compatible modes of 
bio conjugation.5  One approach for the synthesis of multimodal agents is to 
couple all imaging tags to a central scaffold, but this method may necessitate a 
great deal of structural modifications from the single agent.6 Another approach is 
to use the same central molecule armed with various imaging tags but 
synthesized exclusively for different imaging modalities.7 The shortcoming of this 
method is the structural variance that could not only modify the characteristics of 
the central molecule but may also generate incongruity in results obtained from 
various imaging modalities. Therefore, there is a need for having a single imaging 
agent that would retain the characteristics of the central molecule and at the 
same time would reduce the incongruity in imaging results from various 
modalities. 
In recent times, a lot of interest has been generated in the development of 
porphyrins and associated compounds as useful agents for medical imaging and 
therapy owing to the suitable optical properties associated with them.8                                                              
Several metalloporphyrins have been found to be successful in affording imaging 
contrast for near infrared fluorescence (NIR),9 and magnetic resonance imaging 
(MRI).10 Due to their high singlet oxygen quantum yields, Pt(II) and Pd(II) 
coordinated porphyrins form appealing candidates for photodyanamic therapy 
(PDT).11,12 Metal ions like Mn(III) coordinated to porphyrins have been studied as 
MRI contrast agents.13  
Protoporphyrin IX (PPIX) is one of the most common naturally occurring 
porphyrin. It is the iron free form of hemin, which can be synthesized from 
fundamental precursors such as glycine and succinyl coenzyme A or glutamate.14 
PPIX has a large number of applications in medicine but its most practical 
application is as a photosensitizer in PDT.15,16 PDT involves the introduction of 
tumour localizing photosensitizer (possessing minimum dark toxicity) into the 
body. Upon maximum photosensitizer uptake, the tumour is irradiated with light of 
appropriate wavelength. This eventually generates singlet oxygen which is 
considered to be responsible for the irreversible destruction of the tumour.17,18 
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Photofrin which is a hematoporphyrin (HP) derivative has been approved by the 
FDA as a sensitizer for PDT.19 Other first generation porphyrin based 
photosensitizers such as Photogem and Photosan-3 have been approved for 
clinical use in Russia and Brazil.20,21  5-Aminolaevulinic acid (ALA) generates 
endogenous photosensitizer PPIX through the heme biosynthetic pathway, upon 
being internalized by the cells.14,22 Porphyrin complexes labeled with positron 
emitting radioisotopes have been used in analysing the efficiency of targeted 
PDT agents. For example, a 18F labeled porphyrin complex has been evaluated 
as a potential PDT/PET single theranostic agent for cancer.23 However, this 
strategy is difficult to execute due to multiple synthetic steps involved. To this 
point the ability of porphyrins to chelate metal ions becomes instrumental in 
developing PET imaging agents. Recently, a 64Cu-PPIX-bombesin peptide analog 
has been evaluated as a targeted PET imaging and PDT agent.24 In their 
research PPIX was used as a photosensitizer and the bombesin peptide was 
used for targeting gastrin releasing peptide receptor. The 64Cu-PPIX-PEG6-BBN 
analogue was studied as a targeted PDT agent and evaluated for cellular uptake 
in a PC-3 cell line and for PET imaging in the PC-3 tumour bearing mice. 
Taking into account the two most interesting features of porphyrins i.e. 
fluorescence and metal coordinating capability, this study will focus on the 
development of porphyrin-peptide based PET/fluorescence imaging agents. The 
porphyrin used for this study will be the previously discussed PPIX. Since PPIX 
is fluorescent on its own and at the same time can coordinate a metal ion, any 
additional structural alterations are not needed. This not only preserves the 
innate properties of the porphyrin macrocycle but also decreases any disparity 
between the two imaging techniques.  
The usefulness of a solid phase strategy for functionalization of porphyrins has 
been reported in the literature e.g. the synthesis of 5,15-diphenylporphyrin using 
2-chlorotrityl chloride resin.16 Also reported is a scaffold for the synthesis of 
photoactive libraries by attaching 5,15-dibromo-10-(4-hydroxyphenyl)-20-(4-
nitrophenyl) porphyrin to brominated Wang resin.17 Wang resin was utilized as a 
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solid support for the synthesis of Fmoc-protected amine derivatives of PPIX.18 
These results showed that porphyrins are amenable to resin loading and that a 
solid phase strategy can be utilized for synthesizing PPIX-peptide conjugates for 
this project. 
Detection and treatment of cancer can be achieved using imaging agents 
possessing high selectivity for the biological target.5 For this purpose, the imaging 
tag is coupled to a targeting entity that is specific for a receptor which is highly 
expressed in cancer. 
The PET isotope used for this study was 68Ga. The production of 68Ga is by 
means of a generator from parent isotope 68Ge. The scope of applications for 
68Ga based agents has expanded over the past few years. This can be attributed 
to the advantageous physical properties of 68Ga, such as E βmax of 1.8 MeV, 89 % 
positron emission along with a half life of 68 min. The simplicity, availability and 
lower capital cost of 68Ge/68Ga generators has made it more desired for 
research.25 Small scale generators have come a long way since their introduction 
which in turn has made 68Ga available in facilities that do not possess an on-site 
cyclotron.  
The introduction of 68Ga for PET imaging, has a considerable role to play in 
current and future clinical practice. The most commonly used chelator for 68Ga is 
DOTA. In 2001 Henze and coworkers reported the first breakthrough clinical 
work, demonstrating 68Ga-DOTATOC PET imaging in patients with 
meningiomas.26 A lot of research has already been done with 68Ga-DOTA-peptide 
conjugates for imaging different receptors e.g. 68Ga-DOTA-Tyr1-Phe3-Octreotide 
(TOC), 68Ga-DOTA-NaI3-Octreotide (NOC), 68Ga-DOTA-Tyr3-Octreotide (TATE) 
are the three main 68Ga-DOTA-peptide that are currently available for imaging 
somatostatin receptors.27 More recently interest has been generated in evaluation 
of some other chelators for 68Ga including 1,4,7-triazacyclononane-1,4,7-
trisacetic acid (NOTA),28 1,4,7-triazacyclononane, 1-glutaric acid-4,7-acetic acid 
(NODAGA) 29 N,N’-di(2-hydroxybenzyl)ethylenediamine-N,N’-diacetic acid 
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(HBED),30 etc. Another class of molecules that can serve as chelators for 68Ga 
are porphyrins. 
 There are a few reports illustrating the development of 68Ga-porphyrin based 
imaging probes. 68Ga labeled 5,10,15,20-tetrakis(pentafluoro-13 phenyl) 
porphyrin has been synthesized as a potential PET imaging probe. The complex 
was found to be stable in human serum for 5 hours.31 In another report, 68Ga 
labeled 5,10,15,20-tetra(4-methylpyridyl) porphyrin was synthesized and the 
biodistribution studies showed high tumour uptake within 30 minutes post 
injection of the radiotracer.32 Recently, a bimetallic gallium-porphyrin-ruthenium 
bipyridine complex with lysosome specific subcellular localization was 
synthesized.33 
Ga-protoporphyrin IX complex has been previously synthesized and studied as a 
soluble diamagnetic model for malaria pigment by Stillman and coworkers.34 In 
another study, Ga-PPIX-peptide compounds were synthesized where the 
tripeptide sequence RGD was reported as the targeting entity.35 The tripeptide 
RGD was selected as a targeting entity as it has been reported to have high 
affinity for αvβ3 integrin36 which is over expressed in ovarian37 and breast 
cancers.38 
In the present study, the peptide ghrelin is selected as the targeting peptide.  
Ghrelin has a unique hydrophobic n-octanoyl modification in the Ser-3 residue 
that has been found to be essential to bind to the ghrelin receptor, also known as 
the growth hormone secretagogue receptor 1a (GHS-R1a).39 GHS-R1a is a cell 
surface receptor having seven trans-membrane domain. GHS-R1a is 
overexpressed in different tumours such as prostate,40 breast41 and ovarian 
cancer.42 Therefore, GHS-R1a can play a vital role in non-invasively 
differentiating the cancer tissue from the normal tissue over a range of cancers. 
Natural ghrelin (1-28) has a strong affinity for GHSR-1a, yet suffers from in vivo 
instability, which can be overcome through truncation and replacing the amino 
acids in natural ghrelin with unnatural amino acids.43 Structure activity studies 
have found that the N-terminus is essential for binding to the receptor, therefore 
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modifications can only be done at C-terminus. It was also found that the N-
terminal pentapeptide was sufficient for binding to the receptor.39 To improve the 
binding affinity various truncated versions of ghrelin have been studied. The 
ghrelin analogue used for this study is [Dpr3(octanoyl)Tyr8]-ghrelin-(1-8), which 
has been earlier shown to have IC50 of 65.0nM.44  
The goal of this project is to synthesize a 69/71Ga-ghrelin-PPIX analogue as a 
probe for in vitro fluorescence imaging and furthermore, to radiolabel ghrelin-
PPIX with 68Ga to develop the analogous PET agent for imaging of GHSR-1a in 
prostate carcinomas. 
 
2.2 Results and Discussion 
The design of the imaging probe consists of PPIX as the fluorescent tag/metal 
chelator, connected to the peptide targeting entity through a linker. Since the N-
terminus of ghrelin is important for binding to the receptor, PPIX was attached to 
ghrelin at the C-terminus, leaving the N-terminus free for binding. Due to the 
poor solubility of porphyrins a short polar linker is used to attach PPIX to the C-
terminus of ghrelin peptide.  This feature will enhance the solubility of PPIX while 
serving as an attachment point for the targeting moiety.  Our choice of linker is  
polyethylene glycol (PEG) chain which has been shown to increase the 
hydrophilicity.45 By adding a linker the targeting moiety will also be spatially 
removed from the N-terminus of ghrelin and PPIX, decreasing the effect of the 
bulky chelator PPIX on the binding affinity of ghrelin.  The proposed structure of 
the probe is shown in Figure 2.1. 
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Figure 2.1 Structure of proposed imaging probe. 
 
2.2.1 Synthesis of PPIX-ghrelin(1-8) Analogue 
Optimization of methods to load PPIX on resin 
 
The presence of two free carboxylic acid groups on PPIX, makes it highly 
suitable for this study as one carboxylic acid group will act as a point of 
attachment to the solid support and the other carboxylic group can be coupled to 
the amino acids through the linker 2,2’- (ethylenedioxy)bis(ethylamine). For this, 
several attempts were made to first attach PPIX to the Wang resin through one 
of the free carboxylates followed by a one pot reaction coupling it to 2,2' -
(ethylenedioxy)bis(ethylamine). The coupling agents that were used for this step 
were PyBrOP or HATU as activating agents. Several trials were carried out, 
employing different conditions, varying the reaction temperature and the duration 
for which the reaction mixture was heated. The best result that could be obtained 
was a 28% yield for product 2.1.  However, 43% of the unreacted PPIX (as 
determined by HPLC analysis) was remaining. These results were not sufficient 
to continue with, since the reactions were carried out on solid support and could 
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not be purified before continuing with building the peptide chain.  (Scheme 2.1). 
 
 
                                                                                                                   2.1 
                                                                                                                                                                                   
 
Scheme 2.1 Route for synthesis of 2.1 by the on-resin coupling of 2,2’- 
(ethylenedioxy)bis(ethylamine) to PPIX.  
 
 
It was thought that the low yield could be due to two reasons. 1) the first step 
involving the attachment of one carboxylate of PPIX to the Wang resin could be 
problematic, and/or 2) the second carboxylate of PPIX was not activated by the 
coupling agent to be able to couple to 2,2’- (ethylenedioxy)bis(ethylamine). To 
enhance the attachment of PPIX to the resin we tried 2-chlorotrityl chloride as an 
alternative resin. To further rule out any difficulties with the step involving 
attachment of PPIX to resin and to validate that the second carboxylate of PPIX 
could be actually activated and coupled to 2,2'-(ethylenedioxy)bis(ethylamine), a 
comparison was done with a solution phase coupling of PPIX to 2,2'-
(ethylenedioxy)bis(ethylamine), (i.e. without loading PPIX onto 2-chlorotrityl 
chloride resin). (Scheme 2.2) 
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                                                                                 2.2a                           2.2b  
 
Scheme 2.2 Route for coupling of PPIX to 2,2' -(ethylenedioxy)bis(ethylamine) in 
solution. 
 
 
From the HPLC chromatogram a large peak corresponding to PPIX (34%), 
another peak corresponding to product 2.2a (14%) and a major peak 
corresponding to compound 2.2b (43%) was observed. 
From these results, it was concluded that during the first step of attachment of 
PPIX to 2-chlorotrityl resin, both the carboxylates of PPIX were attaching to the 
resin. Therefore, no free carboxylate would be available for the amine to react, 
leading to low reaction yield. Apart from that, the ability of 2,2' -
(ethylenedioxy)bis(ethylamine) to cyclize across the two carboxylic acids of PPIX 
was also observed. Therefore compound 2.3 was synthesized, where one of the 
free amines of 2,2' -(ethylenedioxy)bis(ethylamine) was protected with an Fmoc 
group. In order to prevent PPIX from cyclizing across the resin, it was proposed 
to couple one of the carboxylates to compound 2.3 before loading it onto the 
resin. Even after all these modifications, the yield of coupling PPIX to compound 
2.3 using HATU as a coupling agent was low. The next approach was to form an 
anhydride, instead of an active ester and then couple it to compound 2.3. 
(scheme 2.3). This approach gave the best results so far where the product was 
isolated with the yield of 47%. Now that the linker was attached to one of the 
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carboxyl groups of PPIX, it was loaded onto 2-chlorotrityl chloride resin using the 
other free carboxyl group and the targeting peptide ghrelin can be build off the 
linker. 
Natural ghrelin has a unique octanoyl chain connected to the side chain of Ser-3 
residue though an ester linkage. In order to avoid the enzymatic hydrolysis of 
ester linkage in vivo, the Ser-3 residue was replaced by diaminopropionic acid. 
This modification substitutes the labile ester bond by a more stable amide linkage 
at the octanoyl chain.39 
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Scheme 2.3 Route for synthesis of PPIX-linker-ghrelin analogue 2.8. 
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2.2.2 69/71Ga Coordination 
Compound 2.8 was first coordinated to 69/71Ga, leading to the synthesis of 
compound 2.9 which would be used to demonstrate the affinity for GHS-R1a 
through fluorescence microscopy. Before moving into optical imaging, the effects 
of 69/71Ga coordination on the photophysical characteristics of analogue 2.8 must 
be studied. It would then be incubated with the cells transfected with GHS-R1a 
and the uptake by the cells will be analysed through fluorescence microscopy. 
One way to confirm the successful synthesis of the radioactive analogue 2.10, is 
to compare it to a non-radioactive standard i.e. compound 2.9. The only 
difference between the non-radioactive standard i.e. compound 2.9 and the 
radioactive analogue i.e. compound 2.10 is that of the Ga isotope, therefore both 
appear with the same retention time when analyzed by HPLC chromatography. 
Hence, the 69/71Ga coordinated analogue will not only serve as an applicant for in 
vitro analysis, it will also act as a non-radioactive standard for 68Ga radiolabeling. 
High temperature conditions have been found to be essential for coordination of 
some metal ions to the central porphyrin cavity.31 Coordination of 69/71Ga to PPIX-
RGD analogue was earlier reported using a pH 4.5 sodium acetate/acetic acid 
buffer35, utilizing  microwave in order to reduce the reaction time. All attempts 
made to coordinate 69/71Ga to analogue 2.8 using sodium acetate/acetic acid 
buffer and GaCl3 were unsuccessful. This might be due to the poor solubility of 
compound 2.8 in sodium acetate/acetic acid buffer. Next, coordination attempts 
were carried out in 2,6-lutidine and GaCl3 by conventional heating method 
reported previously.34 It could be observed that the coordination was taking place 
but the yield was very poor as the peptide was breaking down at high reaction 
temperature. In order to decrease the reaction time and temperature such that 
degradation of peptide could be minimized, the reaction was carried out using a 
microwave at 1200C for 1 hour (Scheme 2.4). This led to an improvement in the 
yield.  Additional attempts at this reaction by increasing the reaction 
time/temperature led to degradation of the peptide.  
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Scheme 2.4 Route for coordination to 69/71Ga. 
 
 
2.2.3 Optical Analysis 
To estimate the potential of compound 2.9 for fluorescence microscopy, photo-
physical data was obtained and compared to PPIX (summarized in table 2.1). It 
was observed that there was a blue shift in emission maxima for compound 2.9 
as compared to PPIX. The absorbance maxima did not shift notably upon 
coupling to ghrelin or upon coordination to 69/71Ga. Additionally, there was a 
significant increase in molar extinction coefficient for both compound 2.8 and 2.9 
as compared to PPIX. As expected the absorption spectrum of compound 2.8 
consisted of one Soret band and four Q-bands. The coordination of 69/71Ga could 
be easily confirmed from the absorption spectrum for compound 2.9, as the 
formation of metalloporphyrin leads to the disappearance of two Q-bands. (Figure 
2.2) 
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The fluorescence quantum yields were obtained according to the reported 
comparative methods46, using Rhodamine 6G as the standard. The fluorescence 
quantum yield study gave some interesting results. It has been seen in the 
literature that porphyrin fluorescence generally gets quenched upon coordination 
to metals such as Cu2+, leading to a significant decline in fluorescence quantum 
yield.47  Fluorescence quenching is the process that involves the reduction in 
fluorescence intensity of the substance as it relaxes through non-radiative decay 
of the excited singlet state. It was observed that the fluorescence was not only 
preserved, the fluorescence quantum yield for compound 2.9 was higher than 
compound 2.8, suggesting that fluorescence was not quenched upon Ga3+ 
coordination. It was postulated that metal ions such as Cu2+ being paramagnetic 
cause intersystem crossing to triplet state and loss of energy occurs through non-
radiative processes which leads to decrease in fluorescence intensity. On the 
other hand, Ga3+ being diamagnetic does not participate in intersystem crossing 
therefore fluorescence is not quenched.  
    
 
Compound λex (nm) 
(DMSO) 
λem (nm) 
(DMSO)        
λabs (nm) 
(DMSO) 
ε (M-1 cm-1) 
(DMSO) 
Φ[a]  
(EtOH) 
 
PPIX 405 630 408 17377 0.37 
Compound 2.8 406 628 408 90706 0.53 
Compound 2.9 414 580 415 116653 0.70 
 
 
Table 2.1 Photophysical data for PPIX and PPIX analogues: excitation, emission, 
absorption maxima, molar extinction coefficient, fluorescence quantum yields. 
Slit width was 2 nm. Emission collected in the range 415-800 nm for PPIX, 416-
800 nm for 2.8 and 425-800 nm for 2.9.  
[a]: Quantum yields obtained using rhodamine 6G48 as standard in deoxygenated 
solution using previously reported procedure.46   
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Figure 2.2 Absorption and emission spectra: Absorption for compound 2.8 (blue), 
Absorption for compound 2.9 (red), emission for compound 2.8 (pink), emission 
for compound 2.9 (orange). Recorded for 10-5 M DMSO solution. 
 
 
2.2.4 In Vitro Fluorescence Imaging of 69/71Ga-PPIX-ghrelin(1-8) 
To validate the potential of 2.9 for in vitro confocal fluorescence microscopy, 
OVCAR-8 cells transfected with GHS-R1a were utilized. For this purpose, 
OVCAR-8 cells transfected with GHS-R1a were incubated with the analogue 2.9 
and fluorescence images were obtained after washing and fixing the cells. The 
images depicted the cellular uptake of 2.9 as was evident from the red emission 
from 2.9 (around 580nm) (Figure 2.3a). The applicability of 2.9 for orthogonal 
imaging was demonstrated by co-staining the cells with nuclear stain 4’,6-
diamidino-2-phenylindole (DAPI) (in blue), showing that the cytoplasm and nuclei 
could be differentiated while being imaged simultaneously (Figure 2.3b). Parental 
OVCAR-8 cells (without transfection with GHSR-1a) were used as negative 
control for the experiment. The uptake of 2.9 by parental OVCAR-8 cells was 
minimal as seen in Figure 2.3c. Further, the specific binding of 2.9 for GHS-R1a 
was demonstrated by performing a blocking studies, using a small molecule 
antagonist 36 (developed by Bayer Pharmaceutical Corporation) which has very 
58 
 
 
high affinity for GHS-R1a.49 In a blocking study the uptake of the imaging probe 
for the target is specifically inhibited (blocked) by large excess of a blocking 
compound that has a high affinity for the receptor. At a high concentation, 
blocking of the target can be detected as a loss of fluorescence signal from the 
targeting imaging probe.This confirms the specificity of the targeting imaging 
probe for the target. If the targeting imaging probe is not binding specifically to 
the desired target and is binding some other target, then the presence of excess 
of the blocking compound should not result in the loss of fluorescence signal. 
Figure 2.3e demonstrates blocking of GHS-R1a. All this aids in confirming the 
specificity of 2.9 for the receptor.  
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Figure 2.3 Confocal fluorescence micrographs of OVCAR-8 cells stained with 2.9 
(in red) and DAPI (in blue). (a) Using OVCAR-8 cells transfected with GHS-R1a 
and image obtained by excitation at 559 nm and emission collected between 575-
675 nm. (b) Using OVCAR-8 cells transfected with GHS-R1a and overlay of image 
obtained by excitation at 405 nm and emission collected between 425-475 nm with 
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image 2.3a. (c) Using parental OVCAR-8 cells not transfected with GHS-R1a and 
image obtained by excitation at 559 nm and emission collected between 575-675 
nm. (d) Using parental OVCAR-8 cells not transfected with GHS-R1a and overlay 
of image obtained by excitation at 405 nm and emission collected between 425-
475 nm with image 2.3c. (e) Using OVCAR-8 cells transfected with GHS-R1a and 
blocked with 10X excess of 36 and image obtained by excitation at 559 nm and 
emission collected between 575-675 nm. (f) Using OVCAR-8 cells transfected with 
GHS-R1a and blocked with 10X excess of 36 and overlay of image obtained by 
excitation at 405 nm and emission collected between 425-475 nm with image 2.3e. 
(g) Structure of compound 36 used for blocking study. 
 
 
2.2.5 Optimization of 68Ga Labeling of PPIX-Ghrelin(1-8) 
The insertion of a radiometal through chelation is one of the simplest techniques 
to introduce a radioisotope into the precursor. This not only avoids the multistep 
synthesis associated with other techniques, but also the radiometal conjugates 
usually need minimal purification, if any.50  
Here, we report the synthesis of 68Ga-PPIX-peptide based novel imaging probe. 
Several conditions were analyzed during the optimization of 68Ga chelation. The 
introduction of 68Ga into porphyrins has been previously shown to require high 
temperature31, therefore microwave reactor was employed for labeling compound 
2.8 with 68Ga. Sodium acetate/acetic acid (aq) buffer of pH 4.5 was used in order 
to prevent hydrolysis of free 68Ga as it has been found that at physiological pH 
Ga3+ exists as insoluble hydroxides.51 While using this buffer, no radiolabeled 
product was obtained. This could be attributed to the low solubility of compound 
2.8 in aqueous media. To improve the solubility, the use of organic solvents like 
ethanol and DMF became necessary. Therefore, the ideal solvent system for the 
reaction was found to be a mixture of sodium acetate/acetic acid buffer (pH 4.5), 
tween 20, ethanol and DMF. Different reaction temperatures and reaction times 
were analyzed for the optimization of the reaction conditions. The best result was 
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obtained by heating the reaction mixture in a microwave reactor at 1200C for 60 
minutes. Comparison with the HPLC trace from the standard compound 2.9, 
proved the successful synthesis of compound 2.10. Both the radioactive product 
and the non-radioactive standard appeared at the same retention time as is seen 
in Figure 2.4. 
Even under these conditions the radiolabeling yield was low and insufficient 
product was isolated and therefore no PET images were obtained. There could 
be a number of reasons behind the low radiolabeling yields. Firstly, the solubility 
of compound 2.8 was still not suitable for labeling, even after using a 4-solvent 
mixture system. Secondly, as it is seen in various examples in literature, the 
yields for metal coordination of porphyrins can be increased by increasing the 
reaction time or by increasing the reaction temperature. But in our case any 
further extension in reaction time or increase in reaction temperature led to 
degradation of the peptide, thus leading to low yields. Further optimization is 
required towards improving the yield of the radiolabeling step.  
However, since we were successfully able to label compound 2.8 with 68Ga, this 
validates the ability of PPIX to act as a 68Ga chelator.   
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Scheme 2.5 Route for radiolabeling with 68Ga. 
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Table 2.2 Different conditions for optimization of conditions for radiolabeling with 
68Ga 
 
 
. 
    Solvent  
         1 
Solvent  
     2 
Solvent  
     3 
Solvent  
     4 
Temp 
(0C) 
Time 
(min) 
    Yield 
  (From 
HPLC)  
2,6-lutidine 
 
   120 30 0% 
2,6-lutidine 
 
   120 45 0% 
NaOAc/AcOH 
    (aq) 
   75 40 0% 
NaOAc/AcOH 
    (aq) 
   120 30 0% 
NaOAc/AcOH 
    (aq) 
   120 40 0% 
NaOAc/AcOH 
    (aq) 
DMSO   120 40 0% 
NaOAc/AcOH 
    (aq) 
EtOH   120 40 2% 
NaOAc/AcOH 
    (aq) 
DMF   120 40 3% 
NaOAc/AcOH 
    (aq) 
EtOH DMF Tween 
   20 
120 60 62% 
NaOAc/AcOH 
    (aq) 
EtOH DMF Tween  
   20 
150 25 10% 
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Figure 2.4 UV trace for standard compound 2.9 (blue), AU: 200-800 nm and 
radio chromatogram for compound 2.10 (red), obtained using CsI(Tl) scintillating 
crystal coupled to silicon PIN diode. 
 
 
2.2.6 Competitive Binding Assays (IC50) for PPIX-Ghrelin(1-8) 
In a competitive binding assay, there is a competition between the non-
radioactive competing ligand (the imaging probe) and the radioligand having high 
affinity for the receptor. The half maximal inhibitory concentration (IC50) value 
obtained from the assay provides the concentration of the competing ligand that 
displaces 50% of the specific binding of the radioligand.  The effect of the 
introduction of the chelator PPIX on the binding affinity of the peptide for GHS-
R1a, was studied through a competitive binding assay.   
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The IC50 values for compound 2.8 and 2.9 that were obtained from the 
competitive binding assay were compared to the parent peptide and compared to 
each other to determine the effect of 69/71Ga coordination on the binding affinity 
for the receptor. The IC50 value for the parent sequence [Dpr3,Tyr8] ghrelin(1-8) 
was 65.0 nM, the IC50  values for compounds 2.8 and 2.9  were determined to be 
4.8 µM and 617.1 nM respectively. It is believed that the reason for the decrease 
in binding affinity of peptide upon coupling to PPIX is the presence of the bulky 
chelator PPIX close to the N-terminus of the peptide that is essential for binding 
to the receptor. The linker used for the present study is not suitable to increase 
the distance between PPIX and the N-terminus. Therefore, further optimization is 
required to select a more suitable linker. This will not only improve the binding 
affinity of the PPIX-ghrelin analogue, but may also provide opportunity to 
enhance the solubility by utilizing a more hydrophilic linker. None the less, the 
binding affinity for the 69/71Ga coordinated analogue was better than the one 
without 69/71Ga, confirming the role of Ga coordination in enhancement of binding 
affinity and hence making it a superior targeting entity. 
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                                a                                                             b 
Figure 2.5 Half-maximal inhibitory concentration curve of (a) compound 2.8 and 
(b) compound 2.9 against [125I]-human ghrelin in HEK 293/GHS-R1a cells. 
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2.3 Conclusions 
With the goal of developing PET/fluorescence based dual imaging probes, we 
were able to synthesize a Ga-PPIX-ghrelin (1-8) analogue, which could be 
utilized for both PET and fluorescence imaging without the requirement of going 
through any additional structural alteration. Here PPIX was attached to the C-
terminus of the peptide ghrelin. The synthetic strategy that was developed opens 
ways for conjugating porphyrins, such as PPIX, to a variety of peptides and other 
biomolecules. Chelation to Ga preserved the fluorescent characteristics of the 
imaging agent. Affinity for the GHS-R1a was evident through the fluorescence 
images. A radiolabeled analogue was also synthesized; however, the 
radiochemical yield still needs to be improved before in vivo images can be 
obtained. Once this is achieved this imaging probe will permit in vitro evaluation 
via fluorescence microscopy (69/71Ga), as well as in vivo PET imaging (68Ga). This 
proof of concept study validates the use of Ga-PPIX, as an imaging tag in peptide 
analogues, for simultaneous dual modality optical/PET imaging of biological 
targets.      
 
2.4 Experimental 
Materials and Methods 
All common solvents were purchased from Fischer scientific. All Fmoc protected 
amino acids, coupling agents and resins were purchased from Chem Impex, 
Peptide Internationals and Novabiochem® and were used without further 
purification unless otherwise stated. All reagents were purchased from Sigma 
Aldrich except from GaCl3 which was purchased from Strem Chemicals. The 
germanium/gallium generator was obtained from Eckert and Ziegler. [125I]-ghrelin 
was received from Perkin Elmer. RP-C18 Sep-Pak SPE cartridges were 
purchased from Waters. Flash column chromatography purification was carried 
out with Isolera one using Biotage SNAP Cartridge KP-C18-HS.  For analysis of 
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samples, an analytical Agilent RP-C18 4.6 X 150 mm, 5 µm column was utilized. 
The flow rate was 1.5 mL/min over 25 minutes. For purification of samples, a 
reverse phase preparative HPLC column (Agilent RP-C18 19 X 150 mm, 5 µm) 
was employed. The flow rate in this case was 20 mL/min over 15 minutes. The 
gradient solvent system used were 0.1% TFA in acetonitrile (solvent A) and 0.1% 
TFA in water (solvent B). This system was provided with a Waters 600 controller, 
Waters Prep degasser, Waters Mass Lynx software (version 4.1). For the studies 
on UHPLC-MS, Waters Inc. Acquity UHPLC H-Class system was used. This was 
used in combination with Xevo QTof mass spectrometer (ESI +, cone voltage 
30V). For analytical studies, a Waters Acquity UHPLC BEH C18 2.1 X 50 mm, 
1.7 µm column was utilized. The gradient solvent system employed was 0.1% 
formic acid in acetonitrile (solvent C) and 0.1% formic acid in water (solvent D). 
For analysing the radioactive samples, analytical SunfireTM RP-C18 4.6 X 150 
mm, 5 µm column was used. The system comprised of a Waters 1525 Binary 
HPLC pump with a Water 2487 dual λ absorbance detector and Breeze software 
(version 3.30).  
 
Synthesis of compound 2.3 
In a 1 L, 2-neck round bottom flask, 2,2’- (ethylenedioxy)bis(ethylamine) (3.50 g, 
23.6 mmol) was dissolved in anhydrous chloroform (472 mL, 20 mL/mmol) and 
cooled to 00 C. In a 500 ml round bottom flask, Fmoc chloride (3.05 g, 11.8 mmol) 
was dissolved in anhydrous chloroform (118 mL, 5 mL/mmol). This was added 
dropwise to the solution of 2,2’- (ethylenedioxy)bis(ethylamine) in chloroform and 
stirred at 00 C for 1 hour. The reaction mixture was allowed to stir at r.t. for 16 
hours. The reaction mixture was washed with 5 M sodium chloride (NaCl) (500 
mL X 2), followed by 1 M sodium hydroxide (NaOH) (2 X 150 mL). 1% 
hydrochloric acid (HCl) (150 mL) was added to the organic layer and allowed to 
stir for 30 min. The solution was concentrated in vacuo. The resulting compound 
was purified by flash chromatography using Biotage SNAP Cartridge KP-C18-HS 
60 g (MeOH in 1% HCl/H2O). Fractions were collected in round bottom flask and 
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MeOH was rotary evaporated. Remaining aqueous solution was frozen at 780 C 
and lyophilized overnight which provided a white solid in 31% yield (3.00 g, 7.38 
mmol), purity 95%. HRMS (ESI +): m/z calculated for C21H27N2O4, [M+H]+= 
371.1971; observed, [M+H]+= 371.1961      
 
Synthesis of compound 2.4 
In a round bottom flask Protoporphyrin IX (PPIX) (500 mg, 0.888 mmol) was 
dissolved in anhydrous DCM (45 mL, 50 mL/mmol) and DMF (4.5 mL, 5 
mL/mmol). To this solution, acetic anhydride (252 µL, 2.66 mmol) was added and 
reaction mixture was refluxed for 3.5 hours under N2. The solvent was removed 
using rotary evaporator and left under high vacuum for 2 hours. The brown solid 
obtained was dissolved in anhydrous DCM (20 mL). Compound 2.3 (361 mg, 
0.888 mmol) and N,N-diisopropylamine (DIPEA) (309 µL, 1.77 mmol) were added 
to the reaction mixture and it was allowed to stir at r.t. under nitrogen for 16 
hours. The reaction mixture was then washed with deionized H2O (3 X 20 mL), 
dried over MgSO4, gravity filtered and concentrated in vacuo. The resulting 
compound was purified using flash column chromatography (MeOH (1% 
Triethylamine) /DCM). The fractions were collected in round bottom flask and 
evaporated to dryness using a rotary evaporator. The brown solid was dissolved 
in DCM (150 mL) and washed with H2O (3 X 20 mL). The organic layer was dried 
with MgSO4, gravity filtered and evaporated on rotary evaporator. Compound 2.4 
was obtained as a brown solid in 46% yield (378 mg, 0.413 mmol), purity 95%. 
HRMS (ESI+) : m/z calculated for C55H59N6O7, [M+H]+= 915.4445; observed 
[M+H]+ =  915.4456 
   
Synthesis of compound 2.5 
2-chlorotrityl chloride resin (90 mg, 0.072 mmol) was swelled in anhydrous DCM 
for 15 min. Compound 2.4 (330 mg, 0.360 mmol) was dissolved in anhydrous 
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DCM (2 mL), DIPEA (250 µL, 1.44 mmol) was added to this solution and allowed 
to shake (using IKA-VIBRAX-VXR shaker from Sigma-Aldrich) for 10 minutes. 
The DCM solution of compound 2.4 was added to the resin and was shaken for 3 
hours at r.t. The resin was washed with DMF (4 X 2 mL) and DCM (4 X 2 mL) 
and used for the next step. 
 
Synthesis of PPIX-linker-[Dpr3,Tyr8]ghrelin(1-8) 2.8 
Synthesis of the peptide was carried out using frit bearing peptide synthesis 
vessels, employing solid phase peptide synthesis chemistry. Compound 2.5 was 
initially swelled in DCM for 15 min. Fmoc deprotection was carried out using 2 mL 
of 20% Pip/DMF for two cycles (10 min, 15 min). Activation of amino acids was 
carried out using 3 eq. of HCTU, and 6 eq. of N,N-diisopropylethylamine (DIPEA)  
in 2 mL of DMF. The mixture was then added to the resin and shaken for 60 min. 
These cycles were repeated till all N terminal amino acids were coupled to the 
resin. The deprotection of the allyloxycarbonyl group of diaminopropionic acid 
was carried out under inert atmosphere N2.  To maintain N2 atmosphere, septum 
was attached to the open end of the peptide vessel and the solution was flushed 
with N2. 2 mL of anhydrous DCM was added to the resin. 24 eq. of phenylsilane 
was added. 0.1 eq. of tetrakis(triphenylphosphine) palladium (0) was then added 
and solution was allowed to stir under N2 for 5 min. Peptide vessel was removed 
from inert conditions and allowed to shake for two cycles (10 min, 20 min). Full 
deprotection of peptide was accomplished by adding 3 mL mixture comprising of 
95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIPS), 2.5% H2O to the 
resin and vortexed for 4 hours. The cleaved peptide was precipitated using ice 
cold tert-butyl methyl ether (TBME) and centrifuged at 3000 rpm for 15 min. The 
supernatant was removed and peptide pellet was dissolved in 20% ACN in H2O, 
frozen at -780C and lyophilized to obtain a brown solid. The crude peptide was 
purified using preparative HPLC-MS and the purity was examined using UHPLC. 
The pure product was obtained in 7% yield (24 mg, 0.0136 mmol), purity 93%. 
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HRMS (ESI +): m/z calculated for C88H118N15017, [M+H]+ =1656.8830, observed 
[M+H]+ =1656.8843    
  
69/71Ga Coordination 
In a glove bag assembly under inert N2 atmosphere, compound 2.8 (50 mg, 
0.028 mmol) was dissolved in 2,6-lutidine (2.5 mL) in a microwave vessel. 
Gallium trichloride (GaCl3) (164 mg, 0.933 mmol) was dissolved in 2,6-lutidine 
(0.5 mL) and was added dropwise to the microwave vessel containing PPIX 
solution. The reaction mixture was microwaved at 1200C for 60 min. The reaction 
mixture was allowed to cool to r.t. and brine (15 mL) was added. 20% citric acid 
was then added to acidify the reaction mixture to pH 4. Vacuum filtration was 
carried out and the solid was washed with H2O (3 X 1 mL). The solid was then 
dissolved in MeOH and the solution was concentrated in vacuo. Crude compound   
was then dissolved in ACN (0.1% TFA) and H2O (0.1% TFA) and purified by 
preparative HPLC-MS. The fractions were combined and frozen at -780 C and 
lyophilized to yield the pure compound in 42% yield (17 mg, 0.009 mmol), purity 
95%. HRMS (ESI +) : m/z calculated for C88H115GaN15O17,  [M+H]+ =  1722.7851; 
observed [M+H]+ =1722.7805 
 
Optical Analysis 
UV absorption data was acquired using Varian Carry 300 Bio UV-Vis 
spectrophotometer. Excitation and emission data were acquired using Photon 
Technology International QM-4 SE spectrofluorometer. For calculating molar 
extinction coefficient seven different concentrations were run for each sample. 
Molar extinction coefficient was obtained from the slope of the graph of 
absorbance vs concentration. The absorption, excitation and emission 
wavelengths were determined using DMSO as a solvent. Fluorescence quantum 
yields were determined using the comparative method described by Fery-
Forgues and coworkers.46 Briefly, the absorbance for the solutions of the 
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unknown sample and the standard was measured. The emission spectra were 
also obtained and the area under the curve was determined. Fluorescence 
quantum yields were calculated using Rhodamine 6G as the standard. 
Fluorescence quantum yield for Rhodamine 6G has been reported to be 0.95.48 
Fluorescence quantum yields were determined using the equation: 
ϕx = ϕst [ gradx/gradst ] [ ƞ2x/ƞ2st ] 
where ϕx and ϕst are fluorescence quantum yields for unknown sample and 
standard respectively. gradx and gradst are the gradients from the plot of 
integrated fluorescence intensity vs absorbance for unknown sample and 
standard respectively. ƞ is the refractive index of the solvent used. 
  
Cell Imaging Protocol  
Transfection of OVCAR-8 cells 
HeyA8 and OVCAR8 human ovarian cancer cell lines were maintained in RPMI 
media (Wisent) supplemented with 10% fetal bovine serum (FBS; Wisent). Cells 
were seeded into 6-well tissue culture plates (Sarstedt) at 1.5 x 105 cells per 35-
mm well. The following day, media was changed to OptiMEM (Invitrogen) 
containing 10% FBS prior to transfection. Cells were transfected with 0.5 
micrograms of pCMV6-GHSR1a-EGFP plasmid using LipofectAMINE 3000 
(Invitrogen) as per manufacturer’s instructions. Forty-eight hours later, cells were 
trypsinized and expanded into 4 separate 100-mm tissue culture plates in 
RPMI/10% FBS media. The following day, G418 Sulphate Solution (Wisent) 
treatment at 400 micrograms/mL was started and maintained until colonies were 
visible. GFP-positive colonies were visualized by indirect fluorescence using a 
Leica DMI 4000B inverted microscope, isolated using cloning rings, and 
transferred to 24-well tissue culture plates containing RPMI/10% FBS.  
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For compound 2.9 
OVCAR-8 cells that were transfected with GHS-R1a were released from the 
tissue culture flask by trypsinization and seeded onto coverslips in a 12-well 
tissue culture plate at a cell density of 50000 cells/well. The cells were incubated 
overnight in Roswell Park Memorial Institute medium (RPMI) containing 10% fetal 
bovine serum (FBS) at 370 C with 5% CO2. The serum containing RPMI in each 
well was removed and replaced with serum free RPMI containing a concentration 
of 0.5 µM of compound 2.9 and incubated at 370 C for 1 hour. Cells were then 
washed three times with phosphate buffer saline (PBS), fixed with 4% 
paraformaldehyde and mounted onto slides containing Pro-Long Gold Antifade 
mounting medium with DAPI. For the control experiments, parental OVCAR-8 
cells without GHS-R1a were incubated with compound 2.9. Images were then 
obtained using an Olympus FluoView FV 1000 confocal microscope.   
 
Blocking Studies with 36 
OVCAR-8 cells with GHS-R1a were released from adhesion to tissue cultured 
flask. Cells were resuspended in serum free RPMI. Cells were then incubated 
with 0.5 µM of compound 2.9 at 370C for one hour. 10 X excess of compound 36 
was used as blocking compound for these studies. Cells were washed with PBS 
(3 times), reseeded onto coverslips, cultured in RPMI and allowed to adhere. 
Cells were washed with PBS, after being adhered to coverslips. Cells were then 
fixed with 4% formaldehyde and mounted onto slides. Images were then obtained 
using Olympus FluoView V 1000 confocal microscope.   
 
 
Synthesis of 68Ga-PPIX-linker-[Dpr3,Tyr8]ghrelin(1-8) compound 2.10            
Fresh 68Ga3+ was eluted from 68Ge/68Ga generator using 0.1 M hydrochloric acid 
(HCL) and trapped on Strata X C cation exchange column. The column was 
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eluted with 0.1 M HCl in acetone. 1 mg of compound 2.8 was dissolved in 1 mL of 
DMF. To 100 µl of this solution was added 800 µL of Tween 20 solution in 
acetate buffer (pH 4.5). The solution was further diluted with 100 µl of EtOH. This 
solution was added to a clean glass microwave vessel to which 522 MBq of 
68GaCl3 freshly eluted from Ge-68/Ga-68 generator was added. The reaction 
mixture was heated in a microwave reactor at 1200 C for 35 min. The reaction 
mixture was then passed through Sep Pak SPE cartridge and washed with 1 mL 
of water. The product was eluted off the Sep Pak SPE cartidges with 1 mL of 
EtOH. The activity of EtOH solution was 10 MBq. The reaction progress and 
product purity was analyzed using analytical HPLC.  
 
Competitive Binding Assay IC50     
The affinity for GHS-R1a was determined using a radioligand binding assay. 
Assays were performed using HEK293 cells transfected with GHS-R1a (obtained 
from Dr. Savita Dhanvantari) as receptor source. HEK293 cells were grown in 
MEM (Minimum Essential Media) supplemented with non-essential amino acids 
and 10% fetal bovine serum. For the purpose of transfecting the cells with GHS-
R1a, cells were grown to 70% confluency in a 75cm flask and transfected with 
GHS-R1a-pcDNA 3.1 plasmid (Missouri S and T cDNA Resource Center) using a 
modified calcium phosphate transfection protocol.52 Human [125I]-ghrelin(1-28)  
(PerkinElmer Inc.) was used as radioligand. Human ghrelin(1-28) was used as 
reference to ensure the validity of the results. Compounds 2.8 and 2.9 (at 
concentrations of 10-5 M, 10-6 M, 10-7 M, 10-8 M, 10-9 M, 10-10 M, 10-11 M) and 
[125I]-ghrelin (15,000cpm per assay tube) were mixed in binding buffer (25 mM 
HEPES, 5 mM magnesium chloride, 1 mM calcium chloride, 2.5 mM EDTA, and 
0.4% BSA, pH 7.4). A suspension of membrane from GHS-R1a transfected 
HEK293S cells (50,000 cells per assay tube) was added to the assay tube 
containing test peptides and [125I]-ghrelin(1-28). The resulting suspension was 
incubated for 20 minutes under shaking (550 rpm). Unbound [125I]-ghrelin was 
removed and the amount of [125I]-ghrelin bound to the membranes was measured 
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on a gamma counter. The IC50 was determined by a logistic nonlinear regression 
analysis using Origin. All binding assays were performed in triplicates. 
 
2.5  Acknowledgements 
The competitive binding assays were performed by Dr. Jinqiang Hou. Cells were 
provided by Dr. Trevor Shephard and technical assistance with cell culture was 
provided by Tyler Lalonde. Funding was from the Canadian Institutes for Health 
Research (CIHR), Prostate Cancer Canada and London Regional Cancer 
Program (LRCP). 
 
2.6  References 
(1)  Yankeelov, T. E.; Abramson, R. G.; Quarles, C. C. Nat. Rev. Clin. Oncol. 
2014, 11 (11), 670–680. 
(2)  Louie, A. Chem. Rev. 2010, 110 (5), 3146–3195. 
(3)  Martí-Bonmatí, L.; Sopena, R.; Bartumeus, P.; Sopena, P. Contrast Media 
Mol. Imaging 2010, 5 (4), 180–189. 
(4)  Kang, P.; Liao, M.; Wester, M. R.; Leeder, J. S.; Pearce, R. E. Semin. Nucl. 
Med. 2010, 36 (3), 490–499. 
(5)  Chen, Z. Y.; Wang, Y. X.; Lin, Y.; Zhang, J. S.; Yang, F.; Zhou, Q. L.; Liao, 
Y. Y. Biomed. Res. Int. 2014, 2014. 
(6)  Sun, L.; Ding, J.; Xing, W.; Gai, Y.; Sheng, J.; Zeng, D. Bioconjugate 
Chem. 2016, 27, 1200–1204. 
(7)  Edwards, W. B.; Xu, B.; Akers, W.; Cheney, P. P.; Liang, K.; Rogers, B. E.; 
Anderson, C. J.; Achilefu, S. Bioconjugate Chem. 2008, 19 (1), 192–200. 
(8)  Huang, H.; Song, W.; Rieffel, J.; Lovell, J. F. Front. Phys. 2015, 3 (23), 1–
15. 
(9)  Wu, S. P.; Lee, I.; Ghoroghchian, P. P.; Frail, P. R.; Zheng, G.; Glickson, J. 
D.; Therien, M. J. Bioconjugate Chem. 2005, 16, 542–550. 
(10)  Huang, P.; Qian, X.; Chen, Y.; Yu, L.; Lin, H.; Wang, L.; Zhu, Y.; Shi, J. J. 
Am. Chem. Soc. 2017, 139, 1275–1284. 
75 
 
 
(11)  Borsch, M. Proc SPIE 2010, 7551, 75510G. 
(12)  Stepinac, T. K.; Chamot, S. R.; Rungger-Brändle, E.; Ferrez, P.; Munoz, J. 
L.; Van Den Bergh, H.; Riva, C. E.; Pournaras, C. J.; Wagnières, G. A. 
Investig. Ophthalmol. Vis. Sci. 2005, 46 (3), 956–966. 
(13)  Takehara, Y.; Sakahara, H.; Masunaga, H.; Isogai, S.; Kodaira, N.; Takeda, 
H.; Saga, T.; Nakajima, S.; Sakata, I. Br. J. Cancer 2001, 84 (12), 1681–
1685. 
(14)  Besur, S.; Hou, W.; Schmeltzer, P.; Bonkovsky, H. L. Metabolites 2014, 4 
(4), 977–1006. 
(15)  Kennedy, J. J. Photochem. Photobiol. 1990, 6, 143–148. 
(16)  Moan, J.; Ma, Ã. L.; Iani, Ã. V.; Ã, A. J. J. Invest. Dermatol. 2005, 125 (5), 
1039–1044. 
(17)  Smith, G.; Carroll, L.; Aboagye, E. O. Mol. Imaging Biol. 2012, 14, 653–
666. 
(18)  Dougherty, T. J.; Gomer, C. J.; Henderson, B. W.; Jori, G.; Kessel, D.; 
Korbelik, M.; Moan, J.; Peng, Q. J. Natl. Cancer Inst. 1998, 90 (12), 889–
905. 
(19)  Ormond, A. B.; Freeman, H. S. Materials  2013, 6 (3), 817–840. 
(20)  Trindade, F. Z.; Pavarina, A. C.; Ribeiro, A. P. D.; Bagnato, V. S.; Vergani, 
C. E.; De Souza Costa, C. A. Lasers Med. Sci. 2012, 27 (2), 403–411. 
(21)  Benes, J.; Poucková, P.; Zeman, J.; Zadinová, M.; Sunka, P.; Lukes, P.; 
Kolárová, H. Folia Biol.  2011, 57 (6), 255–260. 
(22)  Josefsen, L. B.; Boyle, R. W. Theranostics 2012, 2 (9), 916–966. 
(23)  Entract, G. M.; Bryden, F.; Domarkas, J.; Savoie, H.; Allott, L.; Archibald, S. 
J.; Cawthorne, C.; Boyle, R. W. Mol. Pharm. 2015, 12 (12), 4414–4423. 
(24)  Mukai, H.; Wada, Y.; Watanabe, Y. Ann. Nucl. Med. 2013, 27 (7), 625–639. 
(25)  Pandey, M. K.; Byrne, J. F.; Jiang, H.; Packard, A. B.; DeGrado, T. R. Am. 
J. Nucl. Med. Mol. Imaging 2014, 4 (4), 303–310. 
(26)  Henze, M.; Schuhmacher, J.; Hipp, P.; Kowalski, J.; Becker, D. W.; Doll, J.; 
Mäcke, H. R.; Hofmann, M.; Debus, J.; Haberkorn, U. J. Nucl. Med. 2001, 
42 (7), 1053–1056. 
(27)  Virgolini, I.; Ambrosini, V.; Bomanji, J. B.; Baum, R. P.; Fanti, S.; Gabriel, 
M.; Papathanasiou, N. D.; Pepe, G.; Oyen, W.; De Cristoforo, C.; Chiti, A. 
Eur. J. Nucl. Med. Mol. Imaging 2010, 37 (10), 2004–2010. 
(28)  Notni, J.; Pohle, K.; Wester, H. J. EJNMMI Res. 2012, 2 (1), 1–28. 
(29)  Bhatt, J.; Mukherjee, A.; Korde, A.; Kumar, M.; Sarma, H. D.; Dash, A. Mol. 
76 
 
 
Imaging Biol. 2017, 19, 59-67. 
(30)  Eder, M.; Neels, O.; Müller, M.; Bauder-Wüst, U.; Remde, Y.; Schäfer, M.; 
Hennrich, U.; Eisenhut, M.; Afshar-Oromieh, A.; Haberkorn, U.; Kopka, K. 
Pharmaceuticals 2014, 7 (7), 779–796. 
(31)  Fazaeli, Y.; Jalilian, A. R.; Amini, M. M.; Ardaneh, K.; Rahiminejad, A.; 
Bolourinovin, F.; Moradkhani, S.; Majdabadi, A. Nucl. Med. Mol. Imaging  
2012, 46 (1), 20–26. 
(32)  Bhadwal, M.; Das, T.; Dev Sarma, H.; Banerjee, S. Mol. Imaging Biol. 
2015, 17 (1), 111–118. 
(33)  Pan, J.; Harriss, B. I.; Chan, C. F.; Jiang, L.; Tsoi, T. H.; Long, N. J.; Wong, 
W. T.; Wong, W. K.; Wong, K. L. Inorg. Chem. 2016, 55 (14), 6839–6841. 
(34)  Bohle, D. S.; Dodd, E. L.; Pinter, T. B. J.; Stillman, M. J. Inorg. Chem. 
2012, 51 (20), 10747–10761. 
(35)  Azad, B. B.; Cho, C. F.; Lewis, J. D.; Luyt, L. G. Appl. Radiat. Isot. 2012, 70 
(3), 505–511. 
(36)  Wang, W.; Wu, Q.; Pasuelo, M.; McMurray, J. S.; Li, C. Bioconjugate 
Chem. 2005, 16 (3), 729–734. 
(37)  Lössner, D.; Abou-Ajram, C.; Benge, A.; Aumercier, M.; Schmitt, M.; 
Reuning, U. J. Cell. Physiol. 2009, 220 (2), 367–375. 
(38)  Zhao, Y.; Bachelier, R.; Treilleux, I.; Pujuguet, P.; Peyruchaud, O.; Baron, 
R.; Clément-Lacroix, P.; Clézardin, P. Cancer Res. 2007, 67 (12), 5821–
5830. 
(39)  Bednarek, M. A.; Feighner, S. D.; Pong, S.; Mckee, K. K.; Hreniuk, D. L.; 
Silva, M. V; Warren, V. A.; Howard, A. D.; Ploeg, L. H. Y. Van Der; Heck, J. 
V. J. Med. Chem. 2000, 43, 4370–4376. 
(40)  Yeh, A. H.; Jeffery, P. L.; Duncan, R. P.; Herington, A. C.; Chopin, L. K. 
Clin. Cancer Res. 2005, 11 (23), 8295–8303. 
(41)  Jeffery, P. L.; Murray, R. E.; Yeh, A. H.; McNamara, J. F.; Duncan, R. P.; 
Francis, G. D.; Herington, A. C.; Chopin, L. K. Endocr. Relat. Cancer 2005, 
12 (4), 839–850. 
(42)  Gaytan, F.; Morales, C.; Barreiro, M. L.; Jeffery, P.; Chopin, L. K.; 
Herington, A. C.; Casanueva, F. F.; Aguilar, E.; Dieguez, C.; Tena-
Sempere, M. J. Clin. Endocrinol. Metab. 2005, 90 (3), 1798–1804. 
(43)  Charron, C. L.; Hickey, J. L.; Nsiama, T. K.; Cruickshank, D. R.; Turnbull, 
W. L.; Luyt, L. G. Nat. Prod. Rep. 2016, 33 (6), 761–800. 
(44)  Charron, C. L.; Hou, J.; McFarland, M. S.; Dhanvantari, S.; Kovacs, M. S.; 
Luyt, L. G. J. Med. Chem. 2017, 60, 7256–7266. 
77 
 
 
(45)  Mandal, A. K.; Sahin, T.; Liu, M.; Lindsey, J. S.; Bocian, D. F.; Holten, D. 
New J. Chem. 2016, 40, 9648–9656. 
(46)  Fery-Forgues, S.; Lavabre, D. J. Chem. Educ. 1999, 76 (9), 1260. 
(47)  Boscencu, R.; Oliveira, A. S.; Ferreira, D. P.; Ferreira, L. F. V. Int. J. Mol. 
Sci. 2012, 13 (7), 8112–8125. 
(48)  Kubin, R.; Fletcher, A. J. Lumin. 1982, 27, 455–462. 
(49)  Rudolph, J.; Esler, W. P.; Connor, S. O.; Coish, P. D. G.; Wickens, P. L.; 
Brands, M.; Bierer, D. E.; Bloomquist, B. T.; Bondar, G.; Chen, L.; Chuang, 
C.; Claus, T. H.; Fathi, Z.; Fu, W.; Khire, U. R.; Kristie, J. A.; Liu, X.; Lowe, 
D. B.; Mcclure, A. C.; Michels, M.; Ortiz, A. A.; Ramsden, P. D.; 
Schoenleber, R. W.; Shelekhin, T. E.; Vakalopoulos, A.; Tang, W.; Wang, 
L.; Yi, L.; Gardell, S. J.; Livingston, J. N.; Sweet, L. J.; Bullock, W. H. J. 
Med. Chem. 2007, 50, 5202–5216. 
(50)  Nedrow, J. R.; Anderson, C. J. In Encyclopedia of Inorganic and 
Bioinorganic Chemistry; 2016; pp 1–11. 
(51)  Hacht, B. Bull. Korean Chem. Soc. 2008, 29 (2), 372–376. 
(52)  Pampillo, M.; Camuso, N.; Taylor, J. E.; Szereszewski, J. M.; Ahow, M. R.; 
Zajac, M.; Millar, R. P.; Bhattacharya, M.; Babwah, A. V. Mol. Endocrinol. 
2009, 23, 2060–2074. 
 
 
 
                                              
 
 
 
 
 
 
                                     
 
78 
 
 
                                  Chapter 3 
 
3 The Development of Ga-peptide-Hematoporphyrin 
Derivatives as Imaging Agents 
 
3.1 Introduction 
Porphyrin and related compounds have been shown to play a crucial role in 
imaging, detecting and treating different types of cancers. Recently, tetra 
sulphonatophenyl porphyrin (TSPP)-TiO2 was studied as a novel fluorescence 
imaging and photodynamic therapeutic agent for rheumatoid arthritis.1  
Porphyrins exhibit some very useful properties including, ability to form stable 
metal complexes and demonstrate specificity for cancer tissues.2 This makes 
them popular not only as sensitizers for PDT but also makes them suitable 
imaging agents. The tendency of porphyrins and metalloporphyrins to accumulate 
in neoplastic tissues has been previously shown.3 
Various types of imaging applications of porphyrins have been reported in the 
literature e.g. macrophages which are known to play an important role in 
inflammation were labeled with silica-tetrakis(4-carboxyphenyl) porphyrin hybrid 
nanotubes (silica-TCPP HNT), injected into mice and imaged by fluorescence 
microscopy. The ex-vivo images showed the accumulation of macrophage 
labeled HNT’s in the liver and demonstrated the ability of these systems to act as 
NIR probes for in vivo imaging.4  
A dinitrotetraphenylporphyrin based probe was studied for MRI and fluorescence 
Zn sensing.5 Zn selective binding units were conjugated to the porphyrin 
analogue. The fluorescence intensity of this probe was found to increase > 10-
fold on binding to Zn. The Mn-coordinated analogue of 
dinitrotetraphenylporphyrin was also synthesized. The relaxivity of this Mn-
79 
 
 
analogue was drastically changed in the presence of Zn, demonstrating the 
potential to act as MRI Zn sensor. Lovell and coworkers utilized mesotetrakis (4-
carboxyphenyl) porphyrin for synthesizing a novel class of optically active 
hydrogels.6 Hydrogels can act as efficient drug delivery systems. The hydrogels 
after being implanted in mice were monitored for 2 months and found to be stable 
and resistant to bleaching. Further, real time image guided surgical resection of 
the implanted hydrogel in vivo was also performed. Novel Mn-porphyrin probes 
have been explored as MRI agents for prostate cancer.7 Phantom studies 
depicted a higher T1 relaxivity change for these porphyrin probes as compared to 
the commercial Gd chelates. High tumour to background contrast was seen after 
single injection of these probes in prostate tumour xenografts. Another Gd-DTTA 
(diethylenetriamine-N,N,N’’,N’’-tetraacetate)-porphyrin complex was synthesized 
for application as MRI contrast agent.8 The relaxivity per gadolinium was found to 
remain high at very high magnetic field. 
Another emerging field of imaging where porphyrins have been shown to have 
played vital role is nuclear imaging. The development of [67Ga]-3,4-
dimethoxylated porphyrin complex as potential SPECT imaging agent has been 
reported.9 Stability tests indicated that 67Ga was still intact in the complex after 
incubation in human serum after 24 hours. Biodistribution studies and SPECT 
images demonstrated a higher uptake in the myocardium. 99mTc-meso-bisphenyl 
porphyrin was evaluated as imaging agent for colorectal adenocarcinoma and 
non-small cell lung cancer.10 The effect of temperature on the radiolabeling 
efficiency was demonstrated and a labeling efficiency > 90% was obtained by 
optimizing the reaction temperature. The complex showed a rapid clearance 
through gastrointestinal and urinary pathways. A higher uptake by the H1299 cell 
line was confirmed by both in vitro and in vivo analysis. 111In labeled porphyrin 
derivatives were analyzed as effective agents for SPECT imaging in wild type 
mice.11 The stability of these complexes was tested in human serum for 2 days. 
Biodistribution and SPECT studies showed rapid clearance through urinary 
excretion depicting that these complexes can act as efficient imaging agents.  
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In another example, 5,10,15,20-tetrakis(pentafluoro-13 phenyl) porphyrin (TFPP) 
was radiolabeled with 68Ga in 30-60 minutes. Stability tests indicated no loss of 
Ga from the complex after incubation with human serum even after 2 days. 
Biodistribution analysis was performed in mice bearing fibrosarcoma tumours and 
higher uptake of the radiotracer in the tumour was seen. Hence, the potential of 
this 68Ga-porphyrin complex to act as PET imaging agent was depicted. 
The porphyrin selected for this project is hematoporphyrin (HP). It has been one 
of the most commonly studied porphyrins. In the 1960’s, the tumour localizing 
fraction from the hematoporphyrin solution was isolated by Schwartz.12 Later, this 
hematoporphyrin derivative was studied by Dougherty and found to have a high 
singlet oxygen quantum yield. The efforts made by Dougherty through 
ultrafiltration led to the isolation of the material known as Photofrin II.13 Later, 
additional purification performed at QLT Photo Therapeutics resulted in the 
isolation of the material which is known as Photofrin® today.14,15 There has been 
a lot of debate on the chemical composition of this material. A lot of difficulties 
were encountered due to the fact that the hematoporphyrin derivative comprised 
of a complex mixture of oligomers and the determination of the exact chain length 
was difficult.16 This material comprised of a mixture of porphyrins linked together 
by ether and ester linkages.17 Photofrin® shows a broad HPLC profile owing to 
the complex nature of this mixture. Nonetheless, due to the selective 
accumulation of Photofrin® at tumour sites, it was later approved by FDA for the 
treatment of lung and esophageal cancer.18  
There are some reports in the literature that demonstrate that HP can be 
coordinated to metal ions. For example gold(III)-HP complex was synthesized 
and used to study cytotoxicity against leukemia and lymphoma derived cell 
lines.19 Pt-HP complexes have also been studied as anticancer agents.20 HP has 
also been coordinated to radiometals such as 111In and a comparison of 
biodistribution of 111In-hematoporphyrin and 111In chloride in tumour bearing mice 
showed a difference in tumour uptake of both these species.21 Effect of metal 
coordination on the fluorescent properties of HP has also been studied in a few 
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cases. Coordination of HP to metal ions such as Co2+ and Cu2+ has been found 
to quench the fluorescence.22 
Besides application as a photosensitizer, hematoporphyrin has also been 
analysed as an effective imaging agent. In one of the examples, hematoporphyrin 
was used for early detection of the surface tumours in mice through fluorescence 
reflectance imaging (FRI).23 The red fluorescence signal from the accumulation of 
hematoporphyrin in tumour was observed within 3 days from the injection of 
cancer cells into the mice i.e. long before the tumour was apparent to the naked 
eye. Recently, HP monomethyl ether (HMEE) loaded poly (lactic-co-glycolic acid) 
(PLGA) microcapsules were developed as ultrasound/photoacoustic contrast 
agent.24 Ultrasound irradiation of sonosensitizers in appropriate frequency can 
lead to permanent damage to tumour cells. HMEE/PGLA microcapsules 
effectively destroyed ovarian cancer SKOV3 cells and prevented cell proliferation. 
99mTc-HP-albumin nanoparticles (ANP) were studied for application in radio 
imaging of lung cancer.25 Here the surface of albumin nanoparticles was modified 
with hematoporphyrin which was then labeled with 99mTc. HP-ANP showed higher 
uptake in the cancer cells and higher accumulation in the mouse lung cancer 
model. 
The efficiency of the imaging probes can certainly be enhanced by developing 
delivery modes that will transport them to the biological site of interest. Therefore, 
there is continuous demand for the development of new targeting strategies. One 
such targeting strategy is to attach the porphyrin to an entity that has high 
specificity and selectivity for a bioreceptor. Several small molecules, peptides, 
antibodies have been conjugated to porphyrins to facilitate selective uptake by 
cancer. A 64Cu-porphyrin-peptide analogue was developed as a targeted PET 
imaging probe for the folate receptor that is expressed in lung, ovarian and breast 
cancer.26 Small animal PET images depicted the uptake of the analogue in the 
folate receptor positive tumours with high tumour to muscle ratio. Gold 
nanoparticles were functionalized with porphyrin through hyaluronic acid that is 
known to have a high affinity for CD44 which is overexpressed in many cancers. 
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The probe could differentiate between cells with different levels of CD44 and also 
demonstrated specific damage to cancer cells such as U-87 overexpressing 
CD44.27 68Ga-porphyrin-peptide conjugate was developed as PET/PDT 
theranostic agent targeted for ɑ6 β1 integrin.28 Azide bearing porphyrin was 
labeled with 68Ga and clicked with the alkyne functionalized peptide specific for ɑ6 
β1 integrin. The evaluation of the therapeutic effects depicted the selectivity of the 
probe for cell line with high integrin expression.  
Bombesin (BN) is a 14-amino acid peptide which was isolated from the skin of 
the toad bombina bombina.29 Consequently, two mammalian bombesin like 
peptides (BN-LP) were isolated: gastrin releasing peptide (GRP) and 
neuromedin-B (NMB). BN and GRP stimulate smooth muscle contraction, play a 
role in the release of gastrin, the secretion of pancreatic enzymes, and act as 
neurotransmitters in the central nervous system.30 Four receptor subtypes 
associated with the BN-LP family have been isolated. These include receptor 
subtype-1 (GRP-R) that binds to both BN and GRP, receptor subtype-2 (NMB-R) 
that binds to NMB, subtype-3 (BRS-3) that is an orphan receptor because its 
natural ligand has not been discovered yet and lastly receptor subtype-4 (BRS-4), 
that exhibits higher affinity for BN than GRP30. These receptors belong to the G-
protein receptor superfamily.31  
GRP-R is overexpressed in several kinds of cancers such as prostate,32 breast,33 
gastrointestinal,34 lung cancer35 etc. Therefore, GRP-R can play a vital role in 
imaging of cancer by developing imaging probes by the attachment of an imaging 
tag to bombesin peptide that has high affinity for GRP-R. Structure activity 
studies demonstrate that the C-terminus is crucial for binding to the receptor 
therefore modifications can be made at the N-terminus. A pan bombesin 
analogue [D-Tyr6,β-Ala11, Phe13, Nle14]-bombesin (6-14), where amino acids at 
position 6,11,13 and 14 are replaced by unnatural amino acids has been found to 
bind all bombesin receptor subtypes with a high affinity.36 The replacement with 
unnatural amino acids also helps in improving the in vivo peptide stability. 
Another report suggested that the presence of D-Tyr6 was not necessary for 
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binding to GRP-R.37 Therefore, the truncated sequence BN (7-14) is sufficient for 
binding to GRP-R.38 
BN (7-14) has been used for the development of various imaging probes. Many 
BN (7-14) analogues with modifications have been shown to be radiolabeled with 
radioisotopes like 64Cu39, 18F40, 99mTc41. Some BN (7-14) have also been reported 
for application in fluorescence imaging of GRR-R with Qdots,42 Alexa Fluor43. In 
one of the examples, [β-Ala11, Phe13, Nle14]-bombesin (7-14) analogue was 
coupled to superparamagnetic iron oxide nanoparticles using click reaction. 
Specific uptake of the probe relative to unfunctionalized nanoparticles was 
demonstrated in prostate cancer PC-3 cells.44 This demonstrated the potential of 
the probe to act as MRI contrast agent for imaging prostate cancer. 
This study will involve the conjugation of hematoporphyrin with [β-Ala11, Phe13, 
Nle14]-bombesin (7-14) for the development of fluorescent/PET based imaging 
probe for GRP-R. 
 
3.2 Results and Discussion 
 Earlier, Ga69/71 has been coordinated to PPIX45,46  and the presence of the 
coordinated Ga69/71 did not quench the fluorescence of PPIX.46  Owing to the 
hydrophobic nature of PPIX, there were problems related to the solubility. Due to 
the presence of isopropanol substituents, HP seems more hydrophilic as 
compared to PPIX. We aimed to develop a Ga-HP-peptide based dual modal 
fluorescence/PET imaging agent for GRP-R. The peptide chosen for this study is 
[β-Ala11, Phe13, Nle14]-bombesin (7-14), which has been shown earlier in the 
literature to be specifically taken up by PC-3 cells expressing GRP-R.44 
HP that is commercially available, consists of not just one species, but is a 
mixture of different porphyrin species. These include: 1) hematoporphyrin where 
two of the pyrrole rings have iso-propanol groups attached, 2) two 
monohydroxyethyl monovinyl deuteroporphyrin derivatives HVD1 and HVD2, 
where one of the isopropyl group is replaced by a vinyl group for each of the 
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HVDs respectively and 3) PPIX, where both the isopropyl groups are replaced by 
vinyl groups. Figure 3.1 shows the structure of the porphyrin species comprising 
a hematoporphyrin mixture. This entire hematoporphyrin mixture can be used for 
imaging and the separation of the porphyrin species comprising this mixture is 
not necessary. The main idea is to be able to conjugate all the porphyrin species 
with the targeting peptide, coordinate to 69/71 Ga and radiolabel with 68Ga and use 
as such for fluorescence and PET imaging.   
 
 
 
 
Figure 3.1 Structures of various porphyrin species comprising hematoporphyrin 
mixture. 
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3.2.1 69/71 Ga Coordination of Hematoporphyrin 
Coordination of certain metal ions to porphyrins typically requires high reaction 
temperature.47 Conventional heating methods often require heating the reaction 
mixtures at elevated temperatures and for longer reaction times.47 This can be a 
limiting factor for the  coordination of Ga3+ to porphyrins particularly if the 
porphyrin has a peptide attached to it owing to the instability of peptide at very 
high temperature. Use of microwave irradiation to coordinate metal ions to 
porphyrins has shown improvement over conventional methods.46 Before moving 
forward with the synthesis of the imaging probe, it was desired to analyze the 
ability of hematoporphyrin to coordinate to 69/71Ga. Hematoporphyrin was first 
coordinated to 69/71Ga using GaCl3. 
Hematoporphyrin is more hydrophilic as compared to PPIX, therefore it was 
possible to perform 69/71Ga coordination under aqueous conditions employing a 
mixture of NaOAc/AcOH (aq) buffer and acetone as solvent system. This is in 
contrast to what was previously found for the coordination of 69/71Ga to PPIX, 
which could not be performed under aqueous conditions and required the use of 
2,6-lutidine. A mixture of 69/71Ga coordinated hematoporphyrin species was 
obtained. Figure 3.2 depicts the structure of 69/71Ga coordinated hematoporphyrin 
mixture.  Compound 3.1 corresponds to Ga coordinated hematoporphyrin 
mixture, 3.2 and 3.3 correspond to the two isomers of Ga coordinated HVD 
where one of the isopropyl group is replaced by vinyl group respectively and 3.4 
corresponds to Ga coordinated PPIX component. The HPLC trace for these 
species is also shown in Figure 3.3. The ratio between the different 69/71Ga 
coordinated hematoporphyrin species was determined to be 2:2:2:1 for 
compounds 3.1:3.2:3.3:3.4 (from the HPLC trace). Compounds 3.2 and 3.3 are 
two isomers that have different retention times on the HPLC but show the same 
mass on the mass spectrum. The formation of 69/71Ga-hematoporphyrin species 
was confirmed from the mass spectrum. The m/z values for these species are 
summarized in Table 3.1.  
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The fluorescence quantum yield for 69/71 Ga-coordinated HP mixture was 
determined to be 0.38, once again confirming that Ga coordination does not 
quench the porphyrin fluorescence. 
 
 
 
 
Figure 3.2 Structures of the 69/71Ga coordinated hematoporphyrin species. 
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Figure 3.3 HPLC chromatogram for 69/71Ga coordinated hematoporphyrin 
species. Compound 3.1 (retention time 1.25 minutes), compound 3.2 or 3.3 
[isomers not assigned] (retention time 1.58/1.66 minutes) and compound 3.4 
(retention time 2.02 minutes). AU: 200-800 nm. 
 
                                                            
                                                          
 Calculated m/z Observed m/z 
3.1 665.1891 665.1689 
3.2 647.1785 647.1469 
3.3 647.1785 647.1469 
3.4 629.1679 629.1655 
 
Table 3.1 Calculated m/z and observed m/z for 69/71Ga-hematoporphyrin species 
3.1, 3.2, 3.3 and 3.4. 
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3.2.2 Optical Analysis 
 
Photo-physical data was obtained and compared to HP (summarized in table 
3.2). It was observed that upon Ga-coordination there was a blue shift in the 
emission maxima as compared to HP. The absorbance maxima did not shift 
significantly upon coordination to 69/71Ga. The coordination of 69/71Ga could be 
easily confirmed from the absorption spectrum, as the formation of 
metalloporphyrin leads to the disappearance of two Q-bands. (Figure 3.4) 
The fluorescence quantum yields were obtained according to the reported 
comparative methods48, using tetraphenylporphyrin as standard.49 Fluorescence 
quantum yield for Ga-coordinated HP mixture was 0.38 as compared to 0.07 for 
the uncoordinated parent HP(mixture of porphyrin species) .  
    
 
Compound λex (nm) 
(DMSO) 
λem (nm) 
(DMSO) 
λabs (nm) 
(DMSO) 
Φ[a]  
(EtOH) 
Hematoporphyrin 
 
399 628 395 0.07 
69/71Ga-Hematoporphyrin  
      species 
405 579 405 0.38 
 
Table 3.2 Photophysical data for HP and 69/71Ga-HP analogues. 
Slit width was 2 nm. Emission collected in the range 409-800 nm for 
hematoporphyrin and 415-800 nm for 69/71 Ga-hematoporphyrin species.  
[a]: Quantum yields obtained using tetraphenyl porphyrin49 as standard in 
deoxygenated solutions using previously reported procedure.48 
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Figure 3.4 Absorption and emission spectra: Absorption for HP mixture (blue), 
Absorption for 69/71Ga-HP analogues (green), emission for compound HP mixture 
(red), emission for 69/71Ga-HP analogues (black). Recorded for 10-5 M DMSO 
solution. 
 
 
3.2.3 Synthesis of HP-AEEA-[β-Ala11, Phe13, Nle14]-Bombesin(7-14) 
Analogues 
The design of the dual modality imaging probe consists of using the peptide 
analogue [β-Ala11, Phe13, Nle14]-bombesin (7-14) as the targeting entity, a linker 
and HP as the fluorescent tag/metal chelator. The C-terminus of bombesin is 
crucial for binding to the receptor. Therefore, HP would be coupled to N-terminus 
of bombesin through a linker, leaving the C-terminus free for binding to the 
receptor. The linker 2-[2-(2-aminoethoxy)ethoxy] acetic acid (AEEA) was selected 
in order to improve the hydrophilic character of the imaging probe and also to 
increase the distance between the peptide and chelator HP, in order to prevent 
the adverse effect of the bulky HP on the binding affinity of the peptide, [β-Ala11, 
Phe13, Nle14]-bombesin (7-14) was coupled to the AEEA linker. This was then 
coupled to hematoporphyrin on resin. A mixture was obtained, where all the 
porphyrin species comprising the hematoporphyrin mixture were coupled to the 
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peptide. Figure 3.6 depicts the HPLC trace for coupling bombesin peptide to the 
hematoporphyrin analogues through the AEEA linker. 
 The metal chosen was Ga, where the 69/71Ga analogue will be used for in vitro 
fluorescence analysis as well as a non-radioactive standard. The 68Ga analogue 
can be used for PET based imaging analysis. The synthetic route for synthesis of 
imaging probe is depicted in Scheme 3.1. 
 
 
 
Figure 3.5 General design of the imaging probe. 
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Scheme 3.1 Route for synthesis of imaging probe comprising hematoporphyrin 
species coupled to bombesin analogue (compounds 3.7, 3.8, 3.9 and 3.10). 
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Figure 3.6 HPLC trace for crude mixture of products obtained by coupling [β-
Ala11, Phe13, Nle14]-bombesin (7-14)-AEEA with HP. Compound 3.7 (retention 
time 1.63 minutes), compound 3.8 and 3.9 (isomers not assigned) (retention time 
2.00-2.13 minutes) compound 3.10 (retention time 2.47 minutes). AU: 200-800 
nm. 
 
3.2.4 69/71Ga Coordination of HP-AEEA-[β-Ala11, Phe13, Nle14]-
Bombesin(7-14) Analogues. 
Next the hematoporphyrin-peptide mixture was coordinated to 69/71Ga. The HPLC 
chromatogram from this reaction looked quite complicated. It was seen from the 
chromatogram that although the HP component, i.e. compound 3.7, and HVD 
components, i.e. compounds 3.8 and 3.9, were coordinated to 69/71Ga. 
Compound 3.10 could not be coordinated to 69/71Ga. Figure 3.7 depicts the HPLC 
trace for 69/71Ga coordination. 
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Various attempts were made to coordinate all the components to 69/71 Ga but 
these attempts were unsuccessful due to decomposition of HP to PPIX and to 
other species and due to decomposition of the peptide. This led to an increase in 
the complexity of the mixture. This mixture of Ga-coordinated and uncoordinated 
porphyrin species could not be used to obtain the photophysical data. Using this 
will not give a correct estimation of the effect of 69/71Ga coordination on the optical 
properties.  
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Scheme 3.2 Route for 69/71Ga coordination. 
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Figure 3.7 HPLC trace for crude mixture of products obtained by coordinating 
69/71Ga to [β-Ala11, Phe13, Nle14]-bombesin (7-14)-AEEA-HP. Compound 3.11 
(retention time 1.01 minutes), compound 3.12 and 3.13 (retention time 1.18-1.48 
minutes). Unreacted compound 3.10 (retention time 1.55 minutes). AU: 200-800 
nm. 
 
3.2.5 68Ga Labeling of Hematoporphyrin 
In order to confirm the potential of HP to chelate to 68Ga, attempts were made to 
radiolabel HP with 68Ga. The radiochromatogram was compared with the HPLC 
trace for the non-radioactive standard (mixture of compounds 3.1, 3.2, 3.3 and 
3.4) (Figure 3.8). After several trials, the best results depicted that although HP 
and HVD were being labeled with 68Ga, no peak corresponding to the 68Ga-PPIX 
component was seen. Any further attempts were leading to the breakdown of HP 
into PPIX and this PPIX component was not coordinating with the radiometal. 
This might be due to solubility issues related to PPIX. There is a difference in the 
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solubility between PPIX and HP and its derivatives HVD. PPIX is more 
hydrophobic than HP, leading to incomplete labeling. Nonetheless, the ability of 
HP to become radiolabeled with 68Ga was demonstrated. 
  
       
  Scheme 3.3 Synthetic route for radiolabeling of HP with 68Ga. 
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Figure 3.8 UV trace for standard compound i.e. mixture of 3.1 (retention time 6 
minutes), 3.2, 3.3 (isomers not assigned) (retention time 7-8 minutes) and 3.4 
(retention time 9 minutes) (blue), AU: 200-800 nm and radiochromatogram for 
68Ga labeling (red) using CsI(Tl) scintillating crystal coupled to silicon PIN diode. 
 
3.3 Conclusions 
Hematoporphyrin (HP) can form metal complexes and possesses fluorescent 
characteristics. We aimed to develop hematoporphyrin based fluorescence/PET 
imaging agents targeting GRP-R, which is highly expressed in prostate cancer 
and can be useful in diagnosis. HP was coordinated to 69/71Ga, where a mixture 
of 69/71Ga-coordinated porphyrin species was obtained and the fluorescent 
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properties were studied. A fluorescence quantum yield of 0.38 was obtained for 
this mixture as compared to the parent uncoordinated hematoporphyrin mixture 
for which fluorescence quantum yield was determined to be 0.07. 
The peptide [β-Ala11, Phe13, Nle14]-bombesin (7-14) has been earlier shown to be 
specifically taken up by the prostate cancer cell line PC-3. HP was first coupled 
through an AEEA linker to the peptide [β-Ala11, Phe13, Nle14]-bombesin (7-14) at 
its N-terminus leaving the C-terminus free as it is needed for binding to the 
receptor. A mixture of porphyrin-peptide species was obtained. This mixture 
comprised of peptide coupled to HP, two HVD isomers and PPIX species leading 
to the synthesis of compounds 3.7, 3.8, 3.9 and 3.10. Upon coordination of this 
mixture to 69/71Ga, a complex mixture of 69/71Ga-HP (3.11) and 69/71Ga-HVD (3.12 
and 3.13) was obtained. Also, some of the porphyrin species were left 
uncoordinated which led to difficulties in purification of this Ga coordinated and 
uncoordinated mixture. In order to maintain consistency, all the porphyrin species 
comprising the hematoporphyrin mixture need to be coordinated to  69/71Ga.   
To focus on the design of a PET imaging probe, HP was radiolabeled with 68Ga. 
Although, we were successful in radiolabeling HP and HVD components, the 
radiolabeling did not go to completion and we were not able to radiolabel the 
PPIX component of the HP mixture.  
The aim of this project was to develop fluorescent Ga-bombesin-hematoporphyrin 
analogues and to analyze the specific binding to GRP-R through fluorescence 
microscopy. Further, the project focussed to develop this probe into PET imaging 
probe  
 
through 68Ga labeling. The ability of hematoporphyrin to coordinate to 69/71Ga and 
act as a useful metal chelator was demonstrated. Fluorescence of 
hematoporphyrin species was not quenched upon coordination to 69/71Ga which 
was evident from the fluorescence quantum yield data. Hematoporphyrin was 
also successfully radiolabeled with 68Ga and this would facilitate the development 
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of 68Ga-hematoporphyrin as a PET imaging probe. Further, the ability of 
hematoporphyrin to be coupled with a peptide was demonstrated. But the gallium 
coordination could not be carried out to completion possibly due to the poor 
solubility of the PPIX component. 
Since the isolation of the Ga-coordinated analogues was problematic, other 
porphyrins should be investigated for use as fluorescent tags and as Ga 
chelators. Structural modifications could be carried out to introduce more 
hydrophilic groups to the porphyrin. These approaches have the potential to aid 
in increasing the solubility of the porphyrin and could improve yields for the metal 
coordination reactions.     
 
3.4 Experimental 
Materials and Methods 
All common solvents were purchased from Fischer scientific. All Fmoc protected 
amino acids, coupling agents and resins were purchased from Chem Impex, 
Peptide International and Novabiochem® and were used without further 
purification unless otherwise stated. All reagents were purchased from Sigma 
Aldrich except for GaCl3 which was purchased from Strem Chemicals. The 
germanium/gallium generator was obtained from Eckert and Ziegler. [125I]-ghrelin 
was received from Perkin Elmer. RP-C18 Sep-Pak SPE cartridges were 
purchased from Waters. For analysis of samples, an analytical Agilent RP-C18 
4.6 X 150 mm, 5 µm column was utilized. The flow rate was 1.5 mL/min over 25 
minutes. For purification of samples, a reverse phase preparative HPLC column 
(Agilent RP-C18 19 X 150 mm, 5 µm) was employed with a flow rate of 20 
mL/min over 15 minutes. The gradient solvent system used were 0.1% TFA in 
acetonitrile (solvent A) and 0.1% TFA in water (solvent B). This system was 
provided with a Waters 600 controller, Waters Prep degasser, Waters Mass Lynx 
software (version 4.1). For the studies on UHPLC-MS, Waters Inc. Acquity 
UHPLC H-Class system was used. This was used in combination with Xevo QTof 
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mass spectrometer (ESI +, cone voltage 30V). For analytical studies, a Waters 
Acquity UHPLC BEH C18 2.1 X 50 mm, 1.7 µm column was utilized. The gradient 
solvent system employed was 0.1% formic acid in acetonitrile (solvent C) and 
0.1% formic acid in water (solvent D). For analysing the radioactive samples, 
analytical SunfireTM RP-C18 4.6 X 150 mm, 5 µm column was used. The system 
comprised of a Waters 1525 Binary HPLC pump with a Water 2487 dual λ 
absorbance detector and Breeze software (version 3.30).  
 
Synthesis of compound 3.1, 3.2, 3.3 and 3.4.   
Hematoporphyrin (10 mg, 0.0167 mmol) was dissolved in 1 mL acetone and 2 mL 
sodium acetate/acetic acid buffer (pH 4.3). GaCl3 (14.7 mg, 0.0836 mmol) was 
dissolved in 1 mL sodium acetate/acetic acid buffer and this solution was added 
to the hematoporphyrin solution. The reaction mixture was heated in a microwave 
reactor at 1200 C for 15 minutes, then cooled to r.t. and passed through RP C-18 
Sep Pak SPE cartridge. The RP C-18 Sep Pak SPE cartridge was then washed 
with water and the products were eluted with ethanol. Analysis of the products 
was carried out by UHPLC-MS with four predominant peaks being identified as 
Ga-coordinate porphyrins obtained in the ratio 2:2:2:1 (3.1:3.2:3.3:3.4). HRMS 
(ESI +): (For 3.1)   m/z calculated for C34H36GaN4O6, 665.1891; observed 
665.1689. (For 3.2/3.3)  m/z calculated for C34H34GaN4O5, 647.1785; observed  
647.1469. (For 3.4)  m/z calculated for C34H32GaN4O5, 629.1679; observed 
629.1655.    
 
Synthesis of [β-Ala11, Phe13, Nle14]-bombesin (7-14) compound 3.5. 
Synthesis of peptide was carried out using peptide synthesis vessel, employing 
solid phase peptide synthesis chemistry. Peptides were synthesized at 0.1 mmol 
scale using Rink amide resin (0.51 mmol/g). Fmoc deprotection was carried out 
using 2 mL of 20% Pip/DMF for two cycles (10 min, 15 min). Activation of amino 
acids was carried out using 3 eq. of HCTU, and 6 eq. of N,N-
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diisopropylethylamine (DIPEA)  in 2 mL of DMF. The mixture was then added to 
the resin and shaken (using IKA-VIBRAX-VXR from Sigma-Aldrich) for 60 min. 
These cycles were repeated until all N terminal amino acids were coupled to the 
resin. A small sample from the crude peptide was cleaved from resin using 0.5 
mL of a mixture of 95 % TFA (trifluoroacetic acid), 2.5 % TIPS (triisopropylsilane) 
and 2.5 % H2O. The cleaved peptide was precipitated from solution using cold 
TBME (tert-butyl methyl ether) and centrifuged (3000 rpm, 10 min) resulting in 
crude peptide pellet. The supernatant was discarded and the peptide pellet was 
dissolved in 40% ACH/H2O, frozen at -78 0C and lyophilized resulting in a brown 
powder. The crude peptide was analysed by analytical UHPLC-MS. HRMS (ESI 
+): m/z calculated for C48H67N13O9, [M+H]+ = 970.5965; observed [M+H]+= 
970.4868    
 
Synthesis of [β-Ala11, Phe13, Nle14]-bombesin (7-14)-AEEA compound 
3.6. 
Fmoc deprotection of peptide 3.5 was carried out using 2 mL of 20% Pip/DMF for 
two cycles (10 min, 15 min). Linker AEEA (116 mg, 0.300 mmol) was dissolved in 
DMF and HCTU (125 mg, 0.3 mmol) and DIPEA (105 µL, 0.600 mmol). This 
solution was then shaken at r.t. for 15 min and then added to the peptide. 
Reaction mixture was shaken at r.t. for 2 hours. The crude product was analysed 
by UHPLC chromatogram. HRMS (ESI +): m/z calculated for C54H78N14O12, 
[M+H]+ = 1115.6704; observed [M+H]1+ = 1115.6001  
 
Synthesis of [β-Ala11, Phe13, Nle14]-bombesin (7-14)-AEEA-HP 
compound (3.7, 3.8, 3.9 and 3.10) 
Fmoc deprotection of peptide 3.6 was carried out using 2 mL of 20% Pip/DMF for 
two cycles (10 min, 15 min). Hematoporphyrin (207 mg, 0.300 mmol) was 
dissolved in DMF:DCM:DMSO (1:1:1) and HATU (115 mg, 0.300 mmol) and 
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DIPEA (105 µL, 0.600 mmol). This solution was then shaken at r.t. for 15 min and 
then added to the peptide solution. Reaction mixture was vortexed at r.t. for 16 
hours. Full deprotection of product was accomplished by adding 3 mL mixture 
comprising of 95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIPS), 2.5% 
H2O to the resin and shaken for 4 hours. The cleaved peptide was precipitated 
using ice cold tert-butyl methyl ether (TBME) and centrifuged at 3000 rpm for 15 
min. The supernatant was removed and peptide pellet was dissolved in 40% ACN 
in H2O, frozen at -780C and lyophilized to obtain a brown solid. The crude peptide 
was purified using preparative HPLC-MS and the purity was examined using 
UHPLC. HRMS (ESI +): (For 3.7) m/z calculated for C88H114N18O17 , [M+2H]2+ = 
848.4382; observed [M+2H]2+ = 848.5945  (For 3.8/3.9) m/z calculated for 
C88H112N18O16 , [M+2H]2+ = 839.4330; observed [M+2H]2+ = 839.5709  (For 3.10) 
m/z calculated for C88H110N18O15 , [M+2H]2+ = 830.4277; observed [M+2H]2+ =  
830.5591.     
                                      
Synthesis of compounds (3.11, 3.12 and 3.13)  
Mixture of compounds 3.7, 3.8, 3.9 and 3.10 (10 mg, 0.00553 mmol) was 
dissolved in 1 mL acetone and 1.5 mL sodium acetate/acetic acid buffer (pH 4.3). 
GaCl3 (5 mg, 0.0276 mmol) was dissolved in 1 mL buffer and added to the above 
solution. The reaction mixture was heated in a microwave reactor at 1200 C for 15 
min. The reaction mixture was passed through RP C-18 Sep Pak SPE cartridge 
and the cartridge was eluted with water and ethanol. Ethanol was evaporated and 
crude product was analyzed using UHPLC. HRMS (ESI +): (For 3.11) m/z 
calculated for C88H112GaN18O17 , [M+2H]2+ = 81.8932; observed [M+2H]2+ = 
881.3821. (For 3.12/3.13) m/z calculated for C88H110GaN18O16 , [M+2H]2+ = 
872.8879; observed [M+2H]2+ = 872.8879.     
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Optical Analysis 
UV absorption data was acquired using Varian Carry 300 Bio UV-Vis 
spectrophotometer. Excitation and emission data were acquired using Photon 
Technology International QM-4 SE spectrofluorometer. The absorption, excitation 
and emission wavelengths were determined using DMSO as a solvent. 
Fluorescence quantum yields were determined using the comparative method 
described by Fery-Forgues and coworkers.48 Briefly, the absorbance for the 
solutions of the unknown sample and the standard was measured. The emission 
spectra were also obtained and the area under the curve was determined. 
Fluorescence quantum yields were estimated using tetraphenylporphyrin as the 
standard. Fluorescence quantum yield for tetraphenylporphyrin has been 
reported to be 0.11 in toluene.49 Fluorescence quantum yields were determined 
using the equation: 
ϕx = ϕst [ gradx/gradst ] [ ƞ2x/ƞ2st ] 
where ϕx and ϕst are fluorescence quantum yields for unknown sample and 
standard respectively. gradx and gradst are the gradients from the plot of 
integrated fluorescence intensity vs absorbance for unknown sample and 
standard respectively. ƞ is the refractive index of the solvent used. 
                                 
Radiolabeling hematoporphyrin with Ga-68. 
Fresh 68Ga3+ was eluted from 68Ge/68Ga generator using 0.1 M hydrochloric acid 
(HCL) and trapped on Strata X C cation exchange column. The column was 
eluted with 0.1 M HCl in acetone. Hematoporphyrin (1 mg, 1.67 µmol) was 
dissolved in 1 mL of acetone. To 100 µl of this solution was added 900 µl of 
sodium acetate/acetic acid buffer (pH 4.3). This solution was added to a clean 
glass microwave vessel to which 516 MBq of 68GaCl3 freshly eluted from 
68Ge/68Ga generator was added. The reaction mixture was heated in a microwave 
reactor at 1200 C for 20 minutes. The reaction mixture was then passed through 
preconditioned RP C-18 Sep Pak SPE cartridge and washed with 1 mL of water. 
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The product was eluted off the sep pak with 1ml of EtOH. The activity of EtOH 
solution was 20 MBq. The reaction progress and product purity was analyzed 
using analytical HPLC.  
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                                   Chapter 4 
 
4 The Development of Ghrelin-Formazanate Boron Difluoride 
Dyes as Imaging Agents 
 
4.1  Introduction   
The extensive interest from chemists, biochemists, and physicists in the use of 
fluorescence has accelerated the development of novel fluorescent dye systems. 
Fluorescent systems have several applications in biology and biotechnology such 
as molecular probes in biomedical analysis, microscopy, cellular imaging, flow 
cytometry, and genotyping assays.1 The synthesis of dyes has been carried out 
since a very long time, with the focus being on the development of compounds 
that have good chemical, photochemical and thermal stability, and excellent 
optical properties.2 Classes of dyes that have been devised systematically 
comprise of porphyrins,3 coumarins,4 xanthenes,5 and cyanines6. One of the most 
common application of these dyes is fluorescence microscopy. Fluorescence 
quenching and photobleaching are two of the limitations associated with 
conventional dyes, therefore, there is a need for the development of novel dyes 
that have better photostability and suitable optical properties.7,8 
Recently, one of the most well studied application of the structurally distinct 
fluorescent dyes includes the development of the methodologies where unique 
reporter entities can be coupled to the targeting agent.9 Various biomolecules 
including DNA, proteins and antibodies are labeled with fluorescent dyes such as 
fluorescein and rhodamine.1 Recent developments in chemical biology and 
molecular library screening has led to the recognition of new ligands having high 
affinity for biological targets as well as identification of novel fluorescent systems. 
The structure and physiochemical characteristics of a dye-conjugate are 
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important factors to be considered for the conservation of the affinity of the 
targeting entity. Most fluorescent dyes are large, consisting of polycyclic rings 
and are charged due to the presence of certain functional groups. These features 
are an obstacle to the development of new imaging agents when targeting moiety 
is a small molecule. Since physiochemical properties of the dye might change the 
solubility and physical properties of the dye-targeting moiety conjugate. This can 
lead to a decrease in the binding affinity for the biological target.10 The features 
for the ideal signaling dye consist of the ease of attachment to the targeting 
entity, effective cellular uptake, and absence of innate activity and toxicity.9 This 
has led to a requirement for developing novel neutral, small, and biocompatible 
fluorescent cores that demonstrate good solubility, optimal photophysical 
characteristics and versatile coupling strategies.1  
Over the last decade there has been a tremendous interest in the development of 
dyes based on 4,4’-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY). BODIPY 
dyes exhibit excellent photophysical properties including narrow absorption and 
emission bands, high molar extinction coefficients and good fluorescence 
quantum yields.2 Owing to all of these favourable spectral properties, BODIPY 
derivatives have a wide range of applications such as chemosensors,11 
sensitizers for dye sensitive solar cells,12 and in photodyanamic therapies13. A 
BODIPY-NLS (nuclear localization sequences) peptide analogue has been 
shown as an effective PDT agent.14 Recently, another group reported the 
application of near infra-red aza-BODIPY loaded polymeric nanoparticles for 
optical cancer imaging.15 Paulus and coworkers investigated the use of 18F-
BODIPY-bombesin GRP receptor PET/fluorescence imaging agent.16 Despite a 
number of favourable characteristics, BODIPY derivatives suffer from some 
drawbacks such as difficult synthesis and small Stokes shifts which is an 
important criterion for application in fluorescence microscopy. 
One class of chelating N-donor ligands that has not been studied very extensively 
are the formazanate ligands. These are derived from formazans. Formazans 
were first reported as 1,5-diphenyl and 1,3,5-triphenyl derivatives.17 The first 
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formazan with pyridine in position 5 was synthesized in 1951 and since then a 
variety of heteroarylformazans have been described in literature along with the 
analysis of their metal complexation characteristics.17 Formazans can exist in 
closed, open, and linear geometric isomers where the meso substituent plays an 
important role in determining the conformation.17,18   
 
 
            closed                    open                          linear 
Figure 4.1 Depiction of closed, open, and linear forms of formazans. 
 
Initially, formazans were used in the dye industry and for histochemistry. More 
recently some interest has been generated in the coordination chemistry of 
formazans.19 A set of transition metal (such as Ni, Fe, Pd) complexes of 3-
cyanoformazanates and 3-nitroformazanates have been described by the Hicks 
group.20  In recent times, Co,21 Zn22 and Na23 complexes of formazans have also 
been reported. Lately, BF2 complexes of 3-cyanoformazanates have been 
reported to demonstrate optimal optical properties including high molar extinction 
coefficients, good fluorescence quantum yields, large Stokes shift, emission in 
the NIR region, and absorption and emission spectra that can be tuned based on 
structural modifications.18 Moreover, the synthetic route for the preparation of 
BF2-formazanate complexes consists of high yielding and convenient steps 
involving low cost and readily available starting materials.18  
There are several examples in the literature which depict fluorescent peptides 
being labeled through radiometalation. On the other hand, there are very few 
illustrations of 18F labeled fluorescent tracers, due to the various challenges 
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encountered during 18F labeling.24,25,26  18F/19F isotope exchange reactions are 
being explored. In this approach, the targeting molecule is altered only at a single 
site that allows both PET and optical labeling. By avoiding increased steric 
demand that would occur if two separate labelling sites were added, there is 
reduced possibility of negatively affecting the targeting ability of the molecule.16  
A significant amount of interest has been generated in the development of dual 
modality imaging agents, where targeting peptides are acting as specific ligands 
for the receptor. These type of imaging agents provide target accumulation and 
rapid clearance from non-target tissues, leading to high contrast images.27 There 
are various examples in literature where a dye-peptide conjugate has been used 
for targeted cancer imaging such as 64Cu-BaAnSarRGD2-Cy5.5, which was 
developed as a PET/optical tumor targeting probe.28 ɑvβ3 integrin targeted tumor 
imaging was displayed using a [18F] BODIPY-RGD conjugate.29    
Chemically and biologically equivalent dual modal PET/fluorescence imaging 
probes provide several advantages including fast screening, direct cellular 
validation, and economic analysis of the stable isotope containing compound 
before scale up of the precursor and radiotracer labeling.30  Research done by 
Perrin and coworkers, and Blower and coworkers, depicted boron as the site for 
radiofluorination. 24,31  Keliher and coworkers reported efficient acid catalysed 
18F/19F exchange of BODIPY dyes.30 Paulus and coworkers examined 18F-
BODIPY-BBN as a gastrin releasing peptide (GRP) receptor targeting probe in 
PC-3 xenograft mouse model.16 Perrin and coworkers described the application 
of rhodamine-cRGD-18F-organotrifluoroborate analogue for in vivo PET and ex 
vivo fluorescence imaging.24 
One of the most commonly studied click reactions is the azide alkyne cycloaddition. 
Copper catalysed azide alkyne cycloaddition reactions have achieved much 
popularity since their discovery in 2001. In this reaction, a terminal azide and a 
terminal alkyne react to form a 1,4-disubstituted 1,2,3-triazole in the presence of a 
Cu(I) catalyst. There are a vast number of applications for these reactions such as 
bioconjugation32, drug discovery33, hybrid materials34, and polymerization35. In the 
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past few decades, these have also been used for designing fluorophores and 
radioligands for developing novel imaging agents e.g. 18F-BODIPY-azide was 
clicked onto a BBN-alkyne derivative and studied as a PET/fluorescence imaging 
tool.16 In another example, rhodamine-PEG azide was coupled to an 
ammoniomethyltrifluoroborate alkyne analogue using Cu(I) click chemistry yielding 
a dual modal PET/fluorescent imaging probe.16 The application of click chemistry 
in synthesizing octreotate based analogues showing high affinity to somatostatin 
receptor has also been demonstrated in the literature.36 Lately copper free strain 
promoted azide alkyne cycloaddition (SPAAC) is drawing much attention. One 
such example depicts the synthesis of an EpCAM aptamer (SYL3C)-DIBO-AF594 
fluorescent conjugate.37  
BF2-formazanate dyes have optimal optical properties for fluorescence imaging 
and can potentially be designed as radioactive analogues through 18F/19F isotope 
exchange reactions. Considering these interesting features of the BF2-formazate 
dyes and the usefulness of click chemistry in coupling the targeting peptide to the 
fluorescent dye as seen through literature, this study is focussed on the 
development of novel BF2-formazate-peptide based PET/fluorescence imaging 
probes synthesized using copper(I) catalyzed click chemistry.  
 
4.2 Results and Discussion 
4.2.1 Study of Fluorescent Properties of FMZ Dyes Using Fibroblast 
Cells. 
With the goal of developing BF2-formazanate-peptide based PET/fluorescence 
imaging probes, the first step was to study the fluorescent properties of these 
dyes in vitro. To study the fluorescence properties of the BF2-formazanate (FMZ) 
dyes, mouse fibroblast cells were incubated with the dye 4.1 (previously 
synthesized)38 and fluorescence images were obtained using a confocal 
fluorescence microscope (Figure 4.2). It was evident from the images that the 
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dye 4.1 was internalized by the cells. The cells were co-stained using the nuclear 
stain DAPI. Some punctate staining could be noticed during these experiments. 
This could be present because of the dye being accumulated in either the 
endoplasmic reticulum and/or the vesicles. 
                  
                                                                   
                                                                     
        
                                 e                                                           f                        
Figure 4.2 Confocal fluorescence micrographs of mouse fibroblast cells stained 
with BF2 formazanate complex 4.1 and DAPI. Images (a) and (b) were visualized 
with excitation at 559 nm and emission collected between 625725 nm, while 
images (c) and (d) are an overlay of images (a) and (b) with those obtained from 
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excitation at 405 nm and emission collected between 425475 nm. (e) Depicts 
the structure of BF2 formazante complex 4.1. (f) Depicts the structure of BF2 
formazante complex 4.2 
The alkyne groups present in 4.2 (previously synthesized by the Gilroy lab), can 
act as a useful tool for attaching it to a targeting peptide by clicking it onto 
terminal azide bearing peptides. The peptides chosen for these studies are 
truncated versions of the peptide ghrelin. Ghrelin is known to have high affinity for 
the GHS-R1a receptor.39 It is the N terminus of ghrelin that is important for 
binding to the receptor, and any modifications here might hamper the binding 
affinity significantly.40 The terminal azide on the lysine can be coupled to the 
alkyne of the formazanate through click chemistry. 
                      
 
Figure 4.3 General structure of the targeted imaging probe. 
 
4.2.2 Trials for 18F/19F Isotope Exchange reaction 
For the synthesis of the radioactive analogue of 4.2, the 18F/19F isotope exchange 
reaction was investigated. A noteworthy advantage of this method is that 
additional synthesis of a non-radioactive standard is not required, as is typically 
the case when developing an 18F-imaging agent. Radiofluorination can be 
confirmed by comparing the HPLC radiochromatogram with the HPLC UV-trace 
for the precursor 4.2, which is also acting as the non-radioactive standard since 
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the only difference is that of the isotope. Purification using semi-preparative 
HPLC is also not required in this method since radiofluorination does not alter the 
composition of the radiotracer, both precursor and radioactive product appear at 
the same retention time and cannot be separated through HPLC. Therefore, C18 
Sep Pak cartridge elution should be used instead of HPLC purification. Initially, 
the fluoride exchange reaction was studied in H2O/DMF under acidic conditions 
at pH 2. These conditions have been found to be successful for radiofluorination 
of ammoniomethyltrifluoroborate (AMBF3).2 
In our case this method proved unsuccessful and no radiofluorination was evident 
from the radio HPLC trace. This may be due to the instability of the dye under 
acidic conditions and due to poor solubility under aqueous conditions. Next, the 
radiofluorination was studied in acetonitrile (ACN). Triflic anhydride (Tf2O) and 
tertiary butanol (t-BuOH) were added to the reaction mixture, generating 
trifluoromethanesulfonic acid (TfOH) in situ. This along with the residual water 
from the 18F was adequate to develop the acidic conditions essential for 18F 
radiofluorination. The reaction was carried out at room temperature and at 60 0C 
for 15 minutes. None of these attempts were successful. Next, we explored the 
use of trimethylsilyl triflate (TMSOTf) as an activator. It was used to activate the 
B-F bond, leading to the formation of triflate which would act as a good leaving 
group for 18F to attack. Again, the reaction was studied at room temperature and 
at 600C. Once again, the method was ineffective. All of these attempts are 
summarized in Table 4.1. 
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Precursor Solvent Reagent Reagent Reagent Temp  
(0 C)  
Time 
 (min) 
  Yield by 
   HPLC 
50nmol DMF/H
2
O 
   
85 15    0 
10µmol ACN Tf
2
O t-BuOH 
 
r.t. 15    0 
10µmol ACN Tf
2
O t-BuOH 
 
60 15    0 
0.25µmol ACN Tf
2
O t-BuOH TMSOTf r.t. 15    0 
0.25µmol ACN Tf
2
O t-BuOH TMSOTf 60 15    0 
 
Table 4.1 Different conditions for optimization of 18F/19F exchange reaction of 4.2. 
 
The use of Lewis acidic reagents for carrying out 18F/19F exchange reaction has 
been shown to avoid the need of activation of B-F through formation of triflate.29 
Among the various Lewis acidic reagents investigated are ZnCl2, AlCl3, AlF3, and 
SnCl4, it has been seen that SnCl4 acts as a phenomenal Lewis acid activator to 
aid 19F/18F isotopic exchange reactions.29  
The classical method for preparation of highly nucleophilic ‘naked’ 18F-, involves 
trapping  [18F]fluoride on a cartridge and elution with Kryptofix [2.2.2] (K2,2,2) in the 
presence of K2CO3.41 Although, K2CO3 helps in preserving the nucleophilicity of 
[18F]fluoride, it might lead to some side reactions.42 Therefore, this was replaced 
by TBAB (tetrabutylammonium bicarbonate) as a phase transfer catalyst. Initially, 
125 µL of 0.075 M TBAB solution, 100 µL of 0.1 M SnCl4/DCM were used and the 
reaction mixture was heated at 45 0C for 30 minutes. 100 µL of 0.1 M SnCl4/DCM 
was added again and reaction mixture was further heated at 65 0C for another 30 
minutes (Table 4.2). The reaction was analysed by HPLC (Figure 4.4). Contrary 
to earlier attempts, new peaks could be seen on the radiochromatogram. These 
were compared to HPLC peak corresponding to non-radioactive standard 4.2. 
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Peak A was found to be very close to the peak corresponding to actual product 
but did not match with the product. Therefore, something was getting 
radiolabeled but it was not our desired product. Addition of extra SnCl4/DCM and 
further heating the reaction mixture led to decrease in peak A and appearance of 
peak B. 
 
 
Precursor 
(µmol) 
  TBAB 
  (µL) 
  SnCl
4
/DCM 
     (0.1 M) 
   Temp 
   (0 C) 
  Time 
  (min) 
1    0.1   125     100 µL  45-50    30 
2    0.1   125    +100 µL   65-70   +30 
 
Table 4.2 Conditions for 18F/19F exchange reaction of 4.2 using 0.1 M SnCl4 
solution and 125 µL TBAB.  
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Figure 4.4 Chromatograms for 18F/19F exchange reaction of 4.2 using 0.1 M 
SnCl4 and 125 µL TBAB. Blue represents the HPLC trace for non-radioactive 
standard, AU: 200-800 nm and red represents the radiochromatogram obtained 
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using CsI(Tl) scintillating crystal coupled to silicon PIN diode. (a) Heating at 450 C 
for 30 minutes. (b) Heating at 650 C for 30 minutes after adding extra SnCl4. 
 
Next, we used 80 µl of 0.075 M TBAB, 100 µL of 0.1 M SnCl4/DCM and the 
reaction was heated at 45 0C for 40 minutes. Reaction mixture was further heated 
for 20 minutes after the addition of more (200µL) of 0.1 M SnCl4. (Table 4.3). 
Again, peak A close to the product was observed (Figure 4.5).  
 
Precursor 
 (µmol) 
 TBAB 
  (µl) 
  SnCl
4
/DCM               
   (0.1 M) 
Temp 
   (0 C) 
 Time 
  (min) 
1    0.1    80     100 µl   45-50     30 
2    0.1    80  +100 µl +100 µl   45-50    +20 
 
Table 4.3 Conditions for 18F/19F exchange reaction of 4.2 using 0.1 M SnCl4 
solution and 80 µL TBAB.   
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Figure 4.5 Chromatograms for 18F/19F exchange reaction of 4.2 using 0.1 M 
SnCl4 and 80 µL TBAB. Blue represents the HPLC trace for non-radioactive 
standard, AU: 200-800 nm and red represents the radiochromatogram obtained 
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using CsI(Tl) scintillating crystal coupled to silicon PIN diode. (a) Heating at 450 C 
for 30 minutes. (b) Heating at 450 C for additional 20 minutes after adding more 
SnCl4. 
Next, we examined the effect of increasing the concentration of SnCl4/DCM on 
radiofluorination. 0.25 M SnCl4/DCM was used and the reaction mixture was 
heated at 45 0C for 25 minutes (Table 4.4). Again, peaks A and B were observed 
on the radiochromatogram (Figure 4.6). 
 
 
Precursor 
 (µmol) 
  TBAB 
   (µl) 
SnCl
4
/DCM 
 (0.25 M) 
  Temp  
   (0C)  
 Time 
  (min) 
1   0.25   125  100 µL   45-50     25 
 
Table 4.4 Conditions for 18F/19F exchange reaction of 4.2 using 0.25 M SnCl4 
solution and 125 µL TBAB.   
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Figure 4.6 Chromatograms for 18F/19F exchange reaction of 4.2 using 0.25 M 
SnCl4 and 125 µL TBAB. Blue represents the HPLC trace for non-radioactive 
standard, AU: 200-800 nm and red represents the radiochromatogram obtained 
using CsI(Tl) scintillating crystal coupled to silicon PIN diode.  
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The next attempt was using 0.25 M SnCl4/DCM and reaction mixture was 
microwaved at 40 0C for 10 minutes (Table 4.5). Again, multiple peaks were 
observed (Figure 4.7). 
 
 
Precursor 
 (µmol) 
TBAB 
 (µL) 
SnCl
4
/DCM  
 (0.25 M) 
MW 
(0 C) 
 Time 
 (min) 
1   0.25  125   100 µL  40    10 
 
Table 4.5 Conditions for 18F/19F exchange reaction of 4.2 using 0.25 M SnCl4 
solution and 125 µL TBAB and microwave at 400 C.   
 
-2 0 2 4 6 8 10 12 14 16
50
100
150
200
250
300
350
400
450
minutes
m
V
0.000
0.005
0.010
0.015
0.020
0.025
B
 
18
F radiochromatogram
 
19
F HPLC trace
0.25M SnCl4(100 microliter)
125 microliter TBAB 
400C, MW, 10 minutes
A
b
s
o
rb
a
n
c
e
A
 
 
Figure 4.7 Chromatograms for 18F/19F exchange reaction of 4.2 using 0.25 M 
SnCl4 and 125 µL TBAB and microwaving at 400 C. Blue represents the HPLC 
trace for non-radioactive standard, AU: 200-800 nm and red represents the 
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radiochromatogram obtained using CsI(Tl) scintillating crystal coupled to silicon 
PIN diode.  
Further 1 M SnCl4/DCM was used and reaction mixture was heated at 50 0C for 
20 minutes (Table 4.6). Peak A decreased and peak B appeared as the major 
peak (Figure 4.8).   
 
 
Precursor 
  (µmol) 
 TBAB     
  (µL) 
  SnCl4/DCM 
     (1 M) 
 Temp 
 (0 C) 
Time 
 (min) 
1     1   125     100 µL    50    20 
 
Table 4.6 Conditions for 18F/19F exchange reaction of 4.2 using 1 M SnCl4 
solution and 125 µL TBAB.   
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Figure 4.8 Chromatograms for 18F/19F exchange reaction of 4.2 using 1 M SnCl4 
and 125 µL TBAB. Blue represents the HPLC trace for non-radioactive standard, 
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AU: 200-800 nm and red represents the radiochromatogram obtained using 
CsI(Tl) scintillating crystal coupled to silicon PIN diode.  
During most of these attempts, peak A was observed as the major peak on the 
radiochromatogram. This peak is very close to the actual product. From all these 
trials, it was hypothesized that although one of the 19F- was getting exchanged 
with 18F- (appearance of peak other than the peak for free 18F- on 
radiochromatogram), it was possible that the other fluoride is getting replaced 
with an OH- group which appeared as peak A very close to the actual F-18 
product.  
Since all the attempts to radiolabel BF2-FMZ dye 4.2 and develop it into a PET 
imaging probe have been unsuccessful, the focus now shifted towards the 
development of BF2-FMZ-peptide based targeted fluorescent imaging probes. 
 
4.2.3 Synthesis of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ Alkyne  
Analogue by Click Chemistry. 
The general design of the imaging agent includes the FMZ dye as the 
fluorescent/PET tag and the peptide as the targeting entity. The peptide selected 
for this study was [Dpr3,Tyr8]ghrelin (1-8). The IC50 of this peptide for GHSR1a is 
65.0 nM, indicating a strong affinity for the receptor. The synthesis of this imaging 
probe was carried out using the copper catalysed click chemistry approach. The 
FMZ dye used for this study was 4.2, which has terminal alkynes to carry out the 
click reaction.  For this, the peptide was synthesized with a lysine azide at the C-
terminus leading to the formation of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9) compound 
4.6. Initially, the trials for the click reaction were carried out using copper sulphate 
and sodium ascorbate. Literature suggests that the pre catalyst for this reaction 
could be Cu(II) salt that can be reduced in situ to Cu(I) species by using it in 
conjunction with a reducing agent.43 Table 6 summarizes the conditions for 
optimization of this reaction. All these reactions gave very poor yield (as seen by 
HPLC). 
124 
 
 
 
  
  CuSO4 
  (eq) 
NaAsc 
 (eq) 
Solvent Time 
(hr) 
Temp 
 (0C) 
1 0.1 0.2 DMF:H2O 16 25 
2 0.1 0.2 DMF:H2O  2 80 
3 0.1 0.2 tBuOH:H2O  2 80 
4 0.1 0.2 ACN:H2O 16 25 
5 0.1 0.2 DMSO:H2O 16 25 
6 0.1 0.2 DMSO:H2O 36 25 
7 0.1 0.2 DMSO:H2O  2 80 
 
Table 4.7 Different conditions for optimization of click reaction of 4.2 with 
compound 4.6 using CuSO4. 
 
Next copper(I) iodide was investigated as the source of copper for the click 
reaction.44  The use of dry solvents and maintaining inert conditions during the 
reaction becomes important in order to prevent the oxidation of Cu(I) species into 
Cu(II). The reaction progress was analysed through HPLC. Again, the yields were 
poor as seen from the HPLC traces. 
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CuI 
(eq) 
NaAsc 
(eq) 
DIPEA 
(eq) 
Solvent Time 
(hr) 
Temp 
(0C) 
Product                    
(%) 
(By HPLC)    
1 0.3 0.3 0.3 DMF:H2O 16 25 20 
2 0.3 0.3 0.035 DMF:H2O 16 25 14 
2 0.3 0.45 0.1 DMF:H2O 16 25 3 
3 0.45 0.69 0.1 DMF:H2O 16 25 4 
4 0.5 0.7 0.1 DMF:H2O 16 25 21 
5 0.7 1.1 - DMF:H2O 16 25 19 
 
Table 4.8 Different conditions for optimization of click reaction of 4.2 with 
compound 4.6. 
 At this stage, the use of a ligand became necessary. pentamethyldiethylene 
triamine (PMDETA) has been demonstrated to act as an effective ligand for 
copper catalysed click reactions.45,46 Hence the synthesis of 
[Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne analogue 4.5 was done using CuI 
and PMDETA. The result from this reaction was the best one so far. Scheme 4.1 
shows the route for the synthesis of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne 
analogue 4.7. 
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Scheme 4.1 Route for synthesis of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne 
analogue 4.7.   
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4.2.4 Optical Analysis of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ 
Alkyne Analogue. 
 In order to explore the potential of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne 
analogue 4.7  for fluorescence microscopy, photophysical data was obtained. 
The absorption and emission wavelengths, molar extinction coefficient, Stokes 
shift and fluorescence quantum yield were determined. The data is summarized 
in Table 4.9. A very interesting feature of the FMZ dyes is the large Stokes shift, 
which is an important criterion for application in fluorescence microscopy. The 
Stokes shift of the FMZ dye increased after coupling to the peptide. Stokes shift 
for the imaging probe was determined to be 138 nm. Both the absorption and 
emission maxima for the click product were red shifted as compared to the FMZ 
dye 4.2 (Figure 4.9). The quantum yield was also slightly increased upon clicking 
the FMZ dye to the peptide.   
 
Compound λabs (nm) 
(DMSO) 
λex (nm) 
(DMSO) 
λem (nm) 
(DMSO) 
ε(M-1 cm-1)            
(DMSO) 
Stokes 
Shift 
(nm) 
 
   ΦF [a]                            
(DMSO) 
FMZ 
alkyne     
4.2 
526 471 639 33300 113 < 0.01 
Analogue  
4.7 
545 546 683 31582 138 0.04 
 
Table 4.9 Photophysical data for FMZ alkyne 4.2 and 
[Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne analogue 4.7 : absorption, 
excitation, emission maxima, molar extinction coefficient (ε), Stokes shift and 
fluorescence quantum yields (ϕF). 
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Slit width was 2 nm. Emission collected in the range 536-800 nm for 4.2 and 555-
800 nm for 4.7.[a] Quantum yields obtained using [Ru(bpy)3][PF6]2  as standard47 
in deoxygenated solutions using previously reported procedure.48 
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                                a                                                            b 
Figure 4.9 Absorption (blue), emission (red) for (a): FMZ dye 4.2. and (b): 
[Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne analogue 4.7. Recorded for 10-5 M 
DMSO solution. 
 
4.2.5 In Vitro Fluorescence Imaging Using OVCAR-8 Cells 
Transfected With GHS-R1a. 
The specific binding of analogue 4.7 for GHS-R1a was demonstrated through 
confocal fluorescence microscopy. For this purpose, OVCAR-8 cells transfected 
with GHS-R1a were incubated with the analogue 4.7 and fluorescence images 
were obtained after washing and fixing the cells. The images depicted the cellular 
uptake of 4.7 as was evident from the red emission from 4.7 (around 680nm) 
(Figure 4.10a). The nuclear stain DAPI was used to visualize the nuclei (in blue). 
In order to get a detailed view of cellular uptake of 4.7, 60X images were also 
obtained (Figure 4.10c and 4.10d). From these images, it was evident that 4.7 
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was taken up in the cytoplasm and it was possible to distinguish the nuclei 
(Figure 4.10d). Parental OVCAR-8 cells (without transfection with GHSR-1a) 
were used for negative control for the experiment. These cells were incubated 
with 4.7 and imaged. As expected, the parental OVCAR-8 cells that did not 
express GHS-R1a showed minimal uptake of 4.7 (Figure 4.10e), as these cells 
do not express GHS-R1a. In order to validate the specific binding of 4.7 for GHS-
R1a, blocking studies were also performed, using a small molecule antagonist 36 
(developed by Bayer Pharmaceutical Corporation) which has very high affinity for 
GHS-R1a.49 For this purpose OVCAR-8 cells expressing the receptor were 
incubated with 4.7 and 10X excess of 36. Figure 4.10g demonstrates the 
displacement of 4.7 by the blocking compound.     
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  Figure 4.10 Confocal fluorescence micrographs of OVCAR-8 cells stained with 
4.7.    
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DAPI stained nuclei are shown in blue and 4.7 in red. (a) Using OVCAR-8 cells 
transfected with GHS-R1a and image obtained by excitation at 559 nm and 
emission collected between 598-698 nm. (b) Using OVCAR-8 cells transfected with 
GHS-R1a and overlay of image obtained by excitation at 405 nm and emission 
collected between 425-475 nm with image 4.10a. (c) Using OVCAR-8 cells 
transfected with GHS-R1a and image obtained by excitation at 559 nm and 
emission collected between 598-698 nm, using 60X objective. (d) Using OVCAR-
8 cells transfected with GHS-R1a and overlay of image obtained by excitation at 
405 nm and emission collected between 425-475 nm with image 4.10c, using 60X 
objective. (e) Using parental OVCAR-8 cells (not transfected with GHS-R1a) and 
image obtained by excitation at 559 nm and emission collected between 598-698 
nm. (f) Using parental (OVCAR-8 cells not transfected with GHS-R1a) and overlay 
of image obtained by excitation at 405 nm and emission collected between 425-
475 nm with image 4.10e. (g) Using OVCAR-8 cells transfected with GHS-R1a and 
blocked with 10X excess of 36 and image obtained by excitation at 559 nm and 
emission collected between 598-698 nm. (h) Using OVCAR-8 cells transfected with 
GHS-R1a and blocked with 10X excess of 36 and overlay of image obtained by 
excitation at 405 nm and emission collected between 425-475 nm with image 
4.10g. (i) Structure of compound 36 used for blocking studies. 
     
4.2.6 Competitive Binding Assays (IC50) 
In order to determine the binding affinity of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ 
alkyne analogue 4.7 for the GHS-R1a receptor, the radioligand competitive 
binding assays were performed. The IC50 value for [Dpr3,Tyr8] ghrelin(1-8) has 
been previously reported to be 65.0 nM,50 the IC50 for 
[Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne analogue 4.7 was determined to be 
166.4 nM (Figure 4.11). Although, attachment of FMZ dye 4.2 to the peptide led 
to decrease in the binding affinity, this value was deemed acceptable as a 
prototype ghrelin-FMZ conjugate for GHS-R1a. But there is certainly scope for 
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improvement in the binding affinity. For this purpose, we decided to use an 
alternate peptide that would have an even better IC50 value to begin with. So, the 
next peptide that was selected for the further experiments was ghrelin (1-18). The 
IC50 for this peptide has previously been determined to be 1.3 nM.50   
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Figure 4.11 Half-maximal inhibitory concentration curve of ghrelin(1-9)-FMZ 
analogue 4.7 against [125I]-human ghrelin in HEK 293/GHS-R1a cells. 
 
4.2.7 Attempted Synthesis of Ghrelin (1-19)-FMZ Analogue 4.11 by 
Click Chemistry  
The synthesis of ghrelin (1-19)-FMZ analogue 4.11 was attempted following the 
same route as followed for the synthesis of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ 
alkyne 4.7 analogue. In this case the click reaction was unsuccessful and did not 
yield any product. Scheme 4.2 depicts the synthetic route followed for the 
synthesis. 
133 
 
 
 
 
 
Scheme 4.2 Route for attempted synthesis of [Dpr3,(Lys(N3))19] ghrelin(1-19)-
FMZ alkyne analogue 4.11.  
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 Some of the factors which have been shown to play a crucial role in the success 
of click reaction are the choice of solvent, the source of Cu(I) species and the 
presence of ligands.43 All these factors were explored and multiple trials were 
carried out. Optimization of conditions for synthesis of this imaging probe was 
carried out by using different solvents e.g. THF, ACN, DMF, DMF/H2O and using 
different sources of copper. Other ligands were evaluated for the reaction, such 
as BPDS51 (bathophenanthroline diphenyl sulphonate). But none of the trials 
yielded any click product. Therefore, it was decided to discontinue with this 
peptide and consider another peptide. 
 
4.2.8 Synthesis of [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ Alkyne  
Analogue by Click Chemistry. 
Several ghrelin (1-8) analogues have been previously synthesized where 
glutamic acid at position 8 has been replaced by other amino acids and the 
structure activity studies revealed that the presence of threonine at position 8 
brings the IC50 value down to 3.2 nM as compared to IC50 valve of 65.0 nM for 
ghrelin (1-8) having tyrosine at the 8th position.50 Therefore, using this peptide for 
clicking with the BF2-FMZ dye might provide an imaging probe with a better 
binding affinity for GHS-R1a.  Further, as seen from the unsuccessful attempts 
for clicking ghrelin (1-19) to BF2-FMZ dye, it appears that ghrelin (1-8) seems to 
be an ideal peptide chain length for the click reactions. Therefore, the next 
peptide to be studied was [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9) i.e. compound 4.14. 
The imaging probe i.e.  [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ methoxy analogue 
4.16 was synthesized using the same approach as was used for the synthesis of 
[Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne analogue 4.7. Scheme 4.3 shows 
the route for the synthesis. 
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Scheme 4.3 Route for synthesis of [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ 
analogue 4.16.   
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 4.2.9 Optical Analysis 
Before moving ahead with the optical imaging using analogue 4.16, it was 
important to compare the optical properties of 4.16 with the parent dye 4.15 in 
order to determine whether the optical properties of this probe are suitable for 
optical imaging.  Therefore, photophysical data was obtained for the imaging 
probe 4.16 (summarized in Table 4.10). Absorption, excitation and emission 
spectra, Stokes shift, molar extinction coefficient and fluorescence quantum yield 
were determined. The absorption and emission maxima were red shifted as 
compared to dye 4.15 (Figure 4.12). There was a significant increase in the 
fluorescence quantum yield for imaging probe 4.16 as compared to the parent 
dye. 
 
Compound λabs(nm)                
(DMSO) 
λex(nm)              
(DMSO) 
λem(nm)              
(DMSO) 
Stokes 
Shift (nm) 
ε(M-1 cm-1)   
(DMSO) 
ΦF[a]                               
(DMSO) 
 
 4.15 546 467 665 119 34500 0.04 
 4.16 
 
560 557 688 128 32235 0.21 
 
Table 4.10 Photophysical data for FMZ alkyne 4.15 and 
[Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ methoxy analogue 4.16 : absorption, 
emission maxima, Stokes shift, molar extinction coefficient (ε), fluorescence 
quantum yields (ϕF). 
Slit width was 2 nm. Emission collected in the range 556-800 nm for 4.15 and 
570-800 nm for 4.16. [a] Quantum yields obtained using [Ru(bpy)3][PF6]2  as 
standard47 in deoxygenated solutions using previously reported procedure.48 
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Figure 4.12 Absorption (blue), emission (red) for (a): FMZ dye 4.15 and (b): 
[Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ methoxy analogue 4.16. Recorded for 10-5 
M DMSO solution. 
 
4.2.10 In Vitro Fluorescence Imaging Using OVCAR-8 Cells 
Transfected with GHS-R1a. 
To demonstrate the potential of 4.16 for in vitro confocal fluorescence 
microscopy, OVCAR-8 cells transfected with GHS-R1a were used. These cells 
were incubated with the analogue 4.16 and fluorescence images were obtained 
after washing and fixing the cells. The images depicted the cellular uptake of 
4.16, as was evident from the red emission from 4.16 (around 680 nm) (Figure 
4.13a). The nuclear stain DAPI was used to visualize the nuclei (in blue). To get a 
more detailed view of the cellular uptake of 4.16, 60X images were also obtained 
(Figure 4.13c and 4.13d). The images demonstrated the uptake of 4.16 in the 
cytoplasm and at the same time the nuclei could be distinguished. Parental 
OVCAR-8 cells (without transfection with GHS-R1a) were used as negative 
control for the experiment. These cells were incubated with 4.16, and the images 
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depicted minimal uptake of 4.16 by the parental OVCAR-8 cells since these cells 
do not express GHS-R1a (Figure 4.13e).  
Further to validate the specific binding of 4.16 for GHS-R1a, blocking studies 
were also performed, using a small molecule antagonist 36 (developed by Bayer 
Pharmaceutical Corporation) which has very high affinity for GHS-R1a.49 Figure 
4.13g demonstrates the displacement of 4.16 by the blocking compound. All this 
aids in confirming the specificity of 4.16 for the receptor.    
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Figure 4.13 Confocal fluorescence micrographs of OVCAR-8 cells stained with                                                                            
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4.16 (in red) and DAPI (in blue). (a) Using OVCAR-8 cells transfected with GHS-
R1a and image obtained by excitation at 559 nm and emission collected between 
575-675 nm. (b) Using OVCAR-8 cells transfected with GHS-R1a and overlay of 
image obtained by excitation at 405 nm and emission collected between 425-475 
nm with image 4.13a. (c) Using OVCAR-8 cells transfected with GHS-R1a and 
image obtained by excitation at 559 nm and emission collected between 575-675 
nm, using 60X objective. (d) Using OVCAR-8 cells transfected with GHS-R1a and 
overlay of image obtained by excitation at 405 nm and emission collected between 
425-475 nm with image 4.13c, using 60X objective. (e) Using OVCAR-8 cells (not 
transfected with GHS-R1a) and image obtained by excitation at 559 nm and 
emission collected between 575-675 nm. (f) Using OVCAR-8 cells (not transfected 
with GHS-R1a) and overlay of image obtained by excitation at 405 nm and 
emission collected between 425-475 nm with image 4.13e. (g) Using OVCAR-8 
cells transfected with GHS-R1a and blocked with 36 and image obtained by 
excitation at 559 nm and emission collected between 575-675 nm. (h) Using 
OVCAR-8 cells transfected with GHS-R1a and blocked with 36 and overlay of 
image obtained by excitation at 405 nm and emission collected between 425-475 
nm with image 4.13g. 
                                                                                                                                                 
4.2.11 Competitive Binding Assays (IC50) 
In order to determine the binding affinity of [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ 
methoxy analogue 4.16 for the GHS-R1a receptor, the radioligand competitive 
binding assays were performed. The IC50 value for [Dpr3,Thr8] ghrelin(1-8) was 
previously determined to be 3.2 nM,50 the IC50 for [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-
9)-FMZ alkyne analogue  was determined to be 89.9 nM (Figure 4.14). Therefore, 
compound 4.16 seems better than compound 4.7, in terms of binding affinity for 
GHS-R1a. 
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Figure 4.14 Half-maximal inhibitory concentration curve of ghrelin(1-9)-FMZ 
analogue 4.16 against [125I]-human ghrelin in HEK 293/GHS-R1a cells. 
 
4.2.12 Alternate Route for Synthesis of Imaging Probe 
The click reaction between the FMZ dyes and the peptides were low yielding so 
far, which could possibly be due to the low solubility of the peptide in THF. In 
order to improve the yield, an alternate strategy was proposed. Since it was 
thought that the peptide might be causing difficulties for the click reaction to 
occur, the peptide should not be clicked to the FMZ dye directly. Instead, it would 
be better to click the FMZ dye to just an azide such as lysine azide (which has 
good solubility in THF). The resulting triazole can be loaded onto the solid 
support and the peptide chain can then be built using solid-phase peptide 
synthesis. Scheme 4.4 shows the proposed synthetic route for this approach. 
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Scheme 4.4 Proposed alternate route for synthesis of ghrelin(1-19)-FMZ alkyne 
analogue 4.20.   
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The first trial for clicking lysine azide and FMZ alkyne dye was carried out using 
CuI and PMDETA at room temperature for 4 hours and overnight. The reactions 
were analysed through HPLC (Figure 4.15a and 4.15b respectively). The HPLC 
chromatogram showed peak C corresponding to the desired product 4.17, along 
with peak A, which is the product without the BF2 part i.e. compound 4.17a and 
peak B in which both the alkynes on FMZ dye are getting clicked to azide part 
from lysine i.e. compound 4.18. More trials were carried out by heating the 
reaction at 40 0C for 4 hours and overnight. The reaction was again analysed by 
HPLC. The results were quite similar to the trials done at room temperature 
(Figure 4.15c and 4.15d respectively).  
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Figure 4.15 HPLC chromatograms for click reaction between FMZ alkyne 4.2 
and lysine azide. (a) Reaction carried out at r.t. for 4 hours. (b) Reaction carried 
out at r.t. overnight. (c) Reaction carried out at 400 C for 4 hours. (d) Reaction 
carried out at r.t. overnight. AU: 200-800 nm. 
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Figure 4.16 Structure of compounds synthesized during click reaction between 
FMZ alkyne 4.2 and lysine azide. 
 
As can be seen by the HPLC chromatograms (Figure 4.15), both the mono-
substituted species 4.17 and the di-substituted 4.18 were formed and since it 
proved difficult to separate these, it was decided to use FMZ dye 4.15. This dye 
would not have two terminal alkynes and instead, one of the alkynes was 
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replaced by a methoxy group. Figure 4.17 shows the structure of the new FMZ 
methoxy alkyne dye 4.15. 
 
 
Figure 4.17 Structure of formazanate methoxy dye 4.15.  
 
4.2.13 Stability Analysis of BF2-Formazanate Dyes 
Before moving on with the peptide synthesis, the stability of the FMZ dye 4.15 
under peptide synthesis conditions was evaluated. First, the stability of the FMZ 
dye 4.15 in TFA (trifluoroacetic acid) which is used for the cleavage of the peptide 
from the resin, was analysed. For the stability study, 20% TFA was used and the 
stability was examined from the HPLC chromatogram (Figure 4.18b). The 
chromatogram depicted that along with the peak corresponding to the dye, an 
additional peak was also observed, which indicated that the dye is breaking down 
in 20% TFA. For cleaving the peptide from the Rink amide resin, 95% TFA is 
required and to cleave off the side chain protecting groups from the amino acids 
comprising the peptide at least 20-30% of TFA is required. But it is clear from the 
stability tests that the dye will not survive under these conditions. One solution to 
this problem is to use 2-chlorotrityl chloride resin. The conditions used to cleave 
the peptide from this resin are very mild, requiring only 1% TFA. Next, the 
stability of the dye in 1% TFA was examined. The chromatogram depicted that 
the dye was stable in 1% TFA (Figure 4.18c). Therefore, by choosing 2-
chlorotrityl chloride resin and carefully selecting the side chain protecting groups, 
the problem associated with the stability of the dye in TFA could be overcome. 
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Figure 4.18 HPLC chromatogram for stability analysis of FMZ methoxy alkyne 
dye 4.15 in TFA. (a) FMZ dye 4.15 in the absence of TFA. (b) In 20% TFA. (c) In 
1% TFA. AU: 200-800 nm. 
Next, the stability of the dye in 20% piperidine/DMF was determined. 20% 
Piperidine/DMF is needed for the removal of Fmoc (fluorenylmethyloxycarbonyl) 
protecting groups from the amine during synthesis of the peptide. It was seen 
from the HPLC chromatogram that along with the peak from FMZ dye 4.15, an 
additional peak was also observed. Although this additional peak was small, as 
we carry out peptide synthesis and go through multiple Fmoc deprotection steps 
(depending upon the length of the peptide) this will greatly reduce the overall 
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yield of the synthesis. Next the stability of the dye in some other bases that could 
be used for Fmoc deprotection such as 5% Piperazine/DMF, Morpholine/DCM, 
and DBU (1,8-diazabiclclo[5.4.0]undec-7-ene) was examined, and analyzed 
through HPLC (Figure 4.19). The dye seemed to be decomposing in these bases 
as well. DBU showed better results than other bases. But DBU must be used in 
conjuction with piperidine in order to remove the dibenzofulvene that is formed as 
a by-product during Fmoc deprotection. 
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Figure 4.19 HPLC chromatograms for stability analysis of FMZ dye 4.15. 
(a) in 5% Piperazine/DMF. (b) in 50% Morpholine/DCM. (c) in 50% DBU/DCM.    
(d) in 2% DBU/DMF. AU: 200-800 nm. 
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The ghrelin peptide analogue used for this project has an octanoyl modification at 
the Diaminopropanoic (Dpr) residue at the 3rd position. To synthesize this, we 
start with Dpr that has alloc (allyloxycarbonyl) protection. After the removal of the 
alloc group, the octanoyl group is coupled. For removal of the alloc group, the 
peptide is treated with phenylsilane and tetrakis triphenylphosphine Pd (0) as a 
catalyst. Next, the stability of the FMZ dye 4.15 under alloc deprotection 
conditions was checked. The HPLC chromatogram showed multiple peaks and a 
peak corresponding to FMZ dye 4.15 could not be seen (Figure 4.20). Therefore, 
the dye was not stable under these conditions. 
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Figure 4.20 HPLC chromatograms for stability analysis of FMZ dye 4.15 in 
Phenylsilane and Tetrakis triphenylphosphine Pd(0). AU: 200-800 nm. 
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4.2.14  Synthesis of [D-Phe6, β-Ala11, Phe13, Nle14] Bombesin 6-14- 
(PEG)7-FMZ Analogue 4.23.    
The results obtained from these stability analyses depict that the FMZ dye would 
not be stable under the conditions used for the peptide synthesis and an alternate 
strategy is desired. 
Keeping all this in mind, an alternate strategy needs to be designed, where the 
Fmoc deprotection step can be avoided. As well as choose a peptide which 
would not involve an alloc deprotection step. For this, solution phase acid-amine 
coupling strategy seemed to be a promising approach. The peptide selected for 
this was bombesin analogue 4.22. Peptide bombesin is known to have high 
affinity for the gastrin releasing peptide receptor that is highly expressed in a 
number of cancers such as prostate,52 and breast cancer.53  
The bombesin peptide chosen for this study was [D-Phe6, β-Ala11, Phe13, Nle14] 
bombesin 6-14. This pan bombesin analogue is known to bind to all bombesin 
receptor subtypes.54,55  To increase the distance between the dye and the 
peptide and also to increase the solubility, the spacer (PEG)7N3-OH was 
selected. 4.15 was clicked to (PEG)7N3-OH leading to the synthesis of compound 
4.21. This was then coupled to the peptide 4.22 in solution, leading to the 
synthesis of the imaging agent 4.23.         
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Scheme 4.5 Route for synthesis of [D-Phe6, β-Ala11, Phe13, Nle14] bombesin 6-
14-(PEG)7-FMZ analogue 4.23.   
 
4.2.15 Optical Analysis  
Again, before evaluating the specific binding of analogue 4.23 for GRP-R through 
optical imaging, it was essential to study the optical properties of analogue 4.23 
and determine if it was a suitable candidate for optical imaging. Therefore, 
photophysical data including absorption, excitation and emission spectra, Stokes 
shift, molar extinction coefficient and fluorescence quantum yield were 
determined and compared to the parent dye 4.15 (Table 4.11). Once again, 
Stokes shift increased slightly upon coupling to the peptide. The absorption and 
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emission maxima were also red shifted as compared to dye 4.15 (Figure 4.21). 
There was an increase in the fluorescence quantum yield for imaging probe 4.23 
as compared to the parent dye. 
 
Compound λabs(nm)                   
(DMSO) 
λex(nm)            
(DMSO) 
λem(nm)               
(DMSO) 
Stokes 
Shift 
(nm) 
ε(M-1 cm-1)    
(DMSO) 
ΦF[a]                                 
(DMSO) 
4.15 546 467 658 112 34500 0.04 
4.23 555 544 690 135 31890 0.12 
 
Table 4.11 Photophysical data for FMZ alkyne 4.15 and [D-Phe6, β-Ala11, Phe13, 
Nle14] bombesin 6-14-(PEG)7-FMZ analogue 4.23 : absorption, emission maxima, 
Stokes shift, molar extinction coefficient (ε), fluorescence quantum yields (ϕF). 
Slit width was 2 nm. Emission collected in the range 556-800 nm for 4.15 and 
565-800 nm for 4.23. 
[a] Quantum yields obtained using [Ru(bpy)3][PF6]2  as standard47 in 
deoxygenated solutions using previously reported procedure.48 
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Figure 4.21 Absorption (blue), emission (red) for (a): FMZ dye 4.15 and (b): [D-
Phe6, β-Ala11, Phe13, Nle14] bombesin 6-14-(PEG)7-FMZ analogue 4.23. 
Recorded for 10-5 M DMSO solution. AU: 200-800 nm. 
 
4.2.16  In Vitro Fluorescence Imaging Using PC-3 Cells. 
The specific binding of analogue 4.23 for GRP-R was demonstrated through 
confocal fluorescence microscopy. For this purpose, Prostate cancer PC-3 cells 
which have natural expression of GRP-R, were incubated with the analogue 4.23 
and the fluorescence images were obtained after washing and fixing the cells. 
The images depicted that 4.23 was internalized by the cells, evident from the red 
emission from 4.23 (around 690 nm) (Figure 4.22a). The nuclear stain DAPI was 
used to visualize the nuclei (in blue). The images depicted the uptake of 4.23 in 
the cytoplasm (Figure 4.22c and 4.22d). Further, specific binding of 4.23 to GRP-
R was depicted through blocking studies that were performed using 10 fold 
excess of peptide 4.22 which has very high affinity for GRP-R. Figure 4.22e 
demonstrates the displacement of 4.23 by the blocking compound 4.22. All this 
aids in confirming the specificity of 4.23 for the receptor.    
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Figure 4.22 Confocal fluorescence micrographs of PC-3 cells stained with 4.23 (in 
red) and DAPI (in blue). (a) Image obtained by excitation at 559 nm and emission 
collected between 605-705 nm. (b) Overlay of image obtained by excitation at 
405nm and emission collected between 425-475 nm with image 4.22a using 40X 
objective. (c) Image obtained by excitation at 559 nm and emission collected 
between 605-705 nm, using 60X objective (d) Overlay of image obtained by 
excitation at 405nm and emission collected between 425-475 nm with image 4.22c, 
using 60X objective. (e) PC-3 cells blocked with 10X excess of 4.22 and image 
obtained by excitation at 405 nm and emission collected between 425-475 nm (f) 
PC-3 cells blocked with 10X excess of 4.22 and overlay of image obtained by 
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excitation at 559 nm and emission collected between 605-705 nm with image 
4.22e. 
 
 
4.2.17 Competitive Binding Assays (IC50) 
In order to determine the binding affinity of [D-Phe6, β-Ala11, Phe13, Nle14] 
bombesin 6-14-(PEG)7-FMZ analogue 4.20 for GRP-R, radioligand competitive 
binding assays were performed. The IC50 value for the parent peptide [D-Phe6, β-
Ala11, Phe13, Nle14] bombesin (6-14) was determined to be 0.7 nM, and the IC50 
for [D-Phe6, β-Ala11, Phe13, Nle14] bombesin 6-14-(PEG)7-FMZ analogue 4.23 
was determined to be 16.3 nM (Figure 4.23). Although, attachment of Fmz dye 
4.15 to the peptide led to decrease in the binding affinity as compared to the 
parent peptide, the IC50 value for analogue 4.23 seemed to prove that this 
analogue has high binding affinity for GRP-R. The binding affinity for this imaging 
probe for GRP-R was also higher than the two previously synthesized imaging 
probes (4.7 and 4.16) for GHS-R1a. Analogue 4.23 is the first example of a BF2-
FMZ-bombesin based fluorescence imaging probe with a good binding affinity for 
GRP-R.  
 
 Figure 4.23 Half-maximal inhibitory concentration curve of bombesin(7-14)-FMZ 
analogue 4.23 against [125I]-bombesin in PC-3 cells. 
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4.3 Conclusions 
GHS-R1a and GRP-R are highly expressed in a variety of cancer types and have 
the potential to be important biomarkers for cancer diagnosis. BF2-Formazanate 
complexes possessing optically and electronically tunable properties have been 
previously synthesized through a straightforward and high yielding synthesis,56 
but have not been reported as conjugates to targeting ligands. In this study, Cu(I) 
catalysed click chemistry was used to synthesize BF2-formazanate-peptide based 
imaging probes targeting the protein receptors GHS-R1a and GRP-R. The 
photophysical data for these novel imaging probes showed red shifted absorption 
and emission wavelengths and a slight increase in Stokes shift as compared to 
the parent formazanate dyes.There was an increase in fluorescence quantum 
yield of imaging probe 4.16 as compared to the parent formazanate dye 4.15. 
An alternate strategy involving the combination of both Cu(I) catalyzed click 
chemistry and acid-amine solution phase coupling was also demonstrated to give 
better yields and this strategy opened the path for improved synthesis of BF2-
formazanate-peptide based imaging probes. 
Attempts to carry out radiofluorination through 18F/19F isotope exchange reactions 
were unsuccessful. While the use of SnCl4 as an acid catalyst led to the formation 
of the 18F labeled species, this radiolabelled material did not correspond to the 
desired product. This could possibly be due to the exchange of one of the 
fluorides by a hydroxide group. Such species (containing OH- and 18F- groups) 
can be used for PET imaging since there is evidence of 18F/19F exchange, but 
this compound will not be identical to the compound (containing two F- groups) 
used for fluorescence imaging and there will be inconsistencies between the 
results from the two techniques.  Nonetheless, all three imaging probes 4.7, 4.16 
and 4.23 demonstrated decent fluorescent properties. Attachment of targeting 
peptides to the formazanate dyes decreased the binding affinity of the resulting 
imaging probes for the receptor target but the imaging probes still maintained 
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sub-micromolar IC50 values. IC50 values were determined to be 166.4 nM, 89.9 
nM and 16.3 nM for imaging probes 4.7, 4.16 and 4.23 respectively, which are 
acceptable considering that these are the first reported examples of BF2-
formazanate-peptide based fluorescence imaging agents. 
The specificity for the receptors was confirmed through the fluorescence 
microscopy studies demonstrating the uptake of the imaging probes by the 
OVCAR-8 cells transfected with GHS-R1a for compounds 4.7 and 4.16 and by 
PC3 cells for 4.23.    
 
 4.4 Experimental 
Materials and Methods 
All common solvents were purchased from Fischer Scientific. All Fmoc protected 
amino acids, coupling agents and resins were purchased from Chem Impex, 
Peptides International and Novabiochem® and were used without further 
purification unless otherwise stated. All reagents were purchased from Sigma 
Aldrich. Compounds 4.1,4.2,4.15 were obtained from Dr. Gilroy’s lab (previously 
synthesized).38 Click reactions were performed under a nitrogen atmosphere, 
using Schlenk reaction vessels.  Reactants along with solvents were added to the 
Schlenk vessels and inert conditions were maintained by performing freeze-
pump-thaw cycles by freezing the reactants using liquid nitrogen and evacuating 
air and filling nitrogen through the Schlenk line. [125I]-ghrelin was received from 
Perkin Elmer. [18F]H218O was obtained from Dr. Mike Kovacs at the Cyclotron and 
PET Radiochemistry Facility at St. Joseph’s Hospital in London, Ontario, Canada.  
RP-C18 Sep-Pak SPE cartridges were purchased from Waters. For analysis of 
samples, an analytical Agilent RP-C18 4.6 X 150 mm, 5 µm column was utilized. 
The flow rate was 1.5 mL/min over 25 minutes. For purification of samples, a 
reverse phase preparative HPLC column (Agilent RP-C18 19 X 150 mm, 5 µm) 
was employed. The flow rate in this case was 20 mL/min over 15 minutes. The 
gradient solvent system used were 0.1% TFA in acetonitrile (solvent A) and 0.1% 
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TFA in water (solvent B). This system was provided with a Waters 600 controller, 
Waters Prep degasser, Waters Mass Lynx software (version 4.1). For the studies 
on UHPLC-MS, Waters Inc. Acquity UHPLC H-Class system was used. This was 
used in combination with Xevo QTof mass spectrometer (ESI +, cone voltage 
30V). For analytical studies, a Waters Acquity UHPLC BEH C18 2.1 X 50 mm, 
1.7 µm column was utilized. The gradient solvent system employed was 0.1% 
formic acid in acetonitrile (solvent C) and 0.1% formic acid in water (solvent D). 
For analysing the radioactive samples, analytical SunfireTM RP-C18 4.6 X 150 
mm, 5 µm column was used. The system comprised of a Waters 1525 Binary 
HPLC pump with a Water 2487 dual λ absorbance detector and Breeze software 
(version 3.30).  
 
Synthesis of 4.3 
Rink amide MBHA resin (192 mg, 0.100 mmol) was used as the solid support for 
the peptide synthesis. Fmoc deprotection was carried out using 2 mL of 20% 
Pip/DMF for two cycles (10 min, 15 min). Fmoc lysine azide (118 mg, 0.300 
mmol), HCTU (124mg, 0.300 mmol) and DIPEA (105 µL, 0.600 mmol) were 
dissolved in DMF (2mL) and shaken (using IKA-VIBRAX-VXR orbital shaker from 
Sigma-Aldrich) for 10 min. This solution was then added to the Rink amide resin 
and shaken for 16 hours at r.t. Kaiser test was used to confirm completion of 
reaction. 
 
General Synthesis of peptides 
Synthesis of peptide was carried out manually employing solid phase peptide 
synthesis chemistry. Peptides were synthesized on 0.1 mmol scale using Rink 
amide MBHA resin (0.52 mmol/g) in peptide synthesis vessels (20 mL Poly prep 
chromatography columns). Fmoc deprotection was carried out using 2 mL of 20% 
Pip/DMF for two cycles (10 min, 15 min). Activation of amino acids was carried 
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out using 3 eq. of HCTU, and 6 eq. of N,N-diisopropylethylamine (DIPEA)  in 2 
mL of DMF. The mixture was then added to the resin and shaken for 60 min. 
These cycles were repeated until all N-terminal amino acids were coupled to the 
resin. The deprotection of the allyloxycarbonyl group of diaminopropionic acid 
(DPA) was carried out under N2 atmosphere. For maintaining N2 atmosphere, a 
septum was attached to the open end of the peptide vessel and the solution was 
flushed with N2. 2 mL of anhydrous DCM (dried over sieves) was added to the 
resin. 24 eq. of phenylsilane (PhSiH4) was added. 0.1 eq. of 
tetrakis(triphenylphosphine) palladium (0) was then added and the solution was 
allowed to stir under N2 for 5 min. The peptide vessel was removed from inert 
conditions and allowed to shake for two cycles (10 min, 20 min). Full deprotection 
of peptide was accomplished by adding 3 mL of a mixture comprising of 95% 
trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIPS), 2.5% H2O to the resin 
and shaking for 4 hours. The cleaved peptide was precipitated using ice cold tert-
butyl methyl ether (TBME) and centrifuged at 3000 rpm for 15 min. The 
supernatant was removed and peptide pellet was dissolved in 40% ACN in H2O, 
frozen at -78 0C and lyophilized to obtain a brown solid. The crude peptide was 
purified using preparative HPLC-MS giving white solid with yields of 20% (200 
mg, 0.159 mmol), purity 98% for 4.6, 14% (253 mg, 0.0970 mmol), purity 96% for 
4.10, 17% (205 mg, 0.172 mmol), purity 98% for 4.14, 27% (223 mg, 0.165 
mmol), purity 98% for 4.22. HRMS (ESI+): (for 4.6) m/z calculated for 
C54H83N14O13, [M+H]+=1135.6186; observed  [M+H]+= 1135.6246,(for 4.10) m/z 
calculated for C102H171N36O30, [M+3H]3+=793.4320;   observed 
[M+3H]3+=792.9659, (for 4.14)  m/z calculated for C49H81N14O13,  
[M+H]+=1073.6029; observed [M+H]+=1073.6096, (for 4.22) m/z calculated for 
C57H77N14O10, [M+H]+=1117.5869; observed  [M+H]+=1117.5967.       
                
Synthesis of 4.7 
Dry THF (2.5 mL) was added to both pentamethyldiethylenetriamine (PMDETA) 
(4.5 µL, 0.0208 mmol) and to compound 4.6 (130 mg, 0.104 mmol) in two 
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different Schlenk vessels and both the solutions were degassed through three 
freeze pump thaw cycles respectively. Dry CuI (4 mg, 0.0208 mmol) was then 
added to the PMDETA solution and stirred at r.t. for 20 min. Compound 4.2 (36 
mg, 0.104 mmol) and CuI-PMDETA solution were added to THF solution of 
compound 4.6 and the reaction mixture was heated at 40 0C for 4 hours. THF 
was removed using a rotary evaporator. The crude compound was dissolved in 
ACN (0.1% TFA) and H2O (0.1% TFA) and purified by preparative HPLC-MS. 
The fractions were combined and frozen at -78 0C and lyophilized to yield the 
pure compound 6% (10 mg, 0.00600 mmol), purity 96%. HRMS (ESI+) : m/z 
calculated for C72H93BF2N19O13, [M+H]+=1479.7183; observed 
[M+H]+=1480.72590 
 
Synthesis of 4.16 
Dry THF (2.5 mL) was added to both PMDETA (4.5 µL, 0.0208 mmol) and to 
compound 4.14 (125 mg, 0.104 mmol) in two different Schlenk vessels and both 
the solutions were degassed through three freeze pump thaw cycles respectively. 
Dry CuI (4 mg, 0.0208 mmol) was then added to the PMDETA solution and 
stirred at r. t. for 20 minutes. Compound 4.15 (37 mg, 0.104 mmol) and CuI-
PMDETA solution were added to the THF solution of compound 4.14 and the 
reaction mixture was heated at 40 0C for 4 hours. THF was removed using a 
rotary evaporator. The crude compound was dissolved in ACN (0.1% TFA) and 
H2O (0.1% TFA) and purified by preparative HPLC-MS. The fractions were 
combined and frozen at -78 0C and lyophilized to yield the pure compound 7% 
(11.7 mg, 0.0076 mmol), purity 98%. HRMS (ESI+) : m/z calculated for 
C66H93BF2N19O14, [M+H]+=1424.7132; observed [M+H]+=1424.7237 
 
General synthesis of 4.17 and 4.18 
Dry THF (1 mL) was added to both PMDETA (10.5 µL, 0.0506 mmol) and to 
Fmoc lysine azide (100 mg, 0.253 mmol) in two different Schlenk vessels and 
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both the solutions were degassed through three freeze pump thaw cycles 
respectively. Dry CuI (10 mg, 0.0506 mmol) was then added to the PMDETA 
solution and stirred at r.t. for 20 min. Compound 4.2 (88 mg, 0.253 mmol) and 
CuI-PMDETA solution were added to the THF solution of Fmoc lysine azide and 
the reaction mixture was either heated at 40 0C for 4 hours and for 16 hours or 
stirred at r. t. for 4 hours and 16 hours. THF was removed using a rotary 
evaporator. The crude compound was analysed by analytical reverse phase 
HPLC.   
 
Synthesis of 4.21 
Dry THF (2.5 mL) was added to both PMDETA (7 µL, 0.0340 mmol) and to 
(PEG)7N3-OH (95 mg, 0.170 mmol) in two different Schlenk vessels and both the 
solutions were degassed through three freeze pump thaw cycles respectively. 
Dry CuI (6.5 mg, 0.0340 mmol) was then added to the PMDETA solution and 
stirred at r. t. for 20 min. Compound 4.15 (60 mg, 0.170 mmol) and CuI-PMDETA 
solution were added to the THF solution of (PEG)7N3-OH and reaction mixture 
was heated at 40 0C for 4 hours. THF was removed using a rotary evaporator. 
The crude compound was dissolved in ACN (0.1% TFA) and H2O (0.1% TFA) 
and purified by preparative HPLC-MS. The fractions were combined and frozen 
at -78 0C and lyophilized to yield the pure compound 35% (54 mg, 0.0410 mmol), 
purity 99%. HRMS (ESI+) : m/z calculated for C66H93BF2N19NaO14,   
[M+Na]+=928.3800 ; observed [M+Na]+= 928.3817 
 
Synthesis of 4.23 
Compound 4.21 (12 mg, 0.0132 mmol) was dissolved in dry DMF (0.5 mL). 
Compound 4.22 (17.8 mg, 0.0132 mmol), HOBt hydrate (hydroxybenzotrizole) 
(0.35 mg, 0.00264 mmol) and DIPEA (5 µL, 0.029 mmol) were added and the 
reaction mixture was cooled to 0 0C in ice bath. After 15 minutes EDC·HCl (N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride) (3 mg, 0.0026 mmol) 
162 
 
 
was added and the reaction mixture for left in ice bath for another 15 min. After 
this the reaction mixture was stirred at r.t. for 16 hours. Solvent was removed 
using a rotary evaporator. The reaction mixture was diluted with DCM and 
washed with deionised water (2 X 5mL). The organic layer was isolated and dried 
over sodium sulfate. DCM was evaporated using a rotary evaporator. The crude 
compound was then dissolved in ACN (0.1% TFA) and H2O (0.1% TFA) and 
purified by preparative HPLC-MS. The fractions were combined and frozen at -78 
0C and lyophilized to yield the pure compound 25% (7 mg, 0.00310 mmol), purity 
98%. HRMS (ESI+) :  m/z calculated for C96H129BF2N23O22,  
[M+2H]2+=1003.4950; observed [M+2H]2+=1003.5022        
 
Optical Analysis 
UV absorption data was acquired using a Varian Carry 300 Bio UV-Vis 
spectrophotometer. Excitation and emission data were acquired using a Photon 
Technology International QM-4 SE spectrofluorometer. For calculating molar 
extinction coefficients seven different concentrations were run for each sample. 
Molar extinction coefficients were obtained from the slope of the graph of 
absorbance versus concentration. The absorption, excitation and emission 
wavelengths and fluorescence quantum yields were determined using DMSO as 
a solvent. Fluorescence quantum yields were determined using the comparative 
method described by Fery-Forgues and coworkers.48 Briefly, the absorbance for 
the solutions of the unknown sample and the standard was measured. The 
emission spectra were also obtained and the area under the curve was 
determined. Fluorescence quantum yields were calculated using [Ru(bpy)3][PF6]2  
as the standard. The quantum yield for [Ru(bpy)3][PF6]2  has been reported to be 
0.095 in acetonitrile.47  
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Cell Imaging Protocol 
Transfection of OVCAR-8 cells 
HeyA8 and OVCAR-8 human ovarian cancer cell lines were maintained in RPMI 
media (Wisent) supplemented with 10% fetal bovine serum (FBS; Wisent). Cells 
were seeded into 6-well tissue culture plates (Sarstedt) at 1.5 x 105 cells per 35-
mm well. The following day, media was changed to OptiMEM (Invitrogen) 
containing 10% FBS prior to transfection. Cells were transfected with 0.5 µg of 
pCMV6-GHSR1a-EGFP plasmid using LipofectAMINE 3000 (Invitrogen) as per 
manufacturer’s instructions. Forty-eight hours later, cells were trypsinized and 
expanded into 4 separate 100-mm tissue culture plates in RPMI/10% FBS media. 
The following day, G418 Sulphate Solution (Wisent) treatment at 400 µg/mL was 
started and maintained until colonies were visible. GFP-positive colonies were 
visualized by indirect fluorescence using a Leica DMI 4000B inverted 
microscope, isolated using cloning rings, and transferred to 24-well tissue culture 
plates containing RPMI/10% FBS.  
 
A) For 4.7 :  
OVCAR-8 cells that were transfected with GHS-R1a were released from the 
tissue culture flask by trypsinization and seeded onto coverslips in a 12-well 
tissue culture plate at a cell density of 50000 cells/well. The cells were incubated 
overnight in Roswell Park Memorial Institute medium (RPMI) containing 10% fetal 
bovine serum (FBS) at 37 0C with 5% CO2. The serum containing RPMI in each 
well was removed and replaced with serum free RPMI containing a concentration 
of 0.1 µM of compound 4.7 and incubated at 37 0C for 1 hour. Cells were then 
washed three times with phosphate buffered saline (PBS), fixed with 4% 
paraformaldehyde in PBS and mounted onto slides containing Pro-Long Gold 
Antifade mounting medium with DAPI. For the control experiments, parental 
OVCAR-8 cells without GHS-R1a were incubated with compound 4.7. Images 
were then obtained using an Olympus FluoView FV 1000 confocal microscope.   
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Blocking Studies with 36 
OVCAR-8 cells with GHS-R1a were released from adhesion to tissue cultured 
flask. Cells were resuspended in serum free RPMI. Cells were then incubated 
with 0.1 µM of compound 4.7 at 37 0C for one hour. 10 X excess of compound 36 
was used as blocking compound for these studies. Cells were washed with PBS 
(3 times), reseeded onto coverslips, cultured in RPMI and allowed to adhere. 
Cells were washed with PBS, after being adhered to coverslips. Cells were then 
fixed with 4% formaldehyde in PBS and mounted onto slides. Images were then 
obtained using Olympus FluoView V 1000 confocal microscope.   
 
B) For 4.16 :  
OVCAR-8 cells that were transfected with GHS-R1a were released from the 
tissue culture flask by trypsinization and seeded onto coverslips in a 12-well 
tissue culture plate at a cell density of 50000 cells/well. The cells were incubated 
overnight in Roswell Park Memorial Institute medium (RPMI) containing 10% fetal 
bovine serum (FBS) at 37 0C with 5% CO2. The serum containing RPMI in each 
well was removed and replaced with serum free RPMI containing a concentration 
of 0.1 µM of compound 4.16 and incubated at 37 0C for 1 hour. Cells were then 
washed three times with phosphate buffered saline (PBS), fixed with 4% 
paraformaldehyde in PBS and mounted onto slides containing Pro-Long Gold 
Antifade mounting medium with DAPI. For the control experiments, parental 
OVCAR-8 cells without GHS-R1a were incubated with compound 4.16. Images 
were then obtained using an Olympus FluoView FV 1000 confocal microscope.   
 
Blocking Studies with 36 
OVCAR-8 cells with GHS-R1a were released from adhesion to tissue cultured 
flask. Cells were resuspended in serum free RPMI. Cells were then incubated 
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with 0.1 µM of compound 4.16 at 37 0C for one hour. 10 X excess of compound 
36 was used as blocking compound for these studies. Cells were washed with 
PBS (3 times), reseeded onto coverslips, cultured in RPMI and allowed to 
adhere. Cells were washed with PBS, after being adhered to coverslips. Cells 
were then fixed with 4% formaldehyde in PBS and mounted onto slides. Images 
were then obtained using Olympus FluoView V 1000 confocal microscope.    
 
C) For 4.23 :  
PC-3 cells were released from the tissue culture flask by trypsinization and 
seeded onto coverslips in a 12-well tissue culture plate at a cell density of 50000 
cells/well. The cells were incubated overnight in F-12K medium containing 10% 
fetal bovine serum (FBS) at 37 0C with 5% CO2. The serum containing F-12K in 
each well was removed and replaced with serum free F-12K containing a 
concentration of 0.5 µM of compound 4.23 respectively and incubated at 37 0C 
for 1 hour. Cells were then washed three times with phosphate buffered saline 
(PBS), fixed with 4% paraformaldehyde in PBS and mounted onto slides 
containing Pro-Long Gold Antifade mounting medium with DAPI. Images were 
then obtained using an Olympus FluoView FV 1000 confocal microscope.   
 
Blocking Studies with [D-Phe6, β-Ala11, Phe13, Nle14] bombesin 6-14. 
PC-3 cells were released from adhesion to tissue cultured flask. Cells were 
resuspended in serum free F-12K. Cells were then incubated with 0.5 µM of 
compound 4.23 respectively at 37 0C for one hour. 10 X excess of [D-Phe6, β-
Ala11, Phe13, Nle14] bombesin 6-14 was used as blocking compound for these 
studies. Cells were washed with PBS (3 times), reseeded onto coverslips, 
cultured in F-12K and allowed to adhere. Cells were washed with PBS, after 
being adhered to coverslips. Cells were then fixed with 4% formaldehyde in PBS 
and mounted onto slides. Images were then obtained using Olympus FluoView V 
1000 confocal microscope.   
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Competitive Binding Assay IC50 
For 4.7 and 4.16  
The affinity for GHS-R1a was determined using a radioligand binding assay. 
Assays were performed using HEK293 cells transfected with GHS-R1a (obtained 
from Dr. Savita Dhanvantari) as receptor source. HEK293 cells were grown in 
MEM supplemented with non-essential amino acids and 10% fetal bovine serum. 
For the purpose of transfecting the cells with GHS-R1a, cells were grown to 70% 
confluency in a 75cm flask and transfected with GHS-R1a-pcDNA 3.1 plasmid 
(Missouri S and T cDNA Resource Center) using a modified calcium phosphate 
transfection protocol.57 Human [125I]-ghrelin(1-28)  (PerkinElmer Inc.) as 
radioligand. Human ghrelin(1-28) was used as reference to ensure the validity of 
the results. Compounds 4.7 and 4.16 (at concentrations of 10-5 M, 10-6 M, 10-7 M, 
10-8 M, 10-9 M, 10-10 M, 10-11 M) and [125I]-ghrelin (15,000 cpm per assay tube) 
were mixed in binding buffer (25 mM HEPES, 5 mM magnesium chloride, 1 mM 
calcium chloride, 2.5 mM EDTA, and 0.4% BSA, pH 7.4). A suspension of 
membranes from GHS-R1a transfected HEK293S cells (50,000 cells per assay 
tube) was added to the assay tube containing test peptides and [125I]-ghrelin(1-
28). The resulting suspension was incubated for 20 minutes under shaking (550 
rpm). Unbound [125I]-ghrelin was removed and the amount of [125I]-ghrelin bound 
to the membranes was measured on a gamma counter. The IC50 was determined 
by a logistic nonlinear regression analysis using Origin. All binding assays were 
performed in triplicate. 
 
For 4.23 
The affinity for GRP-R was determined using a radioligand binding assay. Assays 
were performed using PC-3 cells and [125I]Tyr4-bombesin (PerkinElmer Inc.) as 
GRP-R specific radioligand. PC-3 cells were grown in Ham’s F-12K medium 
supplemented with 10% fetal bovine serum. Compound 4.23 (30 µL, at 
concentrations ranging from 10-12 to 10-6 M) and 20,0000 cpm of [125I]Tyr4-
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bombesin were mixed with the binding buffer (25 mM HEPES, 0.4% BSA, 5 mM 
MgCl2, 1 mM CaCl2, 2.5 mM EDTA in H2O, pH 7.4) in 1.5 mL Eppendorf vials. A 
suspension of 500,000 PC-3 cells in 50 µL binding buffer was added to each vial 
to give a final volume of 300 µL. The vials were shaken at 550 rpm for 1 hour at 
37 °C. Immediately after the incubation, the vials were centrifuged at 13,000 xg, 
and the supernatant removed. The cell pellet was washed with 500 µL of 50 mM 
Tris buffer (pH 7.4), centrifuged again, and the supernatant was removed. The 
amount of [125I]Tyr4-bombesin bound to the cells was measured using a gamma 
counter (Perkin-Elmer). IC50 values were determined by nonlinear regression 
analysis to fit a 4-parameter dose response curve using GraphPad Prism 
(Version 6.0c). All data points were obtained in triplicate. 
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                                    Chapter 5 
 
5 Conclusions 
5.1 Concluding Remarks 
Molecular imaging is a rapidly expanding field which can greatly influence clinical 
oncology. It not only plays a crucial role in diagnosing cancer at early stages, but 
also in determining the extent of the disease, in personalizing treatment and in 
studying the response to therapy.1 Despite all the recent advances in this field, 
very few molecular imaging probes progress from initial discovery through to 
clinical trials. To realize the true potential of molecular imaging, there is a 
continuous demand for the development of new imaging probes. Designing 
imaging probes with suitable pharmacokinetics is a major challenge. An ideal 
imaging probe is expected to have high binding affinity for the target tissue and 
minimal non-specific uptake. Combining the advantages of the different imaging 
modalities can provide more useful data as compared to a single imaging 
modality. The development of dual PET/optical imaging probes is highly desired 
since the high sensitivity of PET can be combined with the high spatial resolution 
of optical imaging methods resulting in a single probe with excellent sensitivity 
and resolution.  
The research in this thesis discusses the development of new targeted imaging 
probes for PET/optical imaging. The major concern during the development of 
multimodality imaging probes is the structural modifications that are required for 
making the probe suitable for detection through the different modalities. 
Porphyrins, owing to their ability to fluoresce and coordinate to metal ions, are 
ideal candidates for this kind of a strategy. In this thesis, porphyrins were 
explored as the imaging tag (fluorescent tag or PET isotope chelator). Previously, 
a PPIX-RGD based analogue was reported that was radiolabeled with 68Ga and 
developed as a dual PET/optical probe for targeting integrins.2 Using a similar 
173 
 
 
concept, the study in chapter 2 focussed on the development of PPIX based 
imaging probe for targeting GRP-R1a. Ghrelin is a relatively new peptide being 
explored for the synthesis of targeted imaging probes for the detection of cancer 
and very few imaging probes have been developed based on it. So far the limited 
number of ghrelin based imaging probes that have been reported in literature are 
either fluorescent probes or nuclear (PET or SPECT) probes, for example, a 
fluorescent ghrelin(1-18) analogue coupled to the dye fluorescein has previously 
been developed.3 Other PET imaging probes comprising of ghrelin derivatives 
coupled to NODAGA-68Ga, have also been reported previously.4  In another 
example, 99mTc labeled ghrelin complexes were developed and were reported to 
have IC50 values of around 45.0 nM.5  
The ghrelin based imaging probes described in this thesis are the first of their 
kind, existing as PET/optical dual imaging probes targeting GHS-R1a. 69/71Ga-
PPIX-ghrelin(1-8) was synthesized and it was observed that Ga-coordination did 
not decrease the fluorescence quantum yield of PPIX. This is a significant 
achievement especially in the case of porphyrins, where a decrease in 
fluorescence quantum yield has been reported in the case of some porphyrins 
upon coordination to certain metal ions such as Cu2+.6 The IC50 value for 69/71Ga-
PPIX-ghrelin(1-8) was found to be 617.1 nM, which is very poor as compared to 
ghrelin (1-8), but is better than uncoordinated PPIX-ghrelin(1-8). The detrimental 
effect of the chelator on the binding affinity of the peptide has been seen in the 
literature. For example, the binding affinity of peptide H2 relaxin for receptor 
RXFP1, was lowered upon conjugation to the chelator DTPA (diethylenetriamine 
pentaacetic acid).7  
PPIX, being a bulky molecule, decreases the affinity of the peptide for the protein 
receptor. Although a 2,2'-(ethylenedioxy)bis(ethylamine) linker was used for 
increasing the distance between PPIX and the N-terminus of ghrelin, this might 
not have been sufficient. The length and the position of the linker are important 
criteria that determine whether the linker will be able to mitigate the effect of the 
chelator on the binding affinity of the peptide. Therefore, more studies focussing 
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on the determination of the optimal linker for the conservation of binding affinity of 
this peptide are needed. Choosing an appropriate linker will not only help in 
improving the binding affinity of our imaging probe, but it will also aid in improving 
the solubility, which has been an issue with PPIX due to its hydrophobic nature.8,9  
Nonetheless, the uptake of the imaging probe by GHS-R1a was confirmed 
through fluorescence microscopy using OVCAR-8 cells transfected with the 
receptor. PPIX-ghrelin (1-8) was successfully radiolabeled with 68Ga, however, 
the yield for radiolabeling was low. Poor solubility of the porphyrin and instability 
of the peptide at high temperature were responsible for the low radiolabeling 
yields. Further optimization of the radiolabeling strategy is needed. The use of a 
more appropriate (hydrophilic) linker will definitely play a vital role in improving 
the radiolabeling yield. Also, it has been seen in the literature that the introduction 
of PEG chains to the porphyrin molecule enhances its solubility.8 In another 
report, the synthesis of hydrophilic porphyrins with cationic groups 
(methylpyridinium or trimethylammonium) or anionic groups (carboxylate or 
sulphonate) was carried out by attachment of polar aromatic groups to meso 
positions of porphyrin through two approaches involving (1) Suzuki and (2) 
Sonogashira coupling.9 Therefore, there is still scope for improving the 
radiolabeling yield by improving the solubility, which likely can be achieved by 
modifying the structure of the porphyrin entity by making it more hydrophilic. 
In continuation of the research done with PPIX-peptide conjugates, chapter 3 
discusses the use of hematoporphyrin (HP) as the fluorescent tag/metal chelator. 
HP was selected as it might have better solubility than PPIX, as it is more 
hydrophilic due to the presence of two isopropanol groups. 69/71Ga-HP species 
were synthesized and once again the Ga-coordination did not quench the 
fluorescence of HP species. 69/71Ga-HP-AEEA-bombesin (7-14) analogues were 
synthesized as potential PET/fluorescent probes for GRP-R. The purification of 
these compounds was problematic as the Ga-coordination did not proceed to 
completion and a mixture of Ga-coordinated and uncoordinated species was 
obtained. Any further increase in temperature, led to the decomposition of HP 
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into PPIX. 68Ga radiolabeling attempts, demonstrated that although the HP and 
the monohydroxyethyl monovinyl deuteroporphyrin (HVD) components of the 
mixture were being labeled with 68Ga, there was still unlabeled PPIX that was 
present and could not be separated. A mixture of Ga-coordinated and 
uncoordinated compounds cannot be used as such for imaging as these might 
have different pharmacokinetics and there will be inconsistencies in the imaging 
results. Therefore, it will be useful to design an alternate hydrophilic porphyrin.  
There are several examples in literature that demonstrate the use of BODIPY 
derivatives in the development of dual modality imaging probes.10,11  This class of 
compounds involves complex synthesis and has small Stokes shift. A new class 
of compounds known as BF2-formazates can be synthesized in good yields 
starting from inexpensive starting materials. Moreover, these have optimal optical 
properties such as high extinction coefficients, fluorescence quantum yields and 
Stokes shift which make them ideal candidates for fluorescence imaging.12,13  
There are no reports of using BF2-formazanates as imaging agents for cancer. 
In order to develop these BF2-formazanate compounds as PET agents, it was 
proposed that a 18F-19F exchange reaction could be used to synthesize 18F 
version of these compounds. Although there was a radiolabeled compound that 
appeared very close to the expected radioproduct on the HPLC 
radiochromatogram, it did not match with the non-radioactive standard, indicating 
that it was not the desired product. It was hypothesized that one of the fluorine 
atoms might be getting exchanged with OH, which would appear at a slightly 
different retention time on the radiochromatogram. Therefore, the PET imaging 
analogue will consist of 18F and OH attached to boron whereas the fluorescent 
probe will have two F atoms attached to boron. These two probes might have 
different pharmacokinetics and the results from fluorescence and PET imaging 
might be inconsistent. This kind of compound cannot be used as dual PET/optical 
probe since the structure of the probe for PET and optical imaging will be 
different and this will lead to inconsistency in results. 
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The proposed solution to this problem could be synthesizing new formazanate 
compounds that would have one OH and one F attached to boron. This will act as 
a non-radioactive standard to confirm that the radiolabeled compound contains 
OH- that replaced one of the F-. Also, once this is confirmed, we will have similar 
compounds (B-F-OH instead of BF2) for both PET and optical imaging.  
Nonetheless, BF2-formazanate compounds were developed into novel targeted 
fluorescence imaging probes for GHS-R1a and GRP-R. Two ghrelin based 
peptides having an additional lysine residue at the C-terminus were attached to 
BF2-formazanate dyes employing CuAAC. The role of the ligand PMDETA in 
promoting these reactions was also demonstrated. The two probes that were 
designed for targeting GHS-R1a were [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ 
alkyne compound 4.7 and [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ methoxy 
compound 4.16. The photophysical data depicted that these probes were red 
shifted as compared to the parent dyes 4.2 and 4.15 respectively. There was an 
increase in the fluorescence quantum yield for probe 4.16 compared to the parent 
dye 4.15 (ΦF for 4.16 was 0.21 and for 4.15 was 0.04). Further, it was observed 
that the probe 4.16 which had a Thr residue replacing the Tyr residue at position 
8, had a better IC50 value (IC50 for 4.16 = 89.9 nM and for 4.7 = 166.4 nM). 
                                                                                                                          
 
                  
                          4.2                                                            4.15 
 
Figure 5.1 Structures of parent BF2-formazanate dyes 4.2 and 4.15. 
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The yield for clicking the ghrelin peptides to BF2-formazanate compounds was 
found to be low. Therefore, an alternate strategy, that involved (a) clicking just the 
lys(N3) residue to the BF2-formazanate and (b) solution phase acid-amine 
coupling reaction, was used and this resulted in an increase in the reaction yield 
(35% vs 6%). Using this strategy, [D-Phe6, β-Ala11, Phe13, Nle14] bombesin 6-14-
(PEG)7-FMZ compound 4.23 was developed as a fluorescent imaging probe for 
GRP-R. Once again, the photophysical data showed that the emission 
wavelength was red shifted, there was a slight increase in the Stokes shift and an 
increase in fluorescence quantum yield as compared to parent dye 4.15. (ΦF for 
4.23 was 0.12 and for parent dye 4.15 was 0.04). The IC50 value for this analogue 
was 16.3 nM.  
Therefore, this new strategy laid the groundwork for developing novel BF2-
formazanate based fluorescence imaging probes for different receptors 
employing different targeting peptide sequences. The specificity for the receptors 
was demonstrated through confocal fluorescence microscopy using OVCAR-8 
cells transfected with GHS-R1a for GHS-R1a receptor and PC-3 cells for GRP-R. 
In order to improve the IC50 values for these probes, some structural 
modifications can be carried out, for example by increasing the distance between 
the BF2-formazanate moiety and the N-terminus of the ghrelin peptide by the 
introduction of suitable linkers or modification in the peptide sequence to obtain a 
peptide with better affinity for the receptor. Structure-activity studies to determine 
an ideal ghrelin sequence for binding were done earlier. But there is still potential 
to optimize the appropriate ghrelin sequence that will provide better results with 
BF2-formazate.  
In conclusion, this thesis focussed on the development of new methods for 
conjugating fluorophores such as porphyrins and BF2-FMZ dyes to biomolecules 
and to radiolabel these probes with 68Ga and 18F respectively. The strategies 
used for developing novel PET/fluorescence multimodality imaging probes, 
eliminated the need for additional structural modification, as the same molecule 
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acted as the fluorescent tag and metal chelator, which will provide consistency in 
the imaging results. The methodologies established in this thesis have opened 
the way for the development of imaging probes which can be designed using a 
variety of peptides for targeting different receptors overexpressed in cancer. 
Although there is still a need to develop improved methodology for 
radiochemistry, these new classes of probes have the potential to act as effective 
imaging agents and contribute to cancer imaging.  
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                                      Chapter 6 
6 Appendix 
 
6.1 Chapter 2 UPLC Traces 
UPLC for 2.3: Analytical 10-70% acetonitrile in water – 4 minutes.  
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0.0
0.2
0.4
0.6
0.8
1.0
A
b
s
o
rb
a
n
c
e
minutes
 
 
 
 
 
 
 
 
 
181 
 
 
UPLC for 2.4: Analytical 60-90% acetonitrile in water – 4 minutes. 
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UPLC for 2.8: Analytical 35-75% acetonitrile in water – 4 minutes. 
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UPLC for 2.9: Analytical 10-70% acetonitrile in water – 4 minutes 
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6.2 Chapter 2 ESI+ Mass Spectrums 
ESI+ Mass Spectrum for 2.3 
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ESI+ Mass Spectrum for 2.4 
 
 
 
ESI+ Mass Spectrum for 2.8 
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ESI+ Mass Spectrum for 2.9 
 
 
 
 
6.3 Chapter 2 IC50 Curves 
IC50 Curve for 2.8 
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IC50 Curve for 2.9 
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6.4 Chapter 3 UPLC Traces 
UPLC for 3.1-3.4: Analytical 10-70% acetonitrile in water - 4 minutes.  
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UPLC for 3.7-3.10: Analytical 20-80% acetonitrile in water - 4 minutes. 
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UPLC for 3.11-3.13: Analytical 20-80% acetonitrile in water - 4 minutes. 
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6.5 Chapter 4 UPLC Traces 
 
UPLC for 4.6: Analytical 10-70% acetonitrile in water - 4 minutes.  
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HPLC for 4.7: Analytical 50-90% acetonitrile in water - 4 minutes. 
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UPLC for 4.10: Analytical 10-70% acetonitrile in water - 4 minutes.  
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UPLC for 4.14: Analytical 10-70% acetonitrile in water - 4 minutes.  
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UPLC for 4.16: Analytical 30-70% acetonitrile in water - 4 minutes. 
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UPLC for 4.21: Analytical 10-70% acetonitrile in water - 4 minutes. 
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UPLC for 4.22: Analytical 10-70% acetonitrile in water - 4 minutes.  
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UPLC for 4.23: Analytical 20-80% acetonitrile in water - 4 minutes. 
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6.6 Chapter 4 ESI+ Mass Spectrums 
ESI+ Mass Spectrum for 4.6 
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ESI+ Mass Spectrum for 4.7 
 
 
ESI+ Mass Spectrum for 4.10 
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ESI+ Mass Spectrum for 4.14 
 
 
ESI+ Mass Spectrum for 4.16 
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ESI+ Mass Spectrum for 4.21 
 
 
ESI+ Mass Spectrum for 4.22 
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ESI+ Mass Spectrum for 4.23 
 
 
 
6.7 Chapter 4 IC50 Curves 
IC50 Curve for 4.7 
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IC50 Curve for 4.16 
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IC50 Curve for 4.23 
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